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The pathogenesis of minimal change nephrotic syndrome (MCNS), the most 
common cause of significant morbidity amongst the childhood 
glomerulonephritides, is unknown.  We have demonstrated that IL-13 
overexpression in the rat resulted in podocyte foot process (FP) effacement with 
B7-1 upregulation and concurrent downregulation of the slit diaphragm proteins 
inducing a minimal change-like nephropathy.  We therefore hypothesized that 
IL-13 and/or other Th2 cytokines could act through the B7-1 danger signaling 
pathway, causing podocyte FP effacement and proteinuria (Figure 1). Our IL-
13 overexpression rat model of MCNS thus provided a platform to study the 
molecular signaling pathways that were differentially regulated, in order to 
better understand the pathogenesis of this intriguing disease. The aims of this 
study were firstly to delineate the glomerular “gene signature” related to our IL-
13 rat model of MCNS through microarray analysis of glomerular transcription 
profile in IL-13 overexpression and control rats; secondly, to validate the in vivo 
microarray results in human podocyte cell culture system; and lastly to 
investigate the mechanism of IL-13-induced B7-1 danger signaling in causing 
podocyte injury. 
 
RNA from glomeruli of six control and six IL-13 overexpressed rats with 
MCNS were reverse transcribed and hybridized into Sentrix® BeadChip Array 
RatRef-12v1. Differentially expressed genes (DEGs) were selected based on the 
criteria of fold change greater than 1.6, coefficient of variance less than 0.7 and 
t-test p<0.05. Gene ontology analysis was done using DAVID and pathway 
analysis was carried out using Ingenuity Pathway Analysis and MetaCoreTM. 
Protein expression of vav1 on the glomeruli and podocytes were validated using 
immunohistochemical staining on rat kidney section as well as 
immunofluorescence staining and Western blotting on podocytes. Morphology 
of podocyte actin cytoskeleton was examined using phalloidin staining. 
RhoA/Rac1 activity in IL-13 stimulated podocytes was measured using ELISA. 
The role of vav1 in IL-13 induced podocyte injury was studied using podocytes 
transfected with siRNA specific for vav1. Gene and protein expression levels 




Transcriptional profile of the glomeruli in IL-13 overexpressed rats showed 
characteristic features of podocyte injury in which more than 87% of genes 
known to be related to podocytes were significantly downregulated.  Gene 
expression of vav1 was highly upregulated in the glomeruli of IL-13 
overexpressed rats and MetaCoreTM pathway analysis of the DEGs suggested a 
possible novel role of vav1 in podocyte cytoskeleton remodeling.  
Immunohistochemical staining confirmed the glomerular expression of vav1, 
which co-localized with synaptopodin in serial sections of the kidney.  
Moreover, the presence of vav1 in cultured podocytes was further confirmed by 
immunofluorescence staining and immunoblotting.  
 
In vitro IL-13 stimulation in podocytes resulted in significant increased 
expression of IL-13Rα2, B7-1 and phosphorylated vav1 compared to controls. 
This was associated with actin cytoskeleton rearrangement and activation of 
Rac1. Additionally, podocytes with vav1 siRNA transfection were protected 
from IL-13 induced actin cytoskeleton changes and Rac1 activity.   
 
In conclusion, we have shown that the direct action of IL-13 in inducing 
podocyte FP effacement in our rat model of MCNS was through activation of 





Figure 1: Proposed Th2 cytokine bias model of MCNS results from primary immune 
disturbance. 
IL-13 and/or other immune mediators may directly or indirectly act on podocytes and cause 
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1.1. Nephrotic Syndrome 
With the decline in acute post-infectious glomerulonephritis, idiopathic 
nephrotic syndrome, in particular minimal change nephrotic syndrome (MCNS) 
is now the most common cause of significant morbidity amongst the childhood 
glomerular diseases both in Singapore and worldwide [1]. Up to 70% of children 
with MCNS will have multiple relapses, of whom at least half will require long-
term steroid therapy or courses of cytotoxic drugs, with their attendant adverse 
effects on growth and puberty, cataract formation, and risk of malignancy. 
Better therapeutic strategies based on a clearer understanding of the etiology of 
the disease are hence required. 
 
1.1.1 Definition of nephrotic syndrome 
Nephrotic syndrome is a kidney disease commonly seen in children. It is 
characterized by proteinuria, hypoalbuminemia, edema and 
hypercholesterolemia. Clinical diagnosis of nephrotic syndrome requires the 
presence of edema, nephrotic-range proteinuria (urinary protein excretion of ≥3 
g/day/1.73m2) and hypoalbuminemia (serum albumin level ≤25 g/L) [2]. 
Hypercholesterolemia associated with MCNS is usually much more severe with 
extremely high total serum cholesterol, typically 10-20 mmol/L [3, 4] (normal 
<5.1mmol/L) [5], primarily due to marked elevation of LDL-cholesterol, 
compared to other diseases with protein loss such as patients with chronic 
nephropathy or those on peritoneal dialysis whose protein losses can reach a 
similar range as nephrotic patients but serum total cholesterol levels rarely 
exceed 7 mmol/L [6]. Upon receiving corticosteroid therapy, the majority of 
children will respond to the treatment, entering remission, which is defined as 
resolution of edema and proteinuria (urine albumin reduced to <0.3 
g/24hr/1.73m2, or a urine protein/creatinine ratio of <0.02 g/mmol) and 






1.1.2 Classification of nephrotic syndrome 
Nephrotic syndrome presenting in the first three months of life, that is, 
congenital nephrotic syndrome, are mainly due to mutations in genes such as 
WT1, nephrin and podocin. More than 90% of children with nephrotic syndrome 
have a primary cause, that is, a disease specific to the kidneys. However, 
secondary causes, such as systemic lupus erythematosus, Henoch-Schonlein 
purpura and viral etiologies (hepatitis B, hepatitis C, parvovirus, human 
immunodeficiency virus (HIV)) have to be excluded. 
 
Primary nephrotic syndrome (also known as idiopathic nephrotic syndrome) can 
be classified histologically into MCNS, focal segmental glomerulosclerosis 
(FSGS), membranous nephropathy (MN), mesangial proliferative 
glomerulonephritis (GN) and membranoproliferative GN (MPGN). The most 
common histopathologic type in children is MCNS, accounting for more than 
80% of all cases [9]. 
 
1.1.3 Treatment of Nephrotic Syndrome 
Prednisolone is the mainstay of treatment for children with idiopathic nephrotic 
syndrome. The treatment regime is 60 mg/m2/day of prednisone for four to six 
weeks, followed by 40 mg/m2 on alternate days for a further six to twelve weeks. 
It is estimated that 70% of patients will respond to this treatment with complete 
resolution of proteinuria and edema, however, up to 40% may have frequent 
relapses or require long-term steroid treatment to maintain in remission.  
 
Based on the responses to corticosteroid treatment, these patients can be 
classified as: i) steroid-sensitive nephrotic syndrome (SSNS); ii) steroid-
resistant nephrotic syndrome (SRsNS); iii) steroid-dependent nephrotic 
syndrome (SDNS); or iv) frequent relapsing nephrotic syndrome (FRNS). 
Patients with SSNS are able to attain remission within eight weeks of treatment 
with corticosteroid treatment; patients with SRsNS fail to attain remission after 
eight weeks of corticosteroid treatment; patients with SDNS are able to respond 
to initial corticosteroid treatment but develop a relapse either while still on 
steroids or within two weeks of discontinuation of treatment following a steroid 
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taper, hence requiring the continued low-dose steroid treatment to prevent 
relapses; patients with FRNS enter complete remission in response to steroid 
treatment but develop four or more relapses in any 12-months period [2]. 
 
In addition to corticosteroid treatment, patients with SDNS and FRNS often 
require other immunosuppressive agents such as cyclophosphamide, 
levamisole, cyclosporine, tacrolimus, and mycophenolate mofetil. Similarly, 
patients with SRsNS require multiple immunosuppressive agents such as 
cyclosporine, tacrolimus, high dose intravenous methylprednisolone, 
mycophenolate mofetil, and rituximab to achieve remission.   
 
Prolonged use of corticosteroids and immunosuppressive agents result in 
adverse side effects such as growth retardation, obesity, infections, 
hypertension, osteoporosis, cataracts, infertility and nephrotoxicity [10-13].  
 
1.1.4 Epidemiology of Nephrotic Syndrome  
The annual incidence of nephrotic syndrome in most countries in the Western 
countries ranges from 2 to 7 new cases per 100,000 children [8, 14-16]. 
Countries in Asia, however, reported a higher incidence of about 16 new cases 
per 100,000 children [17]. 
 
Renal biopsy is commonly recommended for patients who are steroid-resistant.  
Among the 103 biopsy proven cases in the International Study of Kidney 
Disease in Children (ISKDC) series, MCNS, FSGS and MPGN were the most 
common lesions in SRsNS, each accounting for approximately 25% of the 
histological findings [7]. In Singapore, however, MCNS and FSGS formed the 
main fraction of SRsNS cases, accounting for 30% and 49% of the cases 





Table 1: Distribution of children with SRsNS by glomerular histopathology in ISKDC and 
Singapore. 
Histopathologic category ISKDC Singapore 
Minimal change nephrotic syndrome 25 14 
Focal segmental glomerulosclerosis 26 23 
Membranoproliferative glomerulonephritis 27 5 
Mesangial proliferative glomerulonephritis  9 3 
Membranous glomerulonephritis 6 ND 
Chronic glomerulonephritis 3 ND 
Diffuse Mesangial Hypercellularity 4 ND 
Focal Global Glomerulosclerosis 2 2 
Unclassified 1 ND 
Total 103 47 
Adopted from reference [7] and [18]. ND: not determined. 
 
1.2. Minimal change nephrotic syndrome 
MCNS is the most common cause of childhood nephrotic syndrome. Although 
it is not limited to children, studies have reported a median age of onset of four 
years, where MCNS accounts for close to 85% of all cases of childhood 
nephrotic syndrome [9, 19]. Although more than 90% of children with MCNS 
respond to corticosteroid therapy, up to 70% will have multiple relapses 
requiring long-term steroid therapy or courses of cytotoxic drugs, with their 
attendant adverse effects on growth and puberty, cataract formation, and risk of 
malignancy. 
 
In MCNS, the glomeruli appear normal by light microscopy or show a minimal 
increase in mesangial cells and matrix. Findings on immunofluorescence 
microscopy are typically negative, and electron microscopy reveals effacement 
of podocyte foot processes and absence of electron-dense immune deposits in 
the glomeruli [20]. 
 
The underlying mechanism in the majority of patients with nephrotic syndrome 
is a permeability defect in the glomerular filtration barrier that allows the loss 
of protein from the plasma into the urine. However, the fundamental cause and 




1.2.1 Minimal change nephrotic syndrome and the immune system 
In 1974, Shalhoub postulated that lipoid nephrosis, an older term for MCNS, is 
produced by a systemic disorder of T-cell function [21]. He hypothesized that 
the domination of an abnormal clone of T cells results in the production of a 
circulating lymphokine toxic to the glomerular basement membrane (GBM), 
resulting in increased glomerular permeability to protein.  
 
The onset of idiopathic nephrotic syndrome has been associated with prior 
respiratory tract infections or other immunogenic stimuli such as insect stings 
[22, 23], vaccinations [24, 25] or allergic reactions to inhaled allergens [26-29]. 
Clinical observations such as remission induced by measles, the occurrence of 
nephrotic syndrome in lymphoproliferative disease like Hodgkin’s disease [30-
32], leukemia [33], lymphoma [34] and thymoma [35-40], both of which modify 
cell-mediated immunity, and the therapeutic benefits of steroids and 
cyclophosphamide [41], which suppresses cell-mediated responses, all support 
Shalhoub’s hypothesis that MCNS might be related to T-cell dysfunction, 
resulting in the production of a lymphocyte-derived permeability factor that 
induces proteinuria. 
 
The association of interleukin (IL-) 13 (IL-13) with MCNS may also account 
for the relationship of MCNS with Hodgkin’s disease. IL-13 expression is a 
characteristic feature of Hodgkin’s disease. In situ hybridization of lymph node 
tissue from patients with Hodgkin’s disease showed elevated levels of IL-13 
and IL-13 receptor (IL-13Rα1) localized to Reed-Sternberg cells, a malignant 
cell population in Hodgkin’s disease [42-44]. Constitutive phosphorylation of 
signal transducer and activator of transcription 6 (STAT6) in Reed-Sternberg 
cells [45] and inhibition of Hodgkin's lymphoma growth by IL-13Rα2 (decoy 
receptor of IL-13) [46] further implicate IL-13 as an important growth factor in 
Hodgkin’s disease, and may account for the proteinuria in MCNS associated 




In addition, the lack of morphological changes in the kidney suggests that 
MCNS represents a generalized disorder of the immune system resulting in 
renal manifestations, rather than a specific disease of the kidney. A number of 
studies have shown immunologic abnormalities in this disease, including an 
increase in the CD4+CD25+ (IL-2 receptor-α chain) [47], CD4+CD45RO+ and 
CD8+CD45RO+ memory subsets [48] in patients with active relapse, selective 
recruitment of some νβ gene family in CD8+ T cells from nephrotic patients 
with frequent relapses [49], increased NF-κB DNA binding activity in T-cells 
in MCNS patients during relapse [50], as well as abnormalities in serum 
immunoglobulins during nephrotic relapses characterized by depressed IgG, 
and elevated IgM and IgE [51, 52].  
 
Although it is still unclear how an altered immune system may cause proteinuria 
in idiopathic nephrotic syndrome, there is strong evidence suggesting that the 
proteinuria in idiopathic nephrotic syndrome could be mediated by circulating 
factor(s) such as cytokines summarized in Table 2 [9, 53]. Persistent massive 
proteinuria, in turn, contributes to the phenomenon of glomerular hyperfiltration 
and ultimately progressive glomerulosclerosis, through the mediation of other 
cytokines like transforming growth factor-β (TGF-β), produced by the resident 





Table 2: Cytokine profile in MCNS. 
Cytokines Upregulation Downregulation No Change 
Th1-related 
IL-12 [55]  [56] 
IFN-γ [57] [56] [58, 59] 
Th2-related 
IL-4 [60, 61] [59] [57, 58, 62] 
IL-13 [58, 62]   
Th17-related 
IL-23 [63]   
IL-17 [63]   
Treg-related 
IL-10  [63, 64]  
TGF-β  [63]  
General activation 
IL-1 [65] [66] [57, 67] 
IL-2 [57, 59, 65]  [58] 
IL-6  [59] [67] 
TNF-α [67]  [57] 
Chemokines 
IL-8 [68] [57]  
Numbers in brackets corresponds to the published journals as indexed in the reference. 
 
1.2.2 Roles of Th2 cytokines in minimal change nephrotic syndrome 
Studies on the role of cytokines in MCNS suggested MCNS is a result of 
primary immune disturbance, with a Th2 bias [53]. Th2 cytokines are anti-
inflammatory and are associated with B-cells proliferation, class switching of 
B-cells to produce IgE and IgG4, and increased neutralizing antibody 
production [69, 70]. 
 
Our laboratory was the first to demonstrate that IL-13 gene expression was 
upregulated in both CD4+ and CD8+ T-cells in children with steroid-sensitive 
nephrotic syndrome in relapse [58].  This was associated with increased 
intracytoplasmic IL-13 production by CD3+ cells.  We also demonstrated a 
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significant increase in serum IgE levels during nephrotic relapses compared to 
remission, and this correlated with the percentage of IL-13-producing CD3+ 
cells suggesting the presence of polyclonal activation [51].  
 
Our findings were consistent with Kimata’s study where IL-13 was shown to be 
important for the spontaneous production of IgE and IgG4 by peripheral blood 
mononuclear cell (PBMC) from nephrotic patients [62]. Another Th2 cytokine, 
IL-4, was also found to be increased in PBMCs from patients with MCNS, and 
this was associated with increased B-cell expression of the type II IgE receptor 
and high IgE production [61], further supporting the association of atopy with 
nephrotic syndrome. In addition, Sahali et al. showed increased gene expression 
of c-maf, a Th2-specific transcription factor that binds to the IL-4 proximal 
promoter, while IL-12R β2 gene expression was downregulated during relapses 
of MCNS through cDNA library differential screening [71].  
 
Furthermore, we were able to demonstrate that genetic polymorphisms in the 3’ 
untranslated region (3’UTR) of the IL-13 gene correlated with long-term 
outcome of MCNS in Singapore Chinese children, rather than disease 
susceptibility [72]. Moreover, IL-13 mRNA expression in PBMC of patients 
with the haplotype AAT, associated with continuing relapses 5 years from onset, 
was significantly higher than those with the haplotype GCC, associated with 
long-term remission.  Unfortunately, the exact role of IL-13 in the pathogenesis 
of MCNS is not clear. 
 
1.3. Role of podocytes in genesis of nephrotic syndrome 
The ultrafiltration of plasma in the kidney occurs through the capillary wall of 
the glomerulus. The filtration barrier consists of three layers: (i) the glomerular 
endothelial cells (GECs), lining the interior side of the glomerular capillaries; 
(ii) the glomerular basement membrane (GBM); and (iii) the podocytes, lining 
the exterior of the glomerular capillary (Figure 2). Passage of plasma across this 
size-selective barrier results in water, small- and middle-sized molecules 
entering the urinary space; while serum albumin and macromolecules are 
retained in the capillary space. Our current understanding of the pathogenic 
 9 
 
mechanism of nephrotic syndrome suggests that the podocyte is the main 
component of the glomerular filter and the crucial target in the development and 
progression of glomerulopathies. In fact, one of the hallmarks of MCNS is the 
effacement of podocyte foot processes (FP) and the degree of FP effacement 
has been shown to roughly correlate with the amount of proteinuria [73, 74].  
 
Figure 2: Glomerular filtration barrier.  
The filtration barrier is composed of glomerular endothelial cells, the glomerular basement 
membrane (GBM), and the podocytes. Adopted and modified from reference [75]. 
 
Podocytes are terminally differentiated cells with a cell body and large 
cytoplasmic projections (major processes) that divide into long thin processes 
(foot processes). The FP are attached firmly to the underlying GBM and form a 
tight network of interdigitating pattern with FP of neighbouring podocytes, 
which are bridged by ‘slit diaphragms’ (SD) [76]. The SD thus divides the 
plasma membrane of FP to the apical, the lateral (slit diaphragm), and the basal 
domains. In the cytoplasm, these three surfaces are interconnected via the actin-
based cytoskeleton (Figure 3) [77]. Disruption of any of the three domains or 








Figure 3: The three domains of the podocyte FP.  
The FP interdigitates with FP of neighbouring podocytes, bridged by slit SD. The SD divides 
the plasma membrane of FP to the apical, the lateral, and the basal domains. These three surfaces 
are interconnected via the actin-based cytoskeleton in the cytoplasm. Adopted and modified 
from reference [77]. 
 
A wide range of proteins molecules are expressed on the podocytes FP (Figure 
4), with diverse functions, such as structural support, adhesion, signaling and 
movement. The summation of the functions of these molecules forms the basis 
of the glomerular filtration barrier.  
 
Figure 4: Molecules expressed in the podocytes. 
Adopted and modified from reference [75]. 
 
1.3.1 Podocyte apical membrane domain 
The apical surface of podocytes, which faces the urinary space, is covered by 
sialylated, O-glycosylated, and negatively charged transmembrane protein – 
podocalyxin [78].  Podocalyxin deficient mice failed to form FP and SD thus 
causing a block in urine production [79]. Podocalyxin is linked to the actin 
cytoskeleton in the cytoplasm through ezrin [80] and Na+/H+ exchanger 
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regulatory factor 2 (NHERF2) [81]. Disruption of the 
podocalyxin/ezrin/NHERF/actin interaction resulted in drastic loss of FP. 
 
Another protein found at the apical surface of podocytes is glomerular epithelial 
protein 1 (GLEPP1). It is a podocyte-specific receptor tyrosine phosphatase. 
Structurally, it has a large ectodomain with multiple fibronectin type III repeats, 
a transmembrane domain, and a single cytoplasmic phosphatase active site 
sequence [82]. Podocytes of GLEPP1 deficient mice had an amoeboid instead 
of the typical octopoid structure. These mice showed reduced filtration surface 
area, reduced glomerular nephrin content and reduced glomerular filtration rate 
[83]. To date, cytoplasmic ligand of GLEPP1 has not been identified.  
 
1.3.2 Podocyte slit diaphragm 
The SD is characterized as modified adherens junction with rod-like proteins 
forming a zipper-like structure with a constant width of approximately 40 nm 
[84, 85]. The extracellular portion of the SD is composed of the extracellular 
domains of various transmembrane proteins such as nephrin [86-89], Neph1/2/3 
[90-94], P-cadherin [84], VE-cadherin [84, 95] and FAT [96]. The cytoplasmic 
portion of the SD is composed of non-structural proteins like podocin [97, 98], 
TRPC5/6 [99, 100], CD2AP [101], Nck [102], Par3/Par6/aPKC [103], ZO-1 
[104], dendrin [105], JAM4 [106], densin [107], MAGI-1/2 [108], CASK, 
IQGAP1, αII spectrin, and βII spectrin [109].  
 
Nephrin was the first transmembrane protein identified in the SD through 
positional cloning. Mutation in nephrin gene, NPHS1, was found to be the cause 
of congenital nephrotic syndrome of the Finnish type [87] and reduction or 
altered distribution of nephrin expression was reported in patients with MCNS 
and IgAN [110, 111]. Nephrin has a short intracellular domain, a 
transmembrane domain, and an extracellular domain. The intracellular domain 
is connected to the actin cytoskeleton via CD2-associated protein (CD2AP) 
[101] and Nck proteins [102]. The extracellular domain of nephrin forms the 
“bridge” of the filtration slit through homophilic interaction of nephrin 
molecules from neighbouring FP [112]. Nephrin knockout mice showed 
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podocyte FP effacement, lack SD, massive proteinuria, edema and died within 
a day [113]. 
 
Neph1, Neph2, and Neph3 (also known as filtrin) proteins are structurally 
related to nephrin. Studies showed that nephrin can form heterodimers with 
Neph1 or Neph2, but that Neph1 and Neph2 do not interact with each other 
[114, 115]. Neph1 knockout mice had early postnatal death due to podocyte FP 
effacement and proteinuria [116]. In addition, interaction of Neph1 with nephrin 
caused tyrosine phosphorylation of Neph1 by Fyn and recruitment of Grb2, an 
event that is crucial in Neph1-induced actin polymerization [117]. However, 
functional significance of Neph2 or Neph3 is unknown. 
 
P-cadherin, vascular endothelial cadherin (VE-cadherin or cadherin 5) and 
FAT1 are cadherin proteins which have been localized to the slit diaphragm. P-
cadherin is not indispensable for the functional renal filtration barrier [118] and 
P-cadherin deficient mice showed no kidney abnormalities or function [119]. 
The role of VE-cadherin in the podocyte is still unknown [75]. Fat1 is a large 
protein with 34 tandem cadherin-like repeats and is an important regulator of 
actin dynamics via Ena/VASP interaction [120-122]. Fat1 knockout mice 
caused perinatal death, loss of SD, podocyte FP effacement and proteinuria 
[123]. 
 
Podocin was discovered through positional cloning of the gene mutated in early-
onset steroid resistant nephrotic syndrome [97]. It is a member of stomatin 
family of protein containing a prohibitin homology domain for lipid recognition 
motif. It has a hairpin structure with both ends directed into the cytoplasmic side 
of SD. Studies showed that podocin served as the platform for recruitment of 
CD2AP, nephrin and Neph1 to SD [91, 124]. Podocin was also reported to 
cluster and regulate the ion channel TRPC6 thus enabling SD to act as the 
mechanosensor of the podocyte, to sense and respond to mechanical stimuli 
[125]. In addition to serving as a structural protein of the SD,  podocin was 
reported to also serve as a platform that connects the tight junction proteins to 
the actin cytoskeleton via coxsackievirus and adenovirus receptor (CAR) [126]. 
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Podocin knockout mice had podocyte FP effacement, lacked SD, and developed 
proteinuria and died a few days after birth [127]. 
 
TRPC5 or TRPC6 (transient receptor potential canonical type 5 or 6) are the 
two most extensively studied TRPC-channels in nephrotic syndrome. They 
belong to a member of a family of nonselective cation channels, regulating the 
intracellular calcium concentration in response to the activation of G-protein-
coupled receptors and receptor tyrosine kinases. Gain-of-function mutations in 
the TRPC6 gene have been identified in familial FSGS [99, 128] while no 
mutation has yet been reported for TRPC5 in patients with nephrotic syndrome. 
In acquired forms of kidney disease, gene expression of TRPC6 in patients with 
MCNS and MN was found to be significantly higher as compared to control 
patients. In vitro studies suggested that increased TRPC6 expression resulted in 
reorganization of the podocyte actin cytoskeleton and dysregulation of calcium 
influx [129, 130]. In addition, overexpression of wild-type TRPC6 was shown 
to be sufficient to cause proteinuria in mice [129]. Recent studies of the AT1R-
activated TRPC5 and TRPC6 channels delineated the antagonistic roles of 
TRPC5 and TRPC6 in the regulation of actin dynamics and cell motility in 
podocytes [100]. TRPC5 was shown to specifically activate Rac1; whereas 
TRPC6 specifically activates RhoA. 
 
CD2-associated protein (CD2AP) is an adaptor protein which binds directly to 
nephrin and podocin [101, 124] and also interacts with actin [131], actin-binding 
proteins CapZ [132], cortactin [133], and the α-actinin-modulating protein 
synaptopodin [134], thus completing the signaling pathway from SD to actin 
cytoskeleton in the podocytes. CD2AP knockout mice died due to massive 
proteinuria and exhibited FP effacement [135]. 
 
The Nck proteins (Nck1 and Nck2) composed of an SH2 domain, which can 
interact with phosphotyrosines, and SH3 domains, which can recruit proteins 
involved in the regulation of actin assembly. In podocytes, SH2 domain of Nck 
has been shown to interact with tyrosine phosphorylated nephrin following 
phosphorylation through Fyn, while the SH3 domains of Nck bind to neuronal 
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Wiskott–Aldrich syndrome protein (N-WASP) [102, 136, 137]. N-WASP, in 
turn, activates the Arp2/3 complex, thus linking nephrin with the underlying 
actin. Inactivation of Nck proteins in adult mouse podocytes led to reduced 
phosphorylation of nephrin, proteinuria, glomerulosclerosis, and FP effacement 
[138].  
 
Partitioning defective 3 (Par3), partitioning defective 6 (Par6) and atypical 
protein kinase C (aPKC) constitutes the cell polarity complex of the SD [103]. 
Binding of Par3 to nephrin and Neph1 resulting in recruitment of Par6/aPKC to 
the SD.  
 
Dendrin interacts with nephrin and CD2AP [105] and relocalization of dendrin 
to the nucleus of podocytes enhanced TGF-β1-mediated apoptosis in an 
experimental proteinuric model [139]. 
 
ZO-1 is a tight and adherens junction protein of the MAGUK family shown to 
bind with Neph1/2/3 [140] and cortactin [141] thus connecting the membrane 
proteins at the SD complex to the actin cytoskeleton.  
 
MAGI-1 and -2 serve as a platform for nephrin [108], α-actinin-4 [109] and 
synaptopodin [142]. In addition, MAGI-1 links the actin cytoskeleton to 
junctional adhesion molecule-4 (JAM4) [106, 108]. Densin, CASK, IQGAP1, 
αII- and βII-spectrin have also been reported to be associated with the SD [105, 
107, 109, 143] but their role in podocytes remains to be elucidated.  
 
1.3.3 Podocyte basal membrane domain 
The podocytes are attached to the GBM through transmembrane cell receptors, 
such as integrins, tetraspanins and dystroglycans. The predominant integrin in 
podocytes is α3β1 integrin which interacts with the laminin in GBM [144]. Mice 
with α3-knockout died neonatally due to severe abnormalities in the lung and 
kidney epithelia in which the branching of glomerular capillary loops was 
reduced and the podocytes were unable to form mature FP [145]. Conditional 
knockout of α3-chain or the β1-chain in adult mice both resulted in massive 
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proteinuria within a week, extensive FP effacement and widespread lamination 
with protrusions of the GBM [146-148].  
 
β3-chain binds to integrin-linked kinase (ILK) thus connecting the integrin to 
the cytoskeleton [149]. In addition, ILK also connects the GBM with the SD via 
interaction with nephrin, α-actinin, PINCH, and α-parvin [150, 151]. Podocyte 
specific inactivation of ILK in mice developed proteinuria, FP effacement, 
glomerulosclerosis, and died of renal failure [150, 152]. El-Aouni et al. 
observed thickening of the GBM in the mutant mice followed by abnormal 
distribution of α3-integrins [152]; while Dai et al. showed that ILK form a 
complex with nephrin and α-actinin-4, and mutation in mice resulted in 
redistribution of nephrin and α-actinin-4 [150]. Overexpression of ILK in 
podocytes induced Wnt signaling, decreased expression of CD2AP and P-
cadherin, caused podocyte detachment, proliferation [153].  
 
CD151 is a member of the tetraspanin family which interacts with α3β1 integrin 
[154, 155]. CD151 knockout mice developed proteinuria and also showed 
thickening and splitting of the GBM that preceded podocyte FP effacement 
[146]. 
 
In podocytes, dystroglycans are expressed specifically at the basal membrane 
of the FP [156, 157]. Dystroglycan is a heterodimeric transmembrane protein 
consisting of the α- and β-dystroglycan. The extracellular portion of 
dystroglycans binds to laminin and agrin of the GBM; whereas the cytoplasmic 
region of the dystroglycan is connected to the actin cytoskeleton of FP via 
utrophin. Expression of the α- and β-dystroglycan was shown to be significantly 
reduced in patients with MCNS, but normal in healthy kidneys and FSGS [156].  
 
Recently, podocyte FP basal membrane expression of uPAR was reported in 3- 
and 12-month old diabetic rats [158]. Gene expression of Plaur mRNA which 
encodes uPAR was also shown to be higher in patients with FSGS and diabetic 
nephropathy. Plaur knockout mice were protected from lipopolysaccharide 
(LPS)-induced proteinuria and the protective effect was removed after the 
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reconstitution of Plaur gene in LPS injected Plaur knockout mice. uPAR has 
many ligands [159] which includes the urokinase-type plasminogen activator 
(uPA or urokinase) [160], vitronectin [161], and ανβ3-integrin [162]. In 
podocyte cultures and murine models, uPAR was shown to cause vitronectin 
dependent ανβ3-integrin activation, followed by integrin-mediated activation of 
Rac and Cdc42, resulting in reorganization of the actin cytoskeleton and caused 
proteinuria in mice [158]. Activation of ανβ3-integrin was sufficient to induce 
proteinuria and inhibition of ανβ3-integrin activation had an anti-proteinuric 
effect. Vitronectin was also induced during proteinuria, and vitronectin 
knockout mice were protected from LPS-induced proteinuria. Another study 
identified activated nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) 
as a mediator of uPAR expression and β3-integrin activation in podocytes; and 
cyclosporine A (calcineurin inhibitors clinically used to reduce proteinuria in 
FSGS) interrupted NFATc1:uPAR:β3-integrin signaling and proteinuria [163]. 
 
1.3.4 Actin cytoskeleton of foot processes 
In healthy FP, the actin cytoskeleton is bundled in an highly ordered manner 
that run parallel to the longitudinal axis of FP whereas in effaced FP, these 
parallel actin bundles reorganize to dense network of short, branched actin 
filaments [77]. Other than the cytoplasmic proteins mentioned above that 
connect the membrane proteins from the three domains to the cytoskeleton, α-
actinin-4 and synaptopodin are two actin-associated proteins implicated to play 
an important role in regulating the actin cytoskeleton dynamics in podocytes 
FP.   
 
Mutation in the α-actinin-4 coding gene ACTN4 caused autosomal dominant 
FSGS [164]. Transgenic mice with podocyte specific mutation analogous to that 
affecting a human FSGS family developed proteinuria and had histologic 
features consistent with human ACTN4-associated FSGS [165]. The mutation 
was located to the actin-binding domain of α-actinin-4 which caused increased 
binding affinity to actin and abolished the Ca2+ regulation, resulting in FP 
effacement [166]. One study attributed the phenotype observed in the α-actinin-
4 knockout mice to the reduced adhesion of the mutant podocytes to the GBM 
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which caused shedding of podocytes into the urine resulting in kidney failure 
[167]. 
 
Synaptopodin is a proline-rich, actin-associated protein found in dendritic spine 
apparatus of neurons and podocyte FP [168]. In podocytes, synaptopodin was 
shown to bind α-actinin-4 and regulate its actin-bundling activity in which 
synaptopodin knockout podocytes lacked stress fibers [169]. Other interacting 
partners for synaptopodin include CD2AP (found near SD) [134] and MAGI-1 
(found near SD and also basal membrane domain) [142], connecting the 
signaling cascades of the SD and the basal membrane domain. In addition, 
synaptopodin was also shown to regulate RhoA signaling and cell migration in 
kidney podocytes [170]. Synaptopodin was able to compete with Smurf-1 for 
RhoA binding, thereby protecting RhoA from Smurf-1-mediated ubiquitination 
and subsequent proteasomic degradation, resulting in stress fibers formation and 
podocyte migration. Moreover, studies have shown that cyclosporine A seemed 
to have a direct anti-proteinuric effect on podocytes, by blocking the 
calcineurin-mediated dephosphorylation of synaptopodin thus protecting 
synaptopodin from cathepsin L mediated proteolysis and resulting in 
stabilization of the foot process cytoskeleton and resistance to proteinuria [171]. 
 
1.4. Role of IL-13 in nephrotic syndrome  
IL-13 is an important immunoregulatory protein produced by T-cells and 
dendritic cells [172].  It is a 12kDa protein consisting of 132 amino acids.  The 
human IL-13 gene is located on chromosome 5q31, in the same cluster of genes 
encoding IL-3, IL-4, IL-5, IL-9 and granulocyte-monocyte colony stimulating 
factor (GM-CSF) [173].  The receptor for IL-13 is a heterodimer of IL-13 
receptor α1 chain (IL-13Rα1) and IL-4 receptor α chain (IL-4Rα). IL-13 first 
binds to IL-13Rα1 with moderate affinity, followed by subsequent recruitment 
of IL-4Rα which helps to increase the binding affinity for IL-13 and stabilize 
this high affinity interaction [174, 175]. IL-13 receptor α2 chain (IL-13Rα2) is 
another IL-13R which has a higher binding affinity for IL-13 compared to IL-
13Rα1 [176]. IL-13Rα2 is traditionally considered a decoy receptor that 
regulates IL-13 response [177, 178].  However, recent studies suggested that IL-
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13Rα2 may have a role in signaling. IL-13 was shown to upregulate TGF-β in 
macrophages in an IL-13Rα2-dependent manner. Gene silencing of IL-13Rα2 
led to downregulation of TGF-β production [179].  Another study showed that 
IL-13Rα2 was involved in the immune evasion of tumour in mice [180]. 
 
IL-13 receptors are expressed on human B cells, basophils, eosinophils, mast 
cells, endothelial cells, fibroblasts, monocytes, macrophages, respiratory 
epithelial cells, and smooth muscle cells [181]. However, unlike IL-4, it fails to 
activate T cells since IL-13 receptors are virtually absent on T lymphocytes 
[182, 183]. IL-13 acts through its receptors on the cell surface, activating 
predominately the JAK/STAT pathway [181, 184, 185].  The cytoplasmic 
domains of IL-4Rα/IL-13Rα1 complex interact with tyrosine kinases (Tyk) of 
the Janus kinase (JAK) family. In non-hematopoietic cells, JAK2 is 
phosphorylated and activated instead of JAK3; while in hematopoietic cells, 
JAK3 is required for signal transducer and activator of transcription-6 (STAT6) 
[186]. Phosphorylation of Tyk leads to the recruitment and tyrosine 
phosphorylation of STAT6. Phosphorylated STAT6 migrates into the nucleus 
and binds to consensus sequences in the promoter regions of genes regulated by 
IL-4 and IL-13. Transcription factors c-fos, c-jun, and c-myc have been shown 
to be upregulated by IL-13 [187]. 
 
IL-13 exerts diverse functions on different cell types. It promotes B-cell 
proliferation and immunoglobulin isotype switching to IgE in combination with 
CD40/CD40 ligand costimulation [188]. It also promotes eosinophil survival, 
activation, and recruitment [189-191] activates mast cells and hence contributes 
to IgE priming of mast cells [192].  
 
IL-13 also has important functions on non-hematopoietic cells. It induces 
vascular cell adhesion molecule 1 expression in endothelial cells [193];  
enhances proliferation and cholinergic-induced contractions of smooth muscle 
cells [194]; induces chemokines expression in epithelial cells [195], changes 
mucociliary differentiation and decreases ciliary beat frequency of ciliated 




1.4.1 IL-13 as a modulator of monocyte function 
IL-13 is known to be an important modulator of monocyte function. It has been 
shown to induce significant changes in the phenotype and morphology of 
monocytes. It enhances the expression of CD11b, CD11c, CD18, CD29, MHC 
Class II and CD23 [183, 192], whereas it down-regulates the expression of 
CD64, CD16, CD32 and CD14 in a dose-dependent manner [200, 201]. IL-13 
has also been shown to exert its anti-inflammatory activities by inhibiting the 
production of pro-inflammatory cytokines, like IL-12, IL-8, IL-6, TNF-α, IL-
1α and IL-1β, by LPS-activated monocytes [192, 201] and upregulation of anti-
inflammatory molecules like interleukin 1 receptor antagonist (IL-1RA) [202]. 
This may account for the observation that children in nephrotic relapse are more 
susceptible to bacterial infections.  
 
Our laboratory has demonstrated that IL-13 downregulates proinflammatory 
cytokines, IL-8 and TNF-α in LPS-stimulated monocytes from patients with 
MCNS during nephrotic relapses as compared to remission and normal controls 
[203]. This was associated with decreased expression of CD14 and other 
monocyte surface markers, as well as soluble CD14. These results point to a 
major anti-inflammatory effect of IL-13 on monocytes which may place a 
crucial role in the pathogenesis of MCNS. 
 
1.4.2 Role of monocyte/macrophage in nephrotic syndrome 
The function of the monocyte-macrophage system in the pathogenesis of 
nephrotic syndrome has also been evaluated, considering that MCNS is a result 
of a primary immune disturbance, and the irrefutable role of monocytes in the 
host immune system.  
 
Monocytes from SRNS patients with proteinuria were shown to have enhanced 
phagocytosis of opsonized particles and suppressed chemotaxis which might be 
due to the alteration of the monocyte surface receptors and lymphokines [204]. 
In addition, depressed function of Fc-receptors of monocytes and macrophages 




Garin et al. have identified a supernatant factor that caused a significant increase 
in sulfate uptake in rat GBM and they showed that both lymphocytes and 
monocytes were needed for the production of that supernatant factor [206]. 
 
Using reporter podocytes, Takano, Y, et al. showed that bystander macrophages 
and macrophage-derived cytokines IL-1β and TNF-α significantly suppressed 
activity of the nephrin gene promoter in podocytes. The reduced nephrin 
promoter activity was attributed to the activation of the phosphatidylinositol-3-
kinase/Akt pathway [207]. 
  
Whether monocyte deficiency or activation found in MCNS is primary or 
secondary to the postulated T-cell defect in this disease remains to be elucidated.  
 
1.5. Role of IL-13 on podocytes  
As mentioned previously, MCNS is primarily caused by immune disturbance 
characterized by Th2 cytokine bias. However, the mechanism by which this 
observed cytokine imbalance in serum results in subsequent characteristic 
podocyte injury in MCNS is still unknown. Studies have shown that podocytes 
constitutively express functional receptors for cytokines IL-1 [208, 209], IL-4, 
IL-13 [210, 211], IL-10 [210] and TNF-α [212, 213], suggesting that cytokines 
could act directly on podocytes to cause injury. Studies have demonstrated that 
IL-4 and IL-13 increase transcellular ion transport in rat podocyte monolayer 
cultures [211]. Further work revealed that IL-4 and IL-13 induced H+ transport 
in podocytes, thus lowering the pH and affecting the integrity of basal 
membrane matrix by activating the proteolytic enzyme, cathepsin L [214]. 
 
In our experimental rat model of Th2 cytokine-induced MCNS, we have 
demonstrated that overexpression of IL-13 gene resulted in podocyte injury with 
downregulation of nephrin, podocin and dystroglycan and concurrent 
upregulation of B7-1 in the glomeruli [215, 216]. In this experimental model, 
we have demonstrated increased glomerular IL-4Rα and IL-13Rα2 gene 
expression, as well as increased fluorescent signal for IL-4Rα in most of the 
 21 
 
glomeruli of nephrotic rats, suggesting that IL-13 may act directly on podocytes 
in the glomeruli. In addition, there was a significant correlation between serum 
IL-13 levels and B7-1 expression in the glomeruli of the IL-13 overexpressed 
rats with nephrotic syndrome. The concomitant upregulation of B7-1 expression 
in the glomeruli following IL-13 overexpression suggests a possible pathogenic 
link between IL-13 and podocyte dysfunction. 
 
Studies have suggested a novel role for the costimulatory molecule B7-1 in 
podocytes as an inducible modifier of glomerular permselectivity and 
proteinuria [217, 218]. Podocyte-specific expression of B7-1 has been 
implicated as the final common pathway in the genesis of proteinuria in 
glomerulopathies. In genetic, drug-induced, autoimmune, and bacterial toxin-
induced experimental kidney diseases with nephrotic syndrome, B7-1 
expression in podocytes was upregulated. Following in vitro LPS stimulation, 
podocyte expression of B7-1 was increased with concurrent actin cytoskeleton 
reorganization. B7-1 knockout mice were protected from LPS-induced 
proteinuria, suggesting a functional link between podocyte B7-1 expression and 
proteinuria. Specific urinary CD80 (B7-1) excretion was reported in MCNS 
patients in relapse which was not observed in other glomerular diseases [219, 
220]. In addition, renal biopsy results showed high expression of CD80 in 
glomeruli of MCNS patients in relapse but not MCNS patients in remission or 
FSGS patients. CD80 expression was shown to be co-localized with podocin 
expression in the glomeruli from an MCNS patient in relapse. 
 
1.6. Gaps in current knowledge 
Despite recent advances in our understanding of podocyte biology, we do not 
know the exact pathogenesis of MCNS or why some children require long term 
steroid therapy or even cytotoxic drugs while some do not. There is a large body 
of evidence that immunogenic stimuli interacting with immunoregulatory 
proteins, form the basis for the immunopathogenesis of MCNS. We have 
demonstrated increased T-cell production of IL-13 in MCNS patients in relapse 
[58] as well as downregulation of proinflammatory cytokines, IL-8 and TNF-α 
in LPS-stimulated monocytes from patients with MCNS during nephrotic 
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relapses compared to remission and normal controls [203]. This was associated 
with decreased expression of CD14 and other monocyte surface markers, as 
well as soluble CD14. These results point to a major anti-inflammatory effect 
of IL-13 on monocytes. Whether IL-13-induced monokines acts directly on the 
podocytes to cause foot process loss or activate another cascade of enzymes or 
cytokines to mediate proteinuria remains to be elucidated. 
 
Current research by several groups worldwide has been focusing on the 
mechanism by which disruption in podocyte architecture results in podocyte FP 
effacement and proteinuria. As mentioned above, recent studies have suggested 
a novel role for the costimulatory molecule B7-1 in podocytes as an inducible 
modifier of glomerular permselectivity and proteinuria. Stimulation by LPS 
reorganized the podocyte actin cytoskeleton in vitro, and activation of B7-1 in 
cultured podocytes led to reorganization of vital slit diaphragm proteins [217, 
218].  In fact, increased B7-1 expression on podocytes has been described in the 
different models of nephrotic syndrome, namely genetic (α3β1-integrin 
deficiency), toxic (puromycin and adriamycin-induced) and immunological 
(murine lupus nephritis). Therefore, our results from the IL-13 overexpression 
rat model further strengthen the hypothesis that transient upregulation of B7-1 
could occur in MCNS, resulting in nephrotic-range proteinuria [215, 216], and 
also provide an explanation for the possible link between Th2 cytokine bias and 
MCNS. However, the exact mechanism by which IL-13 interacts with the B7-1 
danger signaling pathway remains an enigma. 
 
1.7. Research hypothesis and scope of thesis 
Our current understanding of the pathogenic mechanism of nephrotic syndrome 
suggests that the podocyte is the main component of the glomerular filter and 
the crucial target in the development and progression of glomerulopathies. In 
fact, the hallmark of nephrotic syndrome is effacement of podocyte foot 
processes (FP) seen on electron microscopy.  
 
Studies attempting to elucidate the underlying pathogenesis of MCNS have 
suggested a Th2 cytokine bias. Our group has previously demonstrated that IL-
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13 gene expression was upregulated in CD4+ and CD8+ T-cells of children with 
MCNS in relapse as well as downregulation of proinflammatory cytokines, IL-
8 and TNF-α in LPS-stimulated monocytes from patients with MCNS during 
nephrotic relapses compared to remission and normal controls. We have, in 
addition, shown that IL-13 overexpression in the rat resulted in podocyte injury 
with downregulation of the slit diaphragm proteins, namely nephrin and 
podocin, with upregulation of glomerular B7-1, inducing a minimal change-like 
nephropathy. In this model, we have also demonstrated increased glomerular 
IL-4Rα and IL-13Rα2 gene expression, as well as increased fluorescent signal 
for IL-4Rα in most of the glomerular podocytes of nephrotic rats, suggesting 
that IL-13 may act directly on podocytes in the glomeruli through a possible 
B7-1 mechanism.  In our preliminary studies, we have also shown that 
glomerular gene expression of toll-like receptor-4 (TLR-4) was significantly 
elevated in the IL-13 overexpressed rats, and also correlated significantly with 
glomerular B7-1 expression.  
 
Therefore, we hypothesize that modulation of podocyte actin cytoskeleton in 
MCNS may possibly be a consequent summative effect of immune mediators 
on podocyte B7-1 expression (Figure 5), namely: 
i) direct IL-13 stimulation; 
ii) indirect signaling by other immune mediators through other ligands or 
receptors such as TLR-4. 
As IL-13 is an important modulator of monocyte/macrophage function, it is 
plausible that the indirect action of IL-13 on podocytes may be mediated via 
monocyte/macrophage polarization with consequent secretion of monokine(s) 





Figure 5: Hypothetical Th2 cytokine bias model of MCNS results from a primary immune 
disturbance.  
IL-13 and/or other immune mediators may directly or indirectly act on podocytes and cause 
podocyte FP effacement, resulting in proteinuria and the nephrotic syndrome. 
 
1.7.1 Objectives of the study 
The primary aim of this project is to investigate the molecular mechanisms by 
which IL-13 downregulates the expression of podocyte-specific proteins 
resulting in proteinuria. The specific objectives are as follows: 
A. In vivo rat model:  
1 To characterize the molecular events in the glomeruli of the IL-13 rat 
model of MCNS using cDNA microarray and identifying differentially 
expressed genes (DEGs) induced by IL-13.   
2 To determine the mechanistic link between IL-13 and B7-1 signaling in 
the rat model using pathway analysis tools. 
3 To validate the microarray results both at the gene transcription level, 
using real-time PCR; and at the protein expression level, using 
immunohistochemistry staining.   
B. In vitro human podocyte cell culture: 
1 To set up a human podocyte cell culture system (gift by Professor Moin 
A. Saleem, University of Bristol) to validate the microarray glomerular 
gene expression results from the in vivo rat model.  




a) Quantitate the expression levels of IL-13 receptor subunits, B7-1, 
CTLA-4, TLR-4 and SD proteins, in particular, nephrin, podocin and 
dystroglycan at both gene transcription (real-time PCR) and protein 
level (Western blotting); 
b) Examine podocyte morphology, in particular, cytoskeletal changes 
associated with FP effacement using phalloidin staining and viewing 
with confocal microscopy. 
c) Measure RhoA/Rac1 activity levels in association with IL-13 induced 
podocyte actin cytoskeleton rearrangement. 
3 To perform functional study using podocytes transfected with siRNA 
specific to the selected DEGs, to delineate the mechanistic link of IL-13 
mediated podocyte injury downstream of B7-1 activation. The markers 
for podocyte injury used in this functional assay are stated in 2a, b and 
c. 
 
Knowledge of the signaling pathways involved in the pathogenesis of this 
disease may provide us more targeted treatment at the molecular level, allowing 
us to design new therapeutic strategies. Results of this proposed study should 
thus have an important impact on healthcare costs as nephrotic syndrome is one 
of the more important kidney disorders in childhood, as well as an important 








MATERIALS & METHODS 
2.1. IL-13 overexpression rat model of MCNS  
All animal studies were approved by the Institutional Animal Care and Use 
Committee of the National University of Singapore. Induction of frank 
nephrotic in rats has been reported before [216]. Six-week-old female Wistar 
rats weighing 150-180g were used in this study. Rats were put in metabolic 
cages 24 hours prior to the electroporation to collect 24-hour urine sample and 
the volume of urine was recorded. Before the electroporation, heparinized blood 
was collected from the ventral artery of the tail using a 23G needle. Rats were 
electroporated every 10 days over a period of 72 days with endotoxin-free, 
purified plasmid DNA injected into the quadriceps of rats. An electric current 
consisting 6 pulses of 20 milliseconds each at 160V was generated using the 
“Electro Square Porator ECM830” (BTX Technologies Inc, NY, USA) and 
delivered through the 10mm 2-Needle Array™ tip (BTX Technologies Inc, NY, 
USA) connected to a 2-Needle Array™ electrode (BTX Technologies Inc, NY, 
USA) [221]. Control rats received 200µg of the pCI (Promega, WI, USA) 
mammalian expression vector and test rats received 200µg of the pCI 
mammalian expression vector cloned with the rat IL-13 gene. Once proteinuria 
develops, the rats were euthanised by overdose of anaesthetic (ketamine 
75mg/kg and xylazine 10mg/kg) via intra-peritoneal injection. Heparinized 
blood was collected via cardiac puncture and kidney cortical tissue was 
harvested for isolation of glomeruli as well as snap-frozen and stored at –80oC 
for further use. Both blood and urine were centrifuged at 3,000rpm for 10 
minutes to obtain plasma and remove sediment respectively. Plasma levels of 
albumin, cholesterol, creatinine and IL-13, and urine albumin concentration 
were measured serially to ensure successful induction of frank nephrosis in rats. 
 
2.2. Plasma IL-13 ELISA  
Plasma level of IL-13 was measured using commercially available Enzyme 
Linked Immuno Sorbent Assay (ELISA) kit (Invitrogen, CA, USA) according 
to the manufacturer’s instructions. Briefly, 50μl of samples, IL-13 standards and 
positive controls were added to the wells, followed by 150μl of a biotinylated 
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secondary monoclonal antibody. Plasma from the IL-13 overexpression rats was 
diluted five times, while the control plasma was used undiluted. After two hours 
incubation, the wells were washed with wash buffer provided to remove excess 
biotinylated antibody. Following 30 minutes incubation with 100μl of 
streptavidin-peroxidase, the wells were washed to remove unbound enzyme and 
100μl of stabilized chromogen (substrate) was added to produce colour signal 
in proportion to the amount of IL-13 bound. The colour development was 
stopped by adding 100μl of stop solution and the intensity of the colour was 
measured using a microplate reader (Bio-Rad Laboratories, Inc, CA, USA) with 
wavelength set at 450 nm. The concentrations of IL-13 in the samples were 
determined from the standard curve, factoring in the dilution. 
 
2.3. Plasma albumin quantification 
Plasma albumin level was determined by bromocresol green (BCG) method 
using a commercial reagent kit (Randox Laboratories, Antrim, UK). Briefly, 5μl 
of samples and standard were added to 1.5ml of BCG reagent and incubated for 
5 minutes at room temperature. Two hundred μl of the reaction mixture was 
transferred to the microtiter plate in duplicate and the absorbance of the reaction 
mixtures was read at 600nm using a microplate reader (Bio-Rad Laboratories, 
Inc, CA, USA) against the reagent blank consisting of 0.9% w/v NaCl in 
distilled water. Concentration of albumin in the sample was calculated by 
multiplying the absorbance ratio of the sample (Asample) and the standard 
(Astandard) with the concentration of the standard provided by the manufacturer 
( Asample
Astandard
×	concentration of standard). 
 
2.4. Plasma cholesterol quantification 
Plasma cholesterol level was determined by an enzymatic endpoint method 
[222] using a commercial reagent kit (Randox Laboratories, Antrim, UK). 
Briefly, 10μl of the samples and standard were added to 1ml of the reagent 
provided and incubated for 10 minutes at room temperature. Two hundred μl of 
the reaction mixture was transferred to the microtiter plate in duplicate and the 
absorbance of the reaction mixtures was read at 500nm using a microplate 
reader (Bio-Rad Laboratories, Inc, CA, USA) against the reagent blank 
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consisting of 0.9% w/v NaCl in distilled water. Concentration of cholesterol in 
the sample was calculated by multiplying the absorbance ratio of the sample 
(Asample) and the standard (Astandard) with the concentration of the standard 
provided by the manufacturer ( Asample
Astandard
×	concentration of standard). 
 
2.5. Plasma creatinine quantification 
Plasma creatinine was determined by the alkaline picrate method [223]. Briefly, 
100μl of samples and standards were added to a mixture containing 100μl of 
ddH2O, 100μl of 5% w/v sodium tungstate in distilled water and 100μl of 2/3N 
sulphuric acid and incubated for 10 minutes at room temperature. The mixture 
was then centrifuged at 6,000rpm for 2 minutes. One hundred μl of the 
supernatant was transferred to the microtiter plate in duplicate. Following 20 
minutes incubation with 20μl of saturated aqueous picric acid and 30μl of 1N 
NaOH for colour development, the absorbance of the reaction mixtures was read 
at 490nm using a microplate reader (Bio-Rad Laboratories, Inc, CA, USA). The 
concentrations of creatinine in the samples were determined from the standard 
curve. 
 
2.6. Urine albumin ELISA  
A direct sandwich ELISA was developed [224] to detect the concentration of 
rat albumin in 24-hour urine samples. One hundred μl of rabbit antiserum to rat 
albumin antibody (MP Biomedicals, CA, USA) diluted 1/2000 was used as the 
coating antibody and 50μl of horseradish peroxidase (HRP)-conjugated sheep 
polyclonal antibody to rat albumin secondary antibody (MP Biomedicals, CA, 
USA) diluted 1/20000 was used as the detecting antibody. o-
Diphenylenediamine (OPD) (MP Biomedicals, CA, USA), in citrate buffer pH 
5.0, was used as the substrate for colour development. Rat albumin standards 
(MP Biomedicals, CA, USA) of known concentrations were included in each 
assay. Endpoint absorbance was read at 490nm by a microplate reader (Bio-Rad 
Laboratories, Inc, CA, USA). The total amount of albumin excreted in 24-hour 
urine was calculated by multiplying the concentration of albumin (mg/ml) with 




2.7. Isolation of glomeruli by graded sieving technique  
Glomeruli were isolated from kidney cortical tissue using graded sieving 
technique [225]. The cortical area of the kidney was cut into small pieces and 
pressed through a stainless steel sieve (W.S. TYLER Industrial Group, OH, 
USA) with a sieve diameter of 75μm with a spatula. The tissue was rinsed off 
with ice-cold 1x Hank’s balanced salt solution (HBSS) (Gibco®, Invitrogen Life 
Technologies, CA, USA) to a petri dish placed underneath the sieve. The filtrate 
collected was then passed through a 70μm nylon sieve (Falcon™, BD 
Biosciences, CA, USA) and the filtrate was collected in a 50ml collection tube. 
Glomeruli and large tubular tissue fragments were retained on the nylon sieve 
while red blood cells (RBC) and smaller tissue fragments passed through. The 
70μm nylon sieve was then inverted onto a new 50ml collection tube and the 
glomeruli washed down to the collection tube with 1x HBSS. Glomeruli 
obtained from the graded sieving technique were usually over 95% pure with 
minimal contamination from tubular epithelial cells. 
 
2.8. RNA extraction using TRIzol® reagent 
Total RNA was extracted by TRIzol® reagent (Invitrogen Life Technologies, 
CA, USA). Tissue or cells were lysed in 1ml of TRIzol® reagent and incubated 
for 5 minutes at room temperature for complete dissociation of nucleoprotein 
complexes. Two hundred μl of chloroform (Fisher Scientific, MA, USA) was 
then added per 1ml of TRIzol® reagent and the mixture was shaken vigorously 
for 15 seconds and incubated at room temperature for 3 minutes. The samples 
were then centrifuged at 12000g for 15 minutes at 4oC. Following 
centrifugation, the mixture separated into a lower red, phenol-chloroform phase, 
an interphase, and a colorless upper aqueous phase. RNA remained in the 
aqueous phase. The aqueous phase was transferred to a clean tube and 500μl of 
isopropanol (Fisher Scientific, MA, USA) was added per 1ml of initial TRIzol® 
reagent to precipitate the RNA. Samples were incubated at room temperature 
for 10 minutes and centrifuged at 12000g for 10 minutes at 4oC. The RNA pellet 
was then washed once with 1ml of 75% ethanol (Merck, NJ, USA) per 1ml of 
initial TRIzol® reagent and centrifuged at 7500g for 5 minutes at 4oC. The RNA 
pellet was then air dried briefly and dissolved with RNase-free water. 
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Concentration of RNA was measured using NanoDrop 1000 Spectrophotometer 
(NanoDrop products, Thermo Scientific, DE, USA). 
 
2.9. RNA cleanup using RNeasy Mini-kit  
Glomerular RNA for microarray was further purified using RNeasy Mini-kit 
(QIAGEN GmbH, Hilden, Germany) according to the manufacturer’s 
instructions. (Appendix 2.2)  
 
2.10. Quantification and quality analysis of RNA using Bioanalyzer 6000 
Nano kit (for microarray) 
The integrity of the total glomerular RNA was analysed by measuring the ratio 
of 28s/18s and the RIN number. The samples were processed using the 
Bioanalyzer 6000 Nano kit (Agilent Technologies, Inc, Waldbronn, Germany) 
and analysed using the Bioanalyzer 2100 (Agilent Technologies, Inc, 
Waldbronn, Germany). Briefly, RNA samples with concentration ranging from 
25 to 500ng/μl were used. For gel preparation, 550μl of RNA 6000 Nano gel 
matrix was added into a spin filter and centrifuged at 1,500g for 10 minutes at 
room temperature. Sixty five μl of filtered gel was then aliquoted to 0.5ml 
RNase-free microcentrifuge tube. For gel-dye mix preparation, 1μl of the RNA 
6000 Nano dye concentrated was added to the 65μl aliquot of filtered gel, mixed 
by vortexing and centrifuged at 13,000g for 10 minutes at room temperature. 
Loading of the gel-dye mixture was done on the chip priming station by adding 
9μl of gel-dye mix in the well mark , plunging the syringe in 1ml volume, 
waiting for exactly 30s before releasing the clip and pulling back the plunger 
back to the 1ml position. This is followed by adding 9μl of gel-dye mix in the 
well marked . Five μl of RNA 6000 Nano marker was then added to all the 
sample wells as well as the ladder well marked . The reaction mix was 
completed by adding 1μl of prepared ladder in the well marked  and 1μl of 
sample in the sample wells. The mixture was vortexed by placing the chip on 
the IKA vortexer for 1 minute at 2,400rpm and the chip was read using Agilent 




2.11. Reverse Transcription to Synthesize First Strand cDNA using 
Illumina® TotalPrep RNA Amplification Kit (for microarray) 
Glomerular RNA sample was diluted to 300ng in final volume of 11ul with 
nuclease free water. Reverse Transcription Master Mix, consisting of 1μl of T7 
Oligo (dT) primer, 2μl of 10x First Strand Buffer, 4μl of dNTP Mix, 1μl of 
RNase Inhibitor and 1μl of ArrayScript per reaction, was added to the RNA 
sample. The reactions were run at 42oC for 2 hours followed by cooling at 4oC. 
 
2.12. Second strand cDNA sysnthesis using Illumina® TotalPrep RNA 
Amplification Kit (for microarray) 
Second Strand Master Mix, consisting of 63μl of nuclease free water, 10μl of 
10x Second Strand Buffer, 4μl of dNTP mix, 2μl of DNA polymerase and 1μl 
of RNase H per reaction, was added to the first strand cDNA sample. The 
reactions were run at 16oC for 2 hours followed by cooling at 4oC (for less than 
1 hour). The reactions should proceed to cDNA purification immediately or 
store at -20oC. 
 
2.13. cDNA Purification using Illumina® TotalPrep RNA Amplification 
Kit (for microarray) 
The cDNA was transferred into a 1.5ml microcentrifuge tube containing 250μl 
of cDNA binding buffer. The mixture was then transferred to a cDNA filter 
cartridge and centrifuged at 10,000g for 1 minute. This was followed by 
washing with 500μl of wash buffer and centrifuged at 10,000g for 1 minute. The 
filter cartridge was then transferred to a cDNA elution tube. The cDNA was 
eluted in two steps, first with 10μl of nuclease free water (pre-heated to 55oC), 
incubated at room temperature for 2 minutes and centrifuged at 10,000g for 1.5 
minutes, followed by another 9μl of nuclease free water (pre-heated to 55oC), 
centrifuged at 10,000g for 2 minutes and collected in the same collection tube. 
 
2.14. cRNA synthesis using Illumina® TotalPrep RNA Amplification Kit 
(for microarray) 
In Vitro Transcription Master mix, consisting of 2.5μl of T7 10x Reaction 
buffer, 2.5μl of T7 Enzyme Mix and 2.5μl of Biotin-16-UTP per reaction, was 
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added to the cDNA sample. The reaction was run at 37oC for 14 hours and then 
stopped by adding 75μl of nuclease free water to bring to final volume of 100μl. 
 
2.15. cRNA purification using Illumina® TotalPrep RNA Amplification 
Kit (for microarray) 
The cRNA was transferred into a 1.5ml microcentrifuge tube containing 350μl 
of cRNA binding buffer followed by 250μl of absolute ethanol. The mixture 
was then transferred to a cRNA filter cartridge and centrifuged at 10,000g for 1 
minute. This was followed by washing with 650μl of wash buffer and 
centrifuged at 10,000g for 1 minute. The filter cartridge was then transferred to 
a cRNA elution tube. The cRNA was eluted in two steps, first with 50μl of 
nuclease free water (pre-heated to 55oC), incubated at room temperature for 2 
minutes and centrifuged at 10,000g for 1.5 minutes, followed by another 30μl 
of nuclease free water (pre-heated to 55oC), centrifuged at 10,000g for 1.5 
minutes and collected in the same collection tube. The concentration of the 
cRNA was measured using NanoDrop 1000 Spectrophotometer (NanoDrop 
products, Thermo Scientific, DE, USA). Samples with concentration less than 
150ng/μl was concentrated by vacuum centrifugation. 
 
2.16. cRNA hybridization and array scanning 
Hybridization of 750ng of cRNAs was carried out for 18.5 hours on Sentrix® 
BeadChip Array RatRef-12 v1 (Illumina®, CA, USA) according to the 
manufacturer’s protocol. Array washing was performed followed by staining 
and scanning with BeadArray Reader (Illumina®, San Diego, CA, USA) using 
scan factor 1.5, PMT 531. (Appendix 2.3) 
 
2.17. Microarray analysis 
The raw intensity values of the array were extracted with background 
subtraction via BeadStudio (Illumina®, CA, USA) for analysis. The raw data 
was preprocessed to correct unreliable intensities for each array. The intensities 
with detection p-values greater than 0.05 were considered as unreliable and 
replaced by the intensity with detection p-value equal to 0.05. The preprocessed 
data was normalized by the Cross-Correlation method [226]. Differentially 
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expressed genes (DEGs) were selected based on the criteria of fold change 
greater than 1.6, coefficient of variance less than 0.7 and t-test p<0.05. 
Clustering of samples was generated with Cluster and TreeView software [227]. 
Gene ontology (GO) analysis was done using DAVID [228, 229] and pathway 
analysis were carried out using Ingenuity Pathway Analysis (Ingenuity, CA, 
USA) and MetaCoreTM (GeneGo Inc, MI, USA). 
 
2.18. Real-time PCR  
Single-stranded cDNA was synthesized from 150ng of total RNA using the 
Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen Life 
Technologies, CA, USA), according to the manufacturer’s instructions 
(Appendix 2.4). Quantitative real-time PCR was performed using the 
LightCycler® 480 SYBR Green I Master (Roche, Germany). Briefly, the real-
time PCR was performed in a final volume of 10µl reaction mixture containing 
1µM each of the primers, 5µl of master mix, 1µl of PCR grade water and 2µl of 
cDNA. The thermal cycling conditions consisted of one cycle of 10 minutes at 
95ºC, 45 cycles of 5 seconds at 95ºC, 10 seconds at 58ºC, and 20 seconds at 
72ºC, followed by melting curve analysis and cooling to 40ºC. Standard curves 
were created for each PCR run using serial dilutions of plasmid standards that 
were cloned with the PCR products generated by their respective primers 
(Appendix 2.5). All samples were run in duplicates and copy number for each 
sample was determined from the respective standard curve. Results were 
expressed as an index of the housekeeping gene GAPDH. 
 
2.19. Protein expression study using immunohistochemical technique 
Formalin-fixed, paraffin-embedded kidney tissue was used for detection of vav1 
in the glomeruli using LSAB2 system-HRP (DakoCytomation, Glostrup, 
Denmark). The tissue sections were dewaxed and rehydrated through alcohol 
by going through incubation with two changes of xylene (J.T. Baker® 
Chemicals, Avantor Performance Materials, PA, USA) for 10 minutes each, two 
changes of absolute ethanol (Merck, NJ, USA) for 2 minutes each, followed by 
95% ethanol for 2 minutes and 70% ethanol for 2 minutes. The sections were 
then washed with tap water and incubated with peroxidase for 5 minutes. 
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Following avidin and biotin (DakoCytomation, Glostrup, Denmark) activity 
blocking for 10 minutes each, as well as antigen retrieval with proteinase K 
(DakoCytomation, Glostrup, Denmark) for 5 minutes, sections were 
sequentially incubated with rabbit anti-vav1 (1/50) (Bioworld Technology, Inc, 
MN, USA or Sigma-Aldrich, MO, USA), or mouse anti-synaptopodin (neat) 
(USBiological, MA, USA) primary antibody for 10 minutes, biotinylated goat 
anti-rabbit IgG for 10 minutes, and Streptavidin-HRP for 10 minutes. Staining 
was completed after incubation with 3-3’ diaminobenzine (DAB) Substrate-
Chromogen which produced brown colour precipitation at the antigen site. 
Nuclei were counterstained using Mayer’s hemalum (Merck, NJ, USA) for 1 
minute and blued in 0.05% aqueous ammonia solution (Merck, NJ, USA) for 1 
minute. The sections were dehydrated and cleared by going through incubation 
with 70% ethanol for 1 minute, 95% ethanol for 1 minute, two changes of 
absolute ethanol for 1 minute each and two changes of xylene for 2 minutes 
each. The sections were then mounted with cover slip using DEPEX mounting 
medium (BDH Chemicals, VWR, PA, USA). 
 
2.20. Protein expression study using Western blotting technique 
Protein lysate of 40ug were separated using 12% sodium dodecyl sulfate (SDS)-
polyacrylamide gel and transferred onto a polyvinylidene fluoride (PVDF) 
membrane. Membrane was blocked with 5% non-fat milk for 1 hour and probed 
with the following primary antibodies: rabbit anti-GAPDH (1/10,000) (Sigma-
Aldrich, MO, USA); rabbit anti-vav1 (phospho Y174) (1/2,000) (Bioworld 
Technology, Inc, MN, USA); rabbit anti-vav1 (1/800) (Proteintech Group, Inc, 
IL, USA); rabbit anti-B7-1 (1/3,000) (Epitomics, Inc, CA, USA); and rabbit 
anti-IL-13Rα2 (1/1000) (Proteintech Group, Inc, IL, USA). Following 
incubation with donkey anti-rabbit IgG HRP-conjugated secondary antibodies 
(Santa Cruz Biotechnology, CA, USA), blots were developed using Lumina 
Forte Western HRP Substrate (Merck Millipore, MA, USA) and quantified 




2.21. Culture of human podocytes 
Conditionally immortalized human podocytes (kind gift from Dr. Moin Saleem, 
University of Bristol, UK) [230, 231] were cultured on 100mm type I collagen-
coated petri dishes (Iwaki, Japan) in complete medium consisting of RPMI 1640 
with L-glutamine (Gibco®, Invitrogen Life Technologies, CA, USA), 10% heat-
inactivated Fetal Bovine Serum (Gibco®, Invitrogen Life Technologies, CA, 
USA), 100units/ml Penicillin/Streptomycin solution (Gibco®, Invitrogen Life 
Technologies, CA, USA), ITS cocktail (Sigma-Aldrich, MO, USA) of 10μg/ml 
insulin, 5.5μg/ml of transferrin and 5ng/ml of sodium selenium.  The cells were 
grown at a permissive temperature of 33ºC with 5% CO2. Complete medium 
was changed every two days and cells were observed everyday under the light 
microscope. Upon achieving 90% confluency, the cells were thermoshifted to 
37ºC for differentiation. 
 
Briefly, the culture medium was removed and the culture dishes were washed 
twice with 1xPBS. The cells were then incubated with 1ml of 0.25% of trypsin-
ethylenediaminetetraacetic acid (trypsin-EDTA) solution at 37ºC for 3 minutes. 
Trypsin-EDTA activity was stopped by adding 10ml of complete medium. Cells 
were splited 1/5 and seeded to new petri dishes at a non-permissive temperature 
of 37ºC with 5% CO2  for up to 14 days to allow for differentiation. Fully 
differentiated cells were stimulated with IL-13 (20ng/ml) (R&D Systems, MN, 
USA) for 1 to 48 hours. Unstimulated cells were included as the baseline 
control. Changes in gene expression were assessed using real-time PCR; 
changes in protein expression were analysed using Western blotting; and 
changes in the organization of the actin cytoskeleton were observed after 
phalloidin staining. 
 
2.22. Transfection of human podocytes with sequence specific siRNA 
Differentiated cells were transfected with siRNA specific for vav1 (target 
sequence: 5’-CAGGTGGAGTCAGCCAGCAAA-3’; sense strand: 5’-
GGUGGAGUCAGCCAGCAAATT-3’; antisense strand: 5’-
UUUGCUGGCUGACUCCACCTG-3’) (QIAGEN GmbH, Hilden, Germany). 




Briefly, conditionally immortalized human podocytes were cultured at 33oC and 
shifted to 37oC for differentiation for 10 to 14 days. Sequence specific siRNA 
was diluted in serum-free culture medium to final concentration of 6nM before 
adding 4% (v/v) transfection reagent (INTERFERin™, polyplus transfection, 
NY, USA). The transfection cocktail was incubated at room temperature for 10 
minutes to allow complex formation and then added dropwise to fully 
differentiated cells. Cells were then incubated at 37ºC with 5% CO2 for 24 hours 
before stimulation with 20ng/ml of IL-13 for 24 (for RNA analysis) or 48 hours 
(for protein analysis). 
 
2.23. Immunofluorescence staining of podocytes 
Cells were cultured on collagen-coated coverslips (Iwaki, Japan), fixed with 4% 
paraformaldehyde (Merck, NJ, USA) for 10 minutes, permeabilized with 0.3% 
w/v Triton-X100 (Bio-Rad Laboratories, Inc, CA, USA) in 1xPBS for 3 
minutes, and blocked with 5% w/v BSA (Sigma-Aldrich, MO, USA) in 1xPBS 
for 30 minutes. Cells were stained with following antibodies: rabbit anti-vav1 
(1/50) (Sigma-Aldrich, MO, USA or Abcam, Cambridge, UK) for 1 hour at 
room temperature and secondary antibody of goat polyclonal to rabbit IgG-
FITC (1/200) (Abcam, Cambridge, UK) for 30 minutes at room temperature; or 
FITC-conjugated phalloidin (1/80) (Sigma-Aldrich, MO, USA) for 1 hour at 
room temperature and counterstained nucleus with 4’6-diamidino-2-
phenylindole (DAPI) (1/1000) (Sigma-Aldrich, MO, USA) for 5 minutes. 
Images were taken at randomly selected fields using a confocal microscope 
(Olympus FluoView FV1000, Olympus, Tokyo, Japan). 
 
2.24. Cortical F-actin score index 
A cortical F-actin score index was derived as an indicator of the degree of 
cytoskelal rearrangement.  Cortical F-actin score index was determined from at 
least three independent experiments [232]. In each experiment, at least three 
images were taken blindly from each culture condition. The F-actin cytoskeletal 
reorganization for each cell was scored on a scale ranging from 0 to 3 based on 
the degree of cortical F-actin ring formation (score = 0, no cortical F-actin, 
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normal stress fibers; score = 1, cortical F-actin deposits below half of the cell 
border; score = 2, cortical F-actin deposits exceeding half of the cell border; 
score = 3, complete cortical ring formatting and/or total absence of central stress 
fiber). A minimum of 15 cells were examined from each culture condition in 
each independent experiment, and the cortical F-actin score index for is the 
average score of the counted cells±SEM. 
 
2.25. Podocyte cell culture treatment for RhoA and Rac1 assays 
Differentiated podocytes were cultured on 100mm type I collagen coated dish 
(Iwaki, Japan) and serum starved for 24 hours to inactivate the endogenous 
RhoA activity. Serum starved cells were then incubated with IL-13 (20ng/ml) 
(R&D Systems, MN, USA) for 5, 10, 20 and 30 minutes. Unstimulated 
podocytes were used as baseline control. Each specific time point was first 
completed before proceeding to the next time point so as to allow rapid 
processing of each single time point and hence minimizing changes in signal 
over time. Following the stimulation, culture dishes were placed on ice and 
washed with 10ml of ice cold 1xPBS. Cells were then lysed in 250µl of G-
LISA® Lysis Buffer and the lysate was clarified for 2 minutes at 14,000rpm, 
4°C. Aliquots of lysate for protein quantification, G-LISA, total Rho and Rac1 
assays were snap-frozen in liquid nitrogen and stored at -80oC for further 
experiments. 
 
2.26. RhoA activation assay 
Active RhoA was measured using G-LISA® RhoA Activation Assay Biochem 
KitTM (Cytoskeleton, Inc, CO, USA) according to the manufacturer’s 
instructions and normalized against total RhoA levels (refer to 2.27) 
(Cytoskeleton, Inc, CO, USA) in the cell lysate for accurate comparison of 
RhoA activity among samples. Protein lysate was equalized with Lysis Buffer 
and equal volume of Binding Buffer was added to the lysate. Fifty μl of 
equalized cell lysate samples, Lysis Buffer blank control and RhoA positive 
control were added separately to the wells coated with Rho-GTP-binding 
protein. The plate was placed on MicroMix 5 shaker (DPC Biermann GmbH, 
Bad Nauheim, Germany) at 390rpm, 4°C for 30 minutes. Active, GTP-bound 
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Rho in the cell lysates were bound to the wells. After incubation, the wells were 
washed twice with 200μl of Wash Buffer to remove the inactive GDP-bound 
Rho. Each well was incubated with 200μl of Antigen Presenting Buffer at room 
temperature for exactly 2 minutes and then washed thrice with 200μl of Wash 
Buffer. This was followed by sequential incubation of each well with 50µl of 
diluted anti-Rho primary antibody (1/250) and diluted HRP-conjugated 
secondary antibody (1/62.5) on MicroMix 5 shaker at room temperature for 45 
minutes each. Each incubation was followed by three washes with 200μl of 
Wash Buffer. Fifty μl of HRP detection reagent was added for color 
development and stopped after 15 minutes by adding 50μl of HRP stop solution. 
The intensity of the colour was measured using a microplate reader (Bio-Rad 
Laboratories, Inc, CA, USA) with wavelength set at 490nm. The amount of 
active RhoA in the samples was determined from the Rho control protein which 
is at 1ng with linear OD from 0.05 to 2ng. 
 
2.27. Total Rho assay 
Total RhoA in the samples was measured using Total RhoA ELISA KitTM 
(Cytoskeleton, Inc, CO, USA) according to the manufacturer’s instructions. 
Briefly, 50μl of equalized cell lysate samples, RhoA standard and Lysis Buffer 
blank control were added separately to the wells coated with anti-Rho Igγ 
antibody which has high affinity to all Rho isotypes. The plate was incubated 
for 2 hours at room temperature, followed by washing with 200μl of Wash 
Buffer and incubation with 200μl of Antigen Presenting Buffer at room 
temperature for exactly 2 minutes. This was followed by sequential incubation 
of each well with 50µl of diluted anti-RhoA primary antibody (1/2000) and 
diluted HRP-conjugated secondary antibody (1/250) at room temperature for 1 
hour each. Each incubation was followed by three washes with 200μl of Wash 
Buffer. Eighty μl of HRP detection reagent was added for color development 
and stopped after 20 minutes by adding 80μl of 1.8M sulfuric acid. The intensity 
of the colour was measured using a microplate reader (Bio-Rad Laboratories, 
Inc, CA, USA) with wavelength set at 490nm. The amount of RhoA in the 




2.28. Rac1 activation assay 
Active Rac1 was measured using G-LISA® Rac1 Activation Assay Biochem 
KitTM (Cytoskeleton, Inc, CO, USA) according to the manufacturer’s 
instructions and normalized against total protein concentration. Briefly, 50μl of 
equalized cell lysate samples, Lysis Buffer blank control and Rac1 positive 
control were added separately to the wells coated with Rac-GTP-binding 
protein. The plate was placed on MicroMix 5 shaker (DPC Biermann GmbH, 
Bad Nauheim, Germany) at 390rpm, 4°C for 30 minutes. Active, GTP-bound 
Rac1 in the cell lysates were bound to the wells. After incubation, the wells were 
washed twice with 200μl of Wash Buffer to remove the inactive GDP-bound 
Rac1. Each well was incubated with 200μl of Antigen Presenting Buffer at room 
temperature for exactly 2 minutes and then washed thrice with 200μl of Wash 
Buffer. This was followed by sequential incubation of each well with 50µl of 
diluted anti-Rac1 primary antibody (1/50) and diluted HRP-conjugated 
secondary antibody (1/100) on MicroMix 5 shaker at room temperature for 45 
minutes each. Each incubation was followed by three washes with 200μl of 
Wash Buffer. Fifty μl of HRP detection reagent was added for color 
development and after 20 minutes by adding 50μl of HRP stop solution. The 
intensity of the colour was measured using a microplate reader (Bio-Rad 
Laboratories, Inc, CA, USA) with wavelength set at 490nm. The amount of 
active Rac1 in the samples was determined from the Rac1 control protein which 
is at 2ng with linear OD from 1 to 8ng. 
 
2.29. Statistical analysis 
Statistical analysis was performed using SPSS software (version 17.0 for 
Windows©, SPSS Inc, Ill, USA). Differences between groups were determined 
using the Mann-Whitney test, where p < 0.05 was considered significant. All 





DELINEATING THE MOLECULAR MECHANISM OF IL-13 INDUCED NEPHROTIC 
SYNDROME IN RAT MODEL OF MCNS 
3.1. Introduction 
MCNS is the most common cause of significant morbidity amongst the 
childhood glomerulonephritides. However, its pathogenesis is still unknown. 
Studies attempting to elucidate the underlying pathogenesis have suggested a 
Th2 cytokine bias. Our group has previously demonstrated that IL-13 gene 
expression was upregulated in CD4+ and CD8+ T-cells of children with MCNS 
in relapse [58]. Moreover, IL-13 overexpression in the rat resulted in podocyte 
injury with downregulation of the slit diaphragm proteins, namely nephrin and 
podocin, inducing a minimal change-like nephropathy [215, 216]. In this model, 
increased glomerular IL-4Rα and IL-13Rα2 gene expression, as well as 
increased fluorescent signal for IL-4Rα were demonstrated in most of the 
glomerular podocytes of nephrotic rats, suggesting that IL-13 may act directly 
on podocytes in the glomeruli.  
 
Current understanding of the pathogenetic mechanism of nephrotic syndrome 
suggests that the podocyte is the main component of the glomerular filter and 
the crucial target in the development and progression of glomerulopathies [233-
235]. In fact, one of the hallmarks of nephrotic syndrome is the effacement of 
podocyte FP [236]. Recent studies have suggested a novel role for the 
costimulatory molecule B7-1 in podocytes as an inducible modifier of 
glomerular permselectivity and proteinuria [217, 218]. In genetic, drug-induced, 
autoimmune, and bacterial toxin-induced experimental kidney diseases with 
nephrotic syndrome, B7-1 expression in podocytes was upregulated. In our IL-
13 overexpression rat model of MCNS, upregulation of B7-1 expression was 
also demonstrated in the glomeruli, and this correlated strongly with serum IL-
13 levels. 
 
We therefore hypothesized that IL-13 and/or other Th2 cytokines could act 
through IL-13-induced B7-1 danger signaling, thus causing podocyte 
effacement and proteinuria. 
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3.2. Aim of Chapter 
In this chapter, we aimed to investigate the molecular mechanism by which IL-
13 downregulates the expression of podocyte-specific proteins via B7-1-danger 
signaling, resulting in massive proteinuria. The specific objectives are to: 
1 Characterize the molecular events in the glomeruli of the IL-13 rat 
model of MCNS using cDNA microarray and identifying differentially 
expressed genes (DEGs) induced by IL-13.   
2 Determine the mechanistic link of IL-13 and B7-1 signaling in this rat 
model of MCNS using pathway analysis tools. 
3 To validate the microarray results in the glomerular RNA using real-





3.3.1 Phenotype of rats used for microarray analysis 
Serum IL-13 levels in IL-13-overexpressed rats were significantly higher than 
control rats (788±290 vs. 3.50±1.96 pg/ml, p=0.002). The IL-13-overexpressed 
rats compared to control rats, showed minimal change-like nephropathy 
characterized by increased proteinuria (10000±4800 vs. 286±44.8 ug/24hr, 
p=0.002), hypoalbuminemia (25.0±2.51 vs. 44.7±2.67 g/L, p=0.002), 
hypercholesterolemia (7.23±1.23 vs. 1.66±0.07mmol/L, p=0.002) (Figure 6). 
No significant difference was detected in the serum creatinine levels. (Appendix 
3.1) 
 
Figure 6: Biochemistry profile of rats used in microarray analysis. 
Overexpression of IL-13 in rats resulted in proteinuria, hypoalbuminemia and 
hypercholesterolemia. Asterisk indicates statistically significant differences (p<0.05). 
 
3.3.2 Qualitative measurement of glomerular RNA 
RNA samples used in this microarray study consisted of RNA Integrity Number 
(RIN) values of more than six (Figure 7). The RIN was developed by Agilent 
Technologies to standardize the interpretation of RNA integrity, taking into 
account the entire electrophoretic trace. It has a numbering system from 1 to 10, 




Figure 7: Electropherogram summary of a glomerular RNA sample.  
Figure showed one of the electropherograms for the glomerular RNA used in the microarray. 
Ribosomal RNA ratio (28s/18s) and RIN were stated below the electropherogram. 
 
3.3.3 Glomerular RNA transcriptional profile of IL-13 overexpression rat 
model of MCNS 
Transcriptional profile of the glomeruli in the IL-13 overexpression rats showed 
a distinct regulation pattern. Of the 22,523 genes analyzed in the IL-13-
transfected rats, 1322 genes showed differential regulation of at least 1.6-fold 
compared to control rats. These differentially expressed genes (DEGs) were 
hierarchically clustered into low (green) to high (red) expression level (Figure 
8). Of the 1322 DEGs, 847 (64.1%) genes were down-regulated (with a 
maximum fold change of 6.88) and 475 (35.9%) genes were up-regulated (with 




Figure 8: Hierarchy clustering of the 1322 DEGs. 
The 1322 genes that were differentially regulated in the glomeruli of the IL-13-transfected rats 
compared to control rats were hierarchically clustered. Expression was indicated by a colour 
scale from low (green) to high (red). C indicates biological replicate for control rats, and GII 
indicates biological replicate for IL-13 overexpression rats. 
 
Functional annotation clustering showed that these DEGs were principally 
related to vascular system development, cell adhesion/migration, cellular 
components, immune response, actin cytoskeleton, neuron development and 




Table 3: DEGs were characterized according to their biological process classification 
using Gene Ontology analysis.  
Functional Annotation Cluster Enrichment score 
Vascular system development 9.95 
Cell adhesion 8.00 
Cellular component 6.63 
Cell migration 6.42 
Extracellular matrix 6.31 
Immune response 5.23 
Contractile fibre component 5.20 
Actin cytoskeleton 5.06 
Neuron development 4.84 
Protein binding (SH3 domain) 4.46 
 
A list of podocyte related genes known to be important for the structure and 
function of podocytes was compiled from studies related to podocytes [77, 237-
239] and 201 (15.2%) DEGs fell into this category (Appendix 3.3).  Of the 201 
DEGs, 173 (87.1%) genes were down-regulated 1.6-fold in comparison to 
control rats, with a profile carrying the characteristic signature of podocyte 
injury.  Eleven genes were selected and analyzed using real-time PCR to 
confirm the microarray results. There was good agreement between the real-
time PCR data and the microarray data, with confirmation of the up- or down-
regulation of each gene and the fold change was also of a comparable magnitude 




Figure 9: Microarray validation using real-time PCR quantification. 
Eleven genes were selected and analyzed using real-time PCR to confirm the microarray results. 
Downregulated genes were arbitrarily assigned a negative value. For real-time PCR, gene 
expression levels were normalized using GAPDH and fold change was calculated using formula 
2ΔΔCt (where ΔΔCt was converted to an absolute value). Results were presented as fold change 
± SEM. Asterisk (*) for real-time PCR data indicates significant difference with p < 0.05, 
between the ΔCt of control and IL-13 overexpression rats. The pattern of transcript abundance 
detected for these genes in the array and in real-time PCR showed nearly identical expression 
profiles. BMD (basal membrane domain), AMD (apical membrane domain). 
 
Decreased gene expression levels of podocyte slit diaphragm molecules namely 
kin of IRRE like 2 (Kirrel2 or NEPH2) and cadherin 11 (cdh11) were seen in 
the IL-13-overexpressed rats, as well as actin cytoskeleton related molecules 
namely NCK adaptor protein 2 (Nck2), membrane associated guanylate kinase, 
WW and PDZ domain containing 2 (Magi2), α-catenin (Ctnnal1) and α-actinin-
4 (Actn4). Additionally, downregulation of podocyte basal and apical 
membrane domain protein complex molecules, namely α3 integrin (Itga3) and 
protein tyrosine phosphatase, receptor type, O (Ptpro or GLEPP1) respectively, 
and linkage molecule Ezrin (Ezr), were demonstrated.  However, the gene 
expression of junb was shown to be highly upregulated (3.85-fold) in the 
glomeruli of the IL-13-overexpressed rats.  
 
The other highly upregulated gene (2.49-fold) was vav1 guanine nucleotide 
exchange factor (vav1) whose function in the kidney has not been previously 
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described. Vav2 and vav3 gene expression were not differentially regulated in 
the glomeruli of IL-13 overexpressed nephrotic rats. 
   
3.3.4 Pathway analysis of the differentially regulated genes in IL-13 
overexpressed rat model 
MetaCoreTM pathway analysis of the 1322 DEGs showed that the top pathway 
involved was cytoskeleton remodeling. The genes which were differentially 
regulated in this pathway were summarized in Table 4, in which vav1 showed 
the greatest increase in gene expression (Figure 10).  




Symbol Gene Description 
Fold 
Change 
NM_031836.1 Vegfa vascular endothelial growth factor A -3.67 
XM_216679.4 Lamb1 laminin, beta 1 -2.84 
NM_031520.1 Myh10 myosin, heavy chain 10, non-muscle -2.47 
NM_031005.2 Actn1 actinin, alpha 1 -2.30 
XM_340884.2 Itga3 integrin alpha 3 -2.23 
NM_017198.1 Pak1 p21 (CDKN1A)-activated kinase 1 -2.19 
NM_012604.1 Myh3 myosin, heavy chain 3, skeletal muscle, 
embryonic 
-2.18 
NM_053356.1 Col1a2 collagen, type I, alpha 2 -2.08 
NM_012606.1 Myl3 myosin, light polypeptide 3 -2.06 
XM_343607.3 Col4a1 similar to procollagen, type IV, alpha 3 -1.99 
XM_230950.4 Itgav integrin alpha V -1.97 
XM_573030.2 Myh11 myosin, heavy polypeptide 11, smooth muscle -1.75 
NM_031675.2 Actn4 actinin alpha 4 -1.72 
NM_013151.2 Plat plasminogen activator, tissue -1.66 
XM_232064.4 Tcf3 transcription factor 3 -1.66 
XM_236367.4 Tln2 similar to talin 2 -1.63 
XM_001080622.1 Myh14 myosin, heavy polypeptide 14 -1.63 
NM_012759.1 Vav1 vav 1 oncogene 2.40 
NM_001012002.1 Zap70 zeta-chain (TCR) associated protein kinase 2.00 
XM_232763.4 Lck lymphocyte protein tyrosine kinase 1.99 
NM_021835.3 Jun Jun oncogene 1.88 
XM_219517.3 Map3k11 mitogen-activated protein kinase kinase kinase 
11 
1.82 
NM_053857.1 Eif4ebp1 eukaryotic translation initiation factor 4E 
binding protein 1 
1.68 
Each gene is given a representative GenBank accession number, gene symbol, gene description, 
and fold change (relative to control rats; negative values indicate down regulation). The list of 




Figure 10: Cytoskeleton remodeling pathway involving vav1. 
Figure was exported from MetaCoreTM during pathway analysis. Vav1 was boxed and the fold 
change was indicated in the diagram.  
 
3.3.5. Glomerular gene expression levels of B7-1 interaction partners 
Glomerular gene expression levels of three genes of interest known to interact 
with B7-1, namely TLR4, CTLA4 and CD28, were examined. Gene expression 
levels of these three genes in the microarray analysis did not reach the DEGs 
selection criteria of fold change greater than 1.6, coefficient of variance less 
than 0.7 and t-test p<0.05 (Table 5). 
Table 5: Gene expression of TLR4, CTLA4 and CD28 in the glomeruli of IL-13 








NM_019178.1 Tlr4 toll-like receptor 4 1.57 0.51 0.08 
NM_031674.1 Ctla4 cytotoxic T-lymphocyte-
associated protein 4 
1.41 0.31 0.06 
NM_013121.1 Cd28 Cd28 molecule Not 
detected 
N.A N.A. 
Each gene is given a representative GenBank accession number, gene symbol, gene description, 
fold change (relative to control rats), coefficient of variance (cv) and p-value. N.A., not 




However, on further analysis of the expression levels of these three genes using 
quantitative real-time PCR, gene expression levels of TLR4 (11.5x10-
4±1.37x10-4 vs. 7.3x10-4±0.61x10-4, p=0.02) and CTLA4 (3.04x10-4±0.89x10-4 
vs. 1.01x10-4 ± 0.36x10-4, p=0.04) were significantly upregulated in IL-13 
overexpressed rats as compared to control rats (Figure 11). No significant 
difference was detected in gene expression of CD28 in the IL-13 overexpressed 
rats (9.7x10-3±2.6x10-3) in comparison to control rats (6.3x10-3±1.5x10-3) 
(p=0.38). (Appendix 3.4)  
 
Figure 11: Increased gene expression of TLR4 and CTLA4 in IL-13 overexpressed rats. 
Gene expression index of TLR4, CTLA4 and CD28 in control and IL-13 overexpressed rats. 






Despite advances in the knowledge of podocyte biology, the etiology of MCNS 
remains unknown. We have recently reported that overexpression of IL-13 gene 
could induce a minimal change-like nephropathy with podocyte FP effacement 
and proteinuria [215, 216]. This rat model provided a platform to study the 
molecular signaling pathways that were differentially regulated in the 
glomeruli, in order to better understand the pathogenesis of this intriguing 
disease.  
 
MCNS represents a generalized disorder of the immune system resulting in 
renal manifestations. In this study, genes involved in immune response 
constituted one of the clusters highly enriched in the functional annotation 
analysis of the DEGs. IL-1b, IL-12a, IL-16, IL-18, receptors for interleukin (IL-
1RII, IL-2Rα and IL-2Rγ), surface receptors (CD1d1, CD3δ, CD8b, CD24, 
CD36, CD37, CD38, CD52, CD69, CD83, CD97, CD200, CD247, and TLR6) 
and complement component (C4-2 and Cfb) were differentially regulated in the 
IL-13 overexpressed rats, suggesting that IL-13 is a potent regulator of immune 
response genes in the glomeruli. As IL-13 is an important modulator of 
monocyte/macrophage function, it is also plausible that the glomerulopathy in 
our rat model may be a consequence of direct IL-13 stimulation and/or indirect 
signaling mediated by other immune mediators. Additionally, studies have 
suggested that the podocye itself may intensify immune glomerular injury 
through expression of receptors linked to pathways that induce proinflammatory 
molecules [240, 241]. However, the role of these receptor/surface molecules in 
podocytes remains to be elucidated. 
 
The hallmark of MCNS is glomerular FP effacement, which is the only 
morphologic lesion identifiable on electron microscopy. This has been shown 
to be associated with conspicuous changes in the cytoskeleton of podocytes [77, 
242, 243]. Microarray analysis of the glomeruli in our IL-13 overexpression rat 
model of MCNS revealed that molecules responsible for the key architecture of 
podocytes, namely the SD, actin cytoskeleton, basal and apical membrane 
domain protein complexes and molecules that link to the apical membrane 
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domain, were dysregulated (Figure 12).  Podocytes play a critical role in 
glomerular filtration, hence dysregulation of molecules important for the 
maintenance of the tertiary podocyte FP structure can conceivably result in 
albuminuria and development of frank nephrotic syndrome. 
 
Figure 12: Downregulation of genes related to podocytes was associated with podocyte FP 
effacement in IL-13 overexpression rat model of MCNS. 
Electron microscopy (reproduced from our previous work [216]) showed podocyte foot process 
effacement (arrows) in the glomeruli of IL-13 overexpressed rat. 
 
In addition to the decreased expression of nephrin and podocin previously 
reported in our rat model of MCNS, gene expression of NEPH2 was 
significantly downregulated in the glomeruli of the IL-13 overexpressed rat.  
Neph2 protein is structurally related to nephrin which can form heterodimers 
with nephrin at the SD [114, 115]. Recent studies in Caenorhabditis elegans 
identified Neph2 as a critical regulator of glomerular function required for 
glomerular maintenance and development [244]. Knock down of Neph2 
resulted in loss of SD and leakiness of the glomerular filtration barrier. 
 
A number of DEGs identified in the glomeruli of our IL-13 overexpressed rats 
were reported to be associated with nephrin.  GLEPP1, though found at the 
apical surface of podocytes, was shown to cause reduced glomerular nephrin 
content in GLEPP1-deficient mice [83].  Another molecule, Nck adaptor 
protein, was shown to bind to the phosphorylated form of nephrin.  SH2 domain 
of Nck interacts with tyrosine phosphorylated nephrin, while the SH3 domains 
of Nck bind to N-WASP and mediates interactions with downstream effectors 
of the actin cytoskeleton [102, 136, 245, 246].  Inactivation of Nck proteins in 
adult mouse podocytes reduced phosphorylation of nephrin, caused proteinuria, 
glomerulosclerosis, and FP effacement [138].  This was attributed to the role of 
Nck in facilitating signaling events at the SD by promoting Fyn-dependent 
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phosphorylation of nephrin, which may be important in the regulation of FP 
morphology and response to podocyte injury [247]. 
 
In a study examining the expression of nephrin, podocin and α-actinin-4, normal 
renal tissue showed linear and homogenous expression of these proteins along 
the glomerular capillary walls.  In contrast, in renal tissue of patients with 
nephrotic proteinuria, immunostaining of these proteins showed a fine granular 
appearance.  Moreover, among the 18 patients with nephrotic proteinuria, there 
was loss of at least one of these proteins in the glomeruli [248]. 
 
Decreased expression of ezrin has also been reported in children with nephrotic 
syndrome and the degree of reduced ezrin expression was correlated to severity 
of podocyte injury [249].  Ezrin expression has been noted to be lower in 
children with MCNS as compared to normal renal biopsy samples, and this was 
decreased even more in those with diffuse mesangial proliferation and those 
with FSGS respectively.  
 
One of the DEGs that was highly upregulated in the glomeruli of IL-13 
overexpressed rats was Junb.  Junb is a member of the jun family (jun, junb and 
jund) [250].  Structurally, it contains a JNK docking site, nuclear localization 
signal, basic domain for DNA binding and a leucine zipper domain for 
dimerization. Junb can form homodimers with one another, or dimerize with 
members of Fos and ATF families, to form AP-1 transcription factor. Although 
Junb was initially reported not to be phosphorylated by JNK [251], a later study 
showed that phosphorylation of JunB  at Thr102 and 104 by JNK resulted in 
increased IL-4 expression in T-helper cells [252]. Studies have reported that 
Junb regulates human heme oxygenase 1 (HO-1) gene expression in renal 
epithelial cells [253].  HO-1 mRNA expression within tubular, glomerular and 
Bowman’s epithelial cells have been shown to be more intense with greater 
degrees of proteinuria [254], indicating its role in oxidative stress. 
 
Interestingly, our microarray data showed that podocyte dysregulation in 
glomeruli from IL-13 overexpressed rats with MCNS was also associated with 
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increased gene expression of vav1.  The vav family of proteins consists of three 
isoforms – vav1, vav2 and vav3.  Vav1 is a member of the Dbl family of 
Guanine nucleotide exchange factor (GEF) for the Rho family of GTPases [255-
257]. Vav1 expression is generally restricted to the hematopoietic system [258, 
259], whereas vav2 and vav3, are more widely expressed [258].  In fact, vav2 
has also been described in podocytes [260], although both vav2 and vav3 gene 
expression were not differentially regulated in our IL-13 overexpressed rats.  
Studies have shown that the HIV protein Nef interacts with DIP to increase Src-
mediated phosphorylation of vav2, which is responsible for the loss of RhoA-
mediated stress fiber formation and the increase in Rac1-mediated lamellipodia 
formation and membrane ruffling observed in HIV associated nephropathy 
[260].  Although vav1 has been classically associated with T-cell activation, the 
absence of inflammatory infiltrates in the glomeruli of our IL-13 overexpression 
rat model of MCNS excludes T-cell expression as the source of increased vav1 
gene expression in our microarray data.   
 
We have reported increased glomerular expression of B7-1 in our rat model of 
MCNS.  Previous studies have suggested a novel role for the costimulatory 
molecule B7-1 in podocytes as an inducible modifier of glomerular 
permselectivity and proteinuria [217, 218]. Wild type and SCID mice exposed 
to LPS were shown to develop nephrotic-range proteinuria and upregulation of 
B7-1. These investigators demonstrated that podocytes constitutively expressed 
TLR-4 (a receptor for LPS in antigen presenting cells), as well as CD14 (a co-
receptor of TLR-4) and suggested that podocytes detected LPS through TLR-4, 
resulting in reorganization of the kidney-filtration apparatus, podocyte FP 
effacement and proteinuria. In our current study, gene expression of TLR4 was 
significantly upregulated in the glomeruli of the nephrotic rats, suggesting a 
possible role of TLR-4/B7-1 signaling in the pathogenesis of proteinuria. 
However, the role of this pathway in our rat model of MCNS remains to be 
elucidated.  
 
Other molecules of interest in our model are CTLA-4 (Cytotoxic T-Lymphocyte 
Antigen 4), also known as CD152, and CD28. Both are members of the 
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immunoglobulin superfamily, and are ligands of B7-1 (CD80) as well as CD86. 
CTLA-4 is constitutively expressed on regulatory T cells [261, 262] as well as 
on activated T cells [263, 264], whereas CD28 is constitutively expressed on 
both resting and activated conventional T cells. CTLA-4 interacts with both 
ligands at a higher affinity and avidity than CD28, with the CTLA-4-CD80 
interaction being the strongest [265].  Therefore, CTLA-4 acts as an antagonist 
of CD28-ligand interactions by competing for ligand binding and hence 
functions as a potent negative regulator of the T-cell response. On the other 
hand, CTLA-4 has been shown to be a potent activator of T cell polarization 
needed for motility [266]. Binding of T cell with anti-CTLA-4 and CD3/CTLA-
4 induced rapid T cell polarization with increased formation of lamellipodia, 
filopodia, and uropods. Polarization required activation of PI3K, Vav1, Cdc42, 
and myosin L chain kinase. However, key downstream target of PI3K, protein 
kinase B, as well as Rho kinase and RhoA, were not required. Glomerular  
expression of CTLA-4 has been previously reported[267]. Injection of mice 
with polyIC, a TLR-3 ligand, resulted in significant increase in glomerular 
expression of B7-1 and IL-10 with a mild non-significant increase in CTLA-4, 
and significant decreased expression of synaptopodin. On the other hand, our 
study has demonstrated significantly increased glomerular CLTA-4 expression 
in our IL-13 overexpression rat model of MCNS, suggesting a potential role for 
CTLA-4-B7-1 signaling in inducing podocyte injury.  
 
In summary, we have demonstrated that the transcription profile of the 
glomeruli in our IL-13 overexpressed rats displayed characteristic podocyte 
injury phenotype with significant decreased gene expression of podocyte SD 
molecules, actin cytoskeleton molecules, as well as podocyte basal and apical 
membrane domain protein complex molecules. In addition, the novel finding of 
increased gene expression of vav1 associated with increased B7-1 expression in 
the glomeruli of IL-13 overexpressed rats with MCNS suggest a possible 
downstream role in the regulation of glomerular filtration barrier. Increased 
Junb expression, on the other hand, could reflect its role in oxidative stress 
induced by glomerular proteinuria in this model of MCNS. Increased 
glomerular expression of TLR-4 and CTLA-4 in the IL-13 overexpressed rats 
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suggests that these molecules could play a role in regulation of B7-1 expression. 
The next chapter will explore the significance of the glomerular molecular 
signature in the IL-13 overexpressed rat model by studying the expression of 
these genes in IL-13 stimulated podocytes. In addition, we will address the role 
of vav1 in the kidneys and in particular whether it has a role in the regulation 





NOVEL ROLE OF VAV1 IN PODOCYTES 
4.1. Introduction 
Our current understanding of the pathogenesis of nephrotic syndrome suggests 
that the podocyte is the main component of the glomerular filter and the crucial 
target in the development and progression of glomerulopathies. In MCNS, the 
major morphologic lesion is FP effacement, and the degree of FP effacement 
has been shown to roughly correlate with the amount of proteinuria [73, 74]. 
 
Several studies involving large scale identification of genes in podocytes have 
been carried out. Using cDNA libraries and cDNA microarrays constructed 
from isolated glomeruli of mice, Takemoto et al. identified podocyte enriched 
transcripts in mice [239]. Cultured podocytes were also used in cDNA and 
oligonucleotide microarrays to examine the changing global gene expression 
profiles in response to various conditions [268, 269]. Another study used highly 
purified podocytes isolated from transgenic mice to define podocyte gene 
expression at different developmental stages [237]. These studies enhanced our 
understanding of genes expressed in podocyte and hence facilitated molecular 
characterization of podocytes. 
 
Our findings from the transcription profile of the glomeruli in our IL-13- 
overexpressed rats showed extensive downregulation of podocyte related genes, 
characteristic signature of podocyte FP effacement, with the decreased 
expression of key molecules important for the architecture of podocyte – SD, 
actin cytoskeleton, basal and apical membrane domain protein complexes and 
molecules that link to the AMD. Although both Junb and vav1 were highly 
upregulated in the glomeruli of IL-13 overexpressed rats, MetaCoreTM pathway 





4.2. Aim of chapter 
The aim of this chapter is therefore to identify potential pathways important in 
podocyte injury in the IL-13 overexpressed rat model of MCNS by studying the 
expression of the differentially expressed genes (DEGs) identified by the 
microarray studies as described in the previous chapter, in an in-vitro human 
podocyte culture stimulated by IL-13.  In addition, we will address the role of 
vav1 in the kidneys and in particular whether it has a role in the regulation and 
maintenance of podocyte structure.    
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4.3. Results  
4.3.1 Podocyte cell culture for microarray validation 
Podocyte cell lines were developed by transfection of the human podocytes with 
temperature sensitive SV40-T gene and telomerase gene (kind gift from Dr. 
Moin Saleem, University of Bristol, UK). These cells proliferate at a permissive 
temperature of 33oC and enter growth arrest and differentiate at a non-
permissive temperature of 37oC.  
 
Cells were observed daily under a light microscope to check the morphology, 
distribution and absence of contamination. During proliferation, podocytes were 
polygonal in shape and displayed characteristic cobblestone morphology 
(Figure 13).  
 
Figure 13: Morphology of podocytes at permissive temperature. 
(A) Cells were grown at 33oC for proliferation until reaching 80-90% confluency before 
thermoshift (magnification, x40). (B) Undifferentiated podocytes were polygonal and display 
characteristic cobblestone appearance (magnification, x100). 
 
Once the cells proliferated to 80% confluency, they were split 1:10 and cultured 
at 37oC for differentiation into mature podocytes. Cells were observed to 
continue replicating for the first 4 to 6 days after thermoshifting, following 
which the cells started to increase in size (decrease in nuclear-cytoplasmic 
ratio). The cells gradually changed from the cobblestone morphology into flat, 
irregular shape and arborized phenotype, with the formation of short and more 




Figure 14: Morphology of podocytes at non-permissive temperature. 
The left panel showed cells at x100 magnification; right panel showed cells at x400 
magnification. (A-B) At day 6, podocytes were still replicating at a much slower rate than when 
they were at permissive temperature. (C-D) At day 8, cells ceased proliferation and started to 
form more short and rounded processes. (E-F) At day 10, majority of cells were fully 
differentiated. Cells were arborized with well developed cellular processes.  
 
4.3.2 Microarray validation in IL-13 stimulated human podocytes 
The 11 genes selected for real-time PCR validation in the rat glomeruli were 
further analysed in human podocyte cell culture system. To study the direct 
effect of these genes in IL-13 stimulated human podocytes, fully differentiated 
podocytes were incubated with IL-13 (20ng/ml) for 24 hours and the gene 
expression indices were compared to the respective unstimulated podocytes. 
Vav1 was the only gene that showed the same expression pattern (1.52-fold 
increased expression in IL-13 stimulated podocytes, p=0.02) as the microarray 
profile (Figure 15).  Junb, on the other hand was downregulated in IL-13 




Figure 15: Expression profile for the selected DEGs from glomerular microarray in IL-13 
stimulated podocytes. 
Eleven DEGs selected from the microarray transcriptional profile of the glomeruli in the IL-13 
overexpression rats were analyzed in human podocyte cell culture using real-time PCR. 
Downregulated genes were arbitrarily assigned a negative value. For real-time PCR, gene 
expression levels were normalized using GAPDH and fold change was calculated using the 
formula 2ΔΔCt (where ΔΔCt was converted to an absolute value). Results were presented as fold 
change ± SEM. Asterisk (*) for real-time PCR data indicates significant difference (p<0.05), 
between the ΔCt of unstimulated podocytes and IL-13 stimulated podocytes. Vav1 was the only 
gene that showed the same expression pattern as the microarray profile. 
  
4.3.3 Expression of vav1 in human podocytes 
Gene expression of vav1 in podocytes was demonstrated using PCR (Figure 16). 
 
Figure 16: Gene expression of vav1 in podocytes. 
Representative agarose gel image of vav1 in 1) control unstimulated podocytes and 2) IL-13 
stimulated podocytes. 
 
Subsequently, protein expression of vav1 in podocytes was validated using 
Western blot (Figure 17). These results confirmed the presence of vav1 in the 





Figure 17: Protein expression of vav1 in podocytes. 
Representative gel images of phosphorylated vav1 (p-vav1) and total vav1 in 1) control 
unstimulated podocytes and 2) IL-13 stimulated podocytes. Blots were first incubated with 
antibody against phosphorylated vav1 and then re-probed with antibody against total vav1. 
GAPDH was used as loading control. 
 
The presence of vav1 in podocytes was further validated using 
immunofluorescence staining of vav1 in podocyte cell culture using antibodies 
from two different sources (SAB4503066 and Ab62622) (Figure 18). 
 
Figure 18: Podocytes expression of vav1. 
Immunofluorescence staining of vav1 on podocytes using antibodies from (A, D) Sigma-
Aldrich SAB4503066; and (B, E) Abcam Ab62622. (C, F) showed negative control for the 
immunofluorescence staining, without the primary antibody incubation. Images were taken at 






4.3.4 IL-13 induced B7-1 and vav1 expression in human podocytes 
Following IL-13 stimulation, podocyte gene expression of IL-13Rα2 (1.45x10-
3 ±0.35x10-3 vs. 0.64x10-3±0.10x10-3, p=0.001) and IL-4Rα (1.51x10-2±0.11x10-
2 vs. 1.15x10-2±0.14x10-2, p=0.02) were upregulated compared to controls. This 
was associated with significant higher gene expression of B7-1 (1.74x10-
4±0.25x10-4 vs. 1.00x10-4±0.19x10-4, p=0.001) and vav1 (2.21x10-5±0.26x10-5 
vs. 1.32x10-5± 0.24 x10-5, p=0.002) in IL-13 stimulated podocytes as compared 
to controls (Figure 19). No significant difference was detected in the gene 
expression of TLR4, CTLA4, CD28, IL-13Rα1, nephrin, podocin and 
dystroglycan. (Appendix 4.1) 
 
Figure 19: Increased gene expression of IL-13Rα2, IL-4Rα, B7-1 and vav1 in IL-13 
stimulated podocytes. 
Gene expression for IL-13Rα2, IL-4Rα, B7-1 and vav1 in control and IL-13 stimulated 
podocytes. Expression levels for the four genes were significantly higher in IL-13 stimulated 
podocytes compared to unstimulated podocytes. Asterisk indicates statistically significant 
differences (p<0.05). 
 
Western blot analysis demonstrated increased protein expression of IL-13Rα2 
(0.91±0.10 vs. 0.58±0.06, p=0.01) and B7-1 (0.97±0.12 vs. 0.63±0.11, p=0.04) 
in IL-13 stimulated podocytes compared to controls. No significant difference 
was detected for protein expression of vav1 in IL-13 stimulated podocytes 
(0.95±0.13) compared to controls (1.05±0.19) (p=0.82). However, activated 
phosphorylated form of vav1 was significantly increased in IL-13 stimulated 
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podocytes (3.45±0.63) compared to controls (1.97±0.47) (p=0.05) (Figure 20 
and Figure 21). (Appendix 4.2) 
 
Figure 20: Protein expression of IL-13Rα2, B7-1, phosphorylated vav1, total vav1 in 
podocytes. 
Representative gel images of IL-13Rα2, B7-1, phosphorylated vav1 and total vav1 in 1) control 
unstimulated podocytes and 2) IL-13 stimulated podocytes. GAPDH was used as loading 
control.  
 
Figure 21: Densitometric analysis of IL-13Rα2, B7-1, phosphorylated vav1 and total vav1 
in podocytes. 
Protein expression was determined using Western blot analysis. The intensity of each band was 
quantitated and expressed as an index of the housekeeping gene GAPDH. Values represent the 
mean of ten independent experiments. Protein expression for IL-13Rα2 and B7-1 were 
significantly higher in IL-13 stimulated podocytes. In addition, IL-13 stimulation resulted in 





4.3.5 Identification and validation of vav1 gene and protein expression in 
the rat glomeruli  
Microarray analysis of the glomeruli of IL-13 overexpression nephrotic rats has 
identified the potential biological relevance of vav1, a molecule which has not 
been described in kidneys previously. In addition, our studies on human 
podocytes confirmed the presence of vav1 expression.  To confirm glomerular 
expression of vav1, immunohistochemistry (IHC) staining of vav1 was 
performed on formalin-fixed, paraffin-embedded rat kidney tissue using 
antibodies from two different sources (BS1370 and SAB4503066). Glomeruli 
and tubular epithelial cells showed positive staining of vav1 (Figure 22). No 
different in vav1 signal intensity could be detected in the glomeruli of control 
and IL-13 overexpressed rats using IHC staining (Figure 23). 
 
Figure 22: Glomerular expression of vav1. 
Glomerular histology of vav1 expression in the glomeruli of IL-13 overexpressed rat using 
antibody from (A, D) Bioworld, BS370; and (B, E) Sigma-Aldrich SAB4503066. Brown-colour 
developed at the glomeruli and tubular epithelium cells after incubation with DAB Substrate-
Chromogen. (C, F) showed negative control for the immunohistochemical staining, without the 





Figure 23: Glomerular expression of vav1 in control and IL-13 overexpressed rats. 
Histology of vav1 expression in the glomeruli of (A, B) control or (C, D) IL-13-overexpressed 
rats using antibody from (A, C) Bioworld, BS370; and (B, D) Sigma-Aldrich SAB4503066. 
Brown-colour developed at the glomeruli and tubular epithelium cells after incubation with 
DAB Substrate-Chromogen. Images were taken at x200 magnification. 
 
Rat kidney was sequentially sectioned, and the sections in series were stained 
with synaptopodin or vav1. Matching regions were identified to compare the 
staining pattern of synaptopodin (podocyte marker) and vav1. Regions staining 




Figure 24: IHC analysis of synaptopodin and vav1 in paraffin-embedded renal cortex. 
Renal cortex sections in series from IL-13 overexpressed rat were stained with synaptopodin 
(left column) or vav1 (right column). Matching regions were identified to compare the staining 
pattern of synaptopodin and vav1. Arrows indicated regions of the glomeruli staining positive 






Validation of the glomerular microarray studies in IL-13 stimulated human 
podocytes revealed that vav1 was the only gene showing the same expression 
pattern (1.52-fold increase compared to unstimulated podocytes) as the 
microarray profile.  Junb, on the other hand, was downregulated, though not 
statistically significant, in IL-13 stimulated podocytes, whereas it was 
upregulated in the glomeruli of nephrotic rats.  Similarly, none of the other nine 
downregulated podocyte-specific DEGs in the glomerular microarray profile 
were significantly downregulated in IL-13 stimulated podocytes. 
 
Junb was highly upregulated in the glomeruli of the IL-13 overexpressed 
nephrotic rat.  JunB is a transcription factor shown to be involved in the 
regulation of HO-1 gene expression in renal epithelial cells [253].  The HO-1 
gene is upregulated in oxidative stress, and its expression in glomerular and 
Bowman’s epithelial cells has been shown to be more intense with greater 
degrees of proteinuria [254].  HO-1 plays an important role in maintaining renal 
function by protecting renal epithelial cells from glomerular proteinuria which 
can become a cause of oxidative stress.  It is interesting that our microarray data 
confirmed its marked upregulation in the glomeruli of IL-13 overexpressed 
nephrotic rat. In contrast, IL-13 stimulated cultured podocytes showed a trend 
for downregulation of Junb gene expression compared to unstimulated 
podocytes.  This suggests that IL-13 stimulation per se was not the triggering 
factor for increased Junb expression in the rat model. 
 
We were able to demonstrate vav1 expression in both IL-13 stimulated and 
unstimulated podocytes, indicating the presence of this molecule in podocytes. 
In addition, phosphorylated vav1 was increased in IL-13 stimulated podocytes, 
suggesting that vav1 could have a functional role in podocytes.  In T-cells, 
binding of CD28 to B7-1 results in phosphorylation of vav1 by tyrosine kinases, 
with subsequent activation of Rac1 and actin cytoskeleton remodeling [270, 
271].  Vav1 activates Rac1 and Cdc24, which in turn activates JNK via MEKK1 
and MKK4/7.  Activated JNK phosphorylates transcription factors such as Jun, 
thereby activating AP1 complex, involved in regulation of cell proliferation. 
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Therefore, we postulate that vav1 could play a role in actin cytoskeleton 
remodeling or transcription regulation of genes in podocytes. 
 
The ratio of phosphorylated vav1 to total vavl was 1.97±0.47 in unstimulated 
podocytes, which increased by approximately two-fold to 3.45±0.63 following 
IL-13 stimulation. Several studies had demonstrated presence of 
phosphorylated vav1 under basal states. In an early study of guanine nucleotide 
exchange activity of vav in T cells, Gulbins et al. demonstrated constitutive 
tyrosine phosphorylation of vav1 in resting Jurkat cells at the basal level (Figure 
25A) and the phosphorylation level increased following stimulation with 
monoclonal antibody (mAbs) to CD3 [272]. Basal level of phosphorylated vav1 
was also present in BALB/c splenic T cells (Figure 25B) and the 
phosphorylation level increased substantially following stimulation by anti-
TCR, anti-TCR plus anti-CD4, anti-CD28, and anti-TCR plus anti-CD28 mAbs 
[270]. NIH 3T3 cell expressing wild-type vav showed presence of 
phosphorylated vav1 in unstimulated condition (Figure 25C) which was 
phosphorylated following epidermal growth factor stimulation [273]. Similar 
results were obtained using vav proteins obtained from transient transfections 
in COS-1 cells. CD4+ T cells transduced with wild type vav1 was shown to 
express 20% to 30% phosphorylation of vav1 under basal state (Figure 25D) 
and stimulation with anti-CD3ε and anti-CD28 antibodies resulted four-fold 
increased of phosphorylated vav1 at 1 minute and two-fold increased of 




Figure 25: Basal level of Phosphorylated vav1. 
Figure showed results from different studies. Basal levels of phosphorylated vav1 in these 
studies were highlighted with red box. 
 
We have previously reported that IL-13 overexpression in rats resulted in 
podocyte injury with upregulation of glomerular B7-1.  In our in vivo rat model, 
we have shown increased glomerular IL-4Rα and IL-13Rα2 gene expression, as 
well as increased fluorescent signal for IL-4Rα in most of the glomerular 
podocytes of nephrotic rats, suggesting that IL-13 may act directly on podocytes 
in the glomeruli [215, 216]. Consistent with these findings, our in-vitro studies 
have demonstrated increased gene and protein expression of B7-1 on cultured 
human podocytes stimulated with IL-13.  This further strengthens the 
hypothesis that transient upregulation of B7-1 could occur in MCNS, resulting 
in nephrotic-range proteinuria, and also provide an explanation for the possible 
link between Th2 cytokine bias and MCNS.   
 
We have demonstrated that gene expression of TLR4 and CTLA4 in the IL-13 
stimulated podocytes was not significantly different compared to unstimulated 
podocytes, indicating that upregulation of B7-1 expression in IL-13 stimulated 
podocytes was independent of these two known modulators of B7-1 expression.  
In contrast, increased glomerular expression of these two molecules was seen 
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in the IL-13 overexpression rat model suggesting that the increased glomerular 
B7-1 could also occur via a second signal such as TLR-4.  This gives credence 
to the hypothesis that B7-1 upregulation following IL-13 stimulation in this rat 
model could be sustained by a ‘second-hit’ occurring via another signaling 
receptor, such as TLR-4.  Conceivably, IL-13 stimulation of other immune cells 
such as monocytes could produce mediators that can activate TLR-4 resulting 
in an additional signal for B7-1 upregulation.  As CTLA-4 is a known negative 
regulator of B7-1, the increased glomerular gene expression of CTLA-4 in the 
IL-13 overexpression rat model could be explained by positive feedback 
following increased B7-1 expression.  
 
Reiser et al. have suggested a novel role for the costimulatory molecule B7-1 in 
podocytes as an inducible modifier of glomerular permselectivity and 
proteinuria [217, 218].  They showed that induction of B7-1 on the podocytes 
resulted in an alteration in shape with actin rearrangement that altered 
glomerular permeability and caused proteinuria.  In patients with MCNS, 
urinary CD80 (B7-1) excretion has been reported, a finding not observed in 
other glomerular diseases [219, 220].  Renal biopsy also showed increased 
CD80 expression in glomeruli of MCNS patients in relapse, and this co-
localized with podocin expression in the glomeruli.  However, the mechanistic 
link between B7-1 and actin cytoskeleton remodeling remains to be elucidated.   
 
Using two different sources of primary antibody which detects endogenous 
levels of total vav1 protein, we were able to demonstrate vav1 staining of 
glomerular and tubular epithelial cells in rat kidney.  We further showed that 
vav1 co-localized with synaptopodin in serial sections of the kidney, confirming 
its location in podocytes.  However, protein expression of vav1 was not 
restricted to podocytes as tubular cells also stained positive for vav1. Consistent 
with this finding in the IL-13 overexpression rat model of MCNS, we were able 
to demonstrate significant increase in phosphorylated vav1 expression 
following IL-13 stimulation of cultured human podocytes, which was associated 
with upregulation of B7-1. Therefore it is conceivable that the effect of B7-1 on 
actin cytoskeleton rearrangement could be mediated via vav1 and its 
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downstream activation pathway mediated by Rac1 as has been described in 
activated T-cells [275]. 
 
In summary, we have confirmed the expression of vav1 in glomeruli and 
phosphorylated vav1 in IL-13 stimulated podocytes.  The role of vav1 in 
regulation of actin cytoskeleton remodeling in podocytes will be further 





MECHANISM OF IL-13 INDUCED PODOCYTE INJURY 
5.1. Introduction 
In the previous chapter, we have demonstrated the presence of vav1 in rat 
glomeruli which co-localized with synaptopodin to the podocytes. We have also 
shown that podocyte injury in our rat model of MCNS was associated with 
increased gene expression of vav1. Vav1 is a member of the Dbl family of 
Guanine nucleotide exchange factor (GEF) for the Rho family of GTPases [255-
257]. Rearrangement of the actin cytoskeleton is highly regulated by the activity 
of Rho family GTPases. Rho GTPases switch between a GTP-bound ‘‘active’’ 
state and a GDP-bound ‘‘inactive’’ state. GEFs facilitate the exchange of GDP 
for GTP, thus activating RhoGTPases. 
 
The structure of vav proteins contains several domains which regulate the GEF 
activity (Figure 26). From the amino- to the carboxyl-terminal, it is lined with a 
calponin homology (CH) domain, an acidic (Ac) domain, Dbl homology (DH) 
domain, a pleckstrin homology (PH) domain, a C1 domain, ending with two 
SH3 domains and one SH2 domain [276]. The CH domain inhibits GEF activity 
by binding the cysteine-rich C1 domain; the Ac domain contains several sites 
of tyrosine phosphorylation; the DH domain has catalytic GEF activity for Rho-
family GTPases; the PH domain regulates GEF activity following binding of 
the phospholipids PIP2 and PIP3; the C1 domain contributes to GEF activity by 
binding to the GTPases; and the SH3 and SH2 domains are the binding sites for 
several proteins, e.g. Grb2, SLP-76, ZAP70, Syk, Nef, Zyxin, Ku-70, hnRNP-
K, hnRNP-C, Dynamin2 and VIK-1 [277-280]. 
 
Figure 26: Domain structure of vav1. 
The domain structure of vav1 showing from the amino (N)- to the carboxyl (C)-terminal: a 
calponin homology (CH) domain, an acidic (Ac) domain, Dbl homology (DH) domain, a 
pleckstrin homology (PH) domain, a C1 domain, ending with two SH3 domains and one SH2 
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domain. Ac domain contains several sites of tyrosine phosphorylation. Adopted and modified 
from reference [276]. 
 
In mammals, there are three members in the vav family of proteins – vav1, vav2 
and vav3. Vav1 expression is generally restricted to the hematopoietic system 
[258, 259], whereas vav2 and vav3, are more widely expressed [258]. Each vav 
protein is thought to activate specific GTPases. Vav1 is a GEF for Rac1, Rac2 
and RhoG; vav2 is a GEF for RhoA, RhoB and RhoG; whereas vav3 
preferentially activates RhoA, RhoG and, to a lesser extent, Rac1 [281-283]. 
However, vav1 has also been shown to activate RhoA and Cdc42 [284]. 
Moreover, vav1 was able to stimulate Rac1 and RhoA in ανβ3 integrin-
mediated adhesion of hematopoietic cells [285].  
 
Activation of its GEF activity is mediated via tyrosine phosphorylation of vav1 
[282, 284]. Many pathways are implicated in the vav-mediated reorganization 
of the cytoskeleton in T cells as summarized in Figure 27 [275]. In T-cells, 
binding of CD28 to B7-1 results in tyrosine phosphorylation of vav1 by kinases, 
and the subsequent activation of Rac1 and actin cytoskeleton remodeling [270, 
271].  
 
Figure 27: Vav-mediated regulation of cytoskeleton organization. 




Our finding of B7-1 upregulation following IL-13 stimulation of podocytes, 
which was associated with increased phosphorylation of vav1 has led to the 
hypothesis that IL-13 induced podocyte injury with actin cytoskeleton 
rearrangement could be mediated via B7-1 induced activation of vav1.  This 
would be analogous to the induction of podocyte FP effacement in the IL-13 
overexpressed rat model of MCNS via B7-1 upregulation. 
 
5.2. Aim of chapter 
The aim of this chapter is therefore to investigate the biological relevance of 
vav1 and Rho/Rac1 signaling pathway in inducing podocyte injury using an in-
vitro human podocyte culture system. The specific objectives are as follows:  
1. To study the direct effect of IL-13 on podocyte morphology, in particular, 
cytoskeletal changes associated with FP effacement, using phalloidin 
staining and viewing with confocal microscopy. 
2. To study the role of Rho/Rac1 in IL-13 induced podocyte actin cytoskeleton 
rearrangement. 
3. To validate the role of vav1 in the B7-1-vav1 pathway in actin cytoskeleton 






5.3.1 Effect of IL-13 on podocyte actin cytoskeleton 
As shown in Figure 28, the actin cytoskeleton in the unstimulated podocytes 
was evenly distributed with strong transcellular stress fibers.  IL-13 stimulation 
resulted in actin cytoskeleton rearrangement with weak F-actin signal in the cell 
center and accumulation of F-actin at the cell peripheral, forming a cortical ring-
like structure, suggesting that IL-13 could act directly on podocytes, causing 
podocyte injury.  The cortical F-actin score index, a measure of the degree of 
cytoskelal rearrangement, was significantly increased in IL-13 stimulated 
podocytes (2.31±0.14) as compared to unstimulated podocytes (1.59±0.15) 
(p=0.02) (Figure 29). (Appendix 5.1) 
 
Figure 28: IL-13 induced actin cytoskeleton rearrangement in podocytes. 
Human podocytes were stimulated with IL-13 for one hour and stained with phalloidin for F-
actin (magnification, x60). A) Unstimulated podocytes showed features of larger size and strong 
transcellular stress fibers; B) IL-13 stimulation in podocytes resulted in smaller size and weak 
F-actin signal in the cell center and accumulation of F-actin at the cell peripheral. 
 
Figure 29: Increased cortical F-actin score index in IL-13 stimulated podocytes. 
Cortical F-actin score was determined from at least three independent experiments and the 
cortical F-actin score index was calculated from the ratio of the score of the counted cells to the 




5.3.2 Effect of IL-13 on RhoA and Rac1 activity 
The activity levels of RhoA and Rac1 in IL-13 stimulated podocytes were 
measured using ELISA. Fold change of activated RhoA and Rac1 was 
expressed as ratio of activated RhoA or Rac1 in IL-13 stimulated podocytes 
versus unstimulated podocytes. RhoA activity in IL-13 stimulated podocytes 
remained largely unchanged at 5, 10, 20 and 30 minutes. In contrast, Rac1 
activity in IL-13 stimulated podocytes increased 1.37-fold at 5 minutes to 1.59-
fold at 20 minutes and returned to basal level at 30 minutes (Figure 30). 
Following 20 minutes stimulation of podocytes with IL-13, the Rac1 activity 
level (1.58±0.18) was significantly increased as compared to unstimulated 
podocytes (0.99±0.10) (p=0.01) (Figure 31). (Appendix 5.2) 
 
Figure 30: Time course of RhoA and Rac1 activity following IL-13 stimulation of human 
podocytes. 
Podocytes were stimulated with IL-13 (20ng/ml) and RhoA and Rac1 activity were measured 
at 5, 10, 20 and 30 minutes. The activity levels of RhoA and Rac1 were expressed as mean fold 
change (ratio of IL-13 stimulated:unstimulated podocytes). Asterisk indicates statistically 




Figure 31: Increased Rac1 activity in podocytes incubated with IL-13 for 20 minutes. 
Active Rac1 level was measured and normalized against total protein concentration. Asterisk 
indicates statistically significant differences (p<0.05). 
 
5.3.3 Effect of IL-13 on podocytes transfected with vav1 siRNA  
Following IL-13 stimulation in podocytes transfected with control siRNA, gene 
expression levels of IL-13Rα2 (6.19x10-3±2.38x10-3 vs. 1.28x10-3±0.19x10-3, 
p<0.001), B7-1 (4.36x10-4±1.36x10-4 vs. 1.28x10-4±0.27x10-4, p=0.03) and vav1 
(2.48x10-4±0.70x10-4 vs. 0.71x10-4±0.16x10-4, p=0.04) were significantly 
increased as compared to unstimulated podocytes transfected with control 
siRNA (negative control) (Figure 32). (Appendix 5.3) 
 
Figure 32: Increased gene expression of IL-13Rα2, B7-1 and vav1 in podocytes transfected 
with control siRNA following IL-13 stimulation. 
Gene expression of A) IL-13Rα2, B) B7-1, and C) vav1 in unstimulated podocytes transfected 
with control siRNA, and IL-13 stimulated podocytes with control siRNA transfection. Asterisk 
indicates statistically significant differences (p<0.05). 
 
Western blot analysis showed that following incubation with IL-13, protein 
expression of IL-13Rα2 (1.39±0.20 vs. 0.65±0.07, p=0.009), B7-1 (0.92±0.15 
vs. 0.50±0.08, p=0.02) and phosphorylated vav1 (1.32±0.16 vs. 0.79±0.15, 
p=0.003) were significantly increased in IL-13 stimulated podocytes with 
control siRNA transfection as compared to negative control (Figure 33 and 
Figure 34). Protein expression of vav1 in IL-13 stimulated podocytes with 
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control siRNA transfection remained unchanged as compared to negative 
control (Figure 35). (Appendix 5.4) 
 
Figure 33: Increased protein expression of IL-13Rα2, B7-1 and phosphorylated vav1 in 
podocytes transfected with control siRNA following IL-13 stimulation. 
Protein expression of A) IL-13Rα2, B) B7-1, C) vav1, and D) p-vav1/vav1 in unstimulated 
podocytes transfected with control siRNA, and IL-13 stimulated podocytes with control siRNA 





Figure 34: Protein expression of IL-13Rα2, B7-1, phosphorylated vav1, total vav1 in 
podocytes. 
Representative gel images of IL-13Rα2, B7-1, phosphorylated vav1 and total vav1 in 1) 
unstimulated podocytes transfected with control siRNA and 2) IL-13 stimulated podocytes with 
control siRNA transfection. GAPDH was used as loading control. 
 
 
Figure 35: Vav1 and respective GAPDH blot images from four independent experiments. 
Representative gel images of total vav1 in 1) unstimulated podocytes transfected with control 
siRNA and 2) IL-13 stimulated podocytes with control siRNA transfection. GAPDH was used 
as loading control. 
 
Transfection of podocytes with siRNA specific for vav1 resulted in 84.2% 
reduction in gene expression level of vav1 which translated to reduction in vav1 
protein expression by 42.8% (Figure 36).  
 
Figure 36: Protein expression of vav1 in podocytes. 
Representative gel images of vav1 in podocytes transfected with 1) control siRNA and 2) vav1 
siRNA. GAPDH was used as loading control.  
 
Following IL-13 stimulation, gene expression levels of IL-13Rα2 (3.66x10-3± 
1.19x10-3 vs. 1.28x10-3±0.19x10-3, p=0.04) and B7-1 (3.33x10-4±0.71x10-4 vs. 
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1.28x10-4±0.27x10-4, p=0.01) were significantly increased in vav1 knock down 
podocytes as compared to negative control (Figure 37). 
 
Figure 37: Increased gene expression of IL-13Rα2 and B7-1 in IL-13 stimulated podocytes 
transfected with vav1 siRNA. 
Gene expression of A) IL-13Rα2 and B) B7-1 in unstimulated podocytes transfected with 
control siRNA, and IL-13 stimulated podocytes with vav1 siRNA transfection. Asterisk 
indicates statistically significant differences (p<0.05). 
 
Similarly, increased protein expression levels of IL-13Rα2 (1.23±0.18 vs. 
0.65±0.07, p=0.01) and B7-1 (1.30±0.44 vs. 0.50±0.08, p=0.03) were also 
demonstrated in IL-13 stimulated podocytes transfected with vav1 siRNA in 
comparison to negative control (Figure 38 and Figure 39). 
 
Figure 38: Increased protein expression of IL-13Rα2 and B7-1 in IL-13 stimulated 
podocytes transfected with vav1 siRNA. 
Protein expression of A) IL-13Rα2 and B) B7-1 in unstimulated podocytes transfected with 
control siRNA, and IL-13 stimulated podocytes with vav1 siRNA transfection. Asterisk 





Figure 39: Protein expression of IL-13Rα2 and B7-1 in IL-13 stimulated podocytes 
transfected with vav1 siRNA. 
Representative gel images of IL-13Rα2 and B7-1 in 1) unstimulated podocytes transfected with 
control siRNA and 2) IL-13 stimulated podocytes with vav1 siRNA transfection. GAPDH was 
used as loading control. 
 
5.3.4 Effect of IL-13 on actin cytoskeleton in podocytes transfected with 
vav1 siRNA  
As shown in Figure 40, transfection of podocytes with control siRNA did not 
change the arrangement of actin cytoskeleton, with bright actin staining in the 
center of the cells. Following stimulation with IL-13 in podocytes transfected 
with control siRNA, less stress fibers were formed at the center of the cells. 
Podocytes transfected with vav1 siRNA showed similar features as that of 
podocytes transfected with control siRNA. However, IL-13 stimulation in 
podocytes transfected with vav1 siRNA showed strong stress fibers content at 
the center of the cells indicating that vav1 siRNA transfection had prevented the 
action of IL-13 on actin cytoskeleton rearrangement.   
 
Figure 40: Vav1 knock down podocytes were protected from IL-13 induced actin 
cytoskeleton rearrangement. 
Human podocytes were stained with phalloidin for F-actin (magnification, x60). A) Podocytes 
tranfected with control siRNA showed features of larger size and strong transcellular stress 
fibers; B) IL-13 stimulation in podocytes transfected with control siRNA resulted in smaller 
size and weak F-actin signal in the cell center and accumulation of F-actin at the cell peripheral; 
C) Podocytes transfected with vav1 siRNA showed similar features as that of podocytes 
transfected with control siRNA; D) IL-13 stimulation in podocytes transfected with vav1 siRNA 




Similarly, cortical F-actin score index was significantly increased in IL-13 
stimulated podocytes with control siRNA transfection (2.41±0.10) as compared 
to unstimulated podocytes with control siRNA transfection (1.48±0.05) 
(p=0.05). Transfection of podocytes with vav1 siRNA did not affect the cortical 
F-actin score index compared to that of negative controls. No significant 
difference in cortical F-actin score index was detected in IL-13 stimulated vav1 
knock down podocytes (1.57±0.10) as compared to the unstimulated podocytes 
with control siRNA transfection (1.48±0.05) (p=0.28) (Figure 41). (Appendix 
5.5) 
 
Figure 41: Cortical F-actin index in podocytes transfected with control siRNA or vav1 
siRNA. 
Graph showing cortical F-actin index in podocytes transfected with control siRNA (negative 
control), IL-13 stimulated podocytes with control siRNA transfection, podocytes transfected 
with vav1 siRNA; and IL-13 stimulated vav1 knock down podocytes.  
 
5.3.5 Effect of IL-13 on RhoA and Rac1 activity in podocytes transfected 
with vav1 siRNA 
Rac1 activity level was significantly increased in podocytes transfected with 
control siRNA following IL-13 stimulation (1.17±0.15) as compared to negative 
control (0.71±0.10) (p=0.05) (Figure 42B); while no statistical difference in the 
RhoA activity level was detected (Figure 42A). Following IL-13 stimulation of 
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podocytes transfected with vav1 siRNA, no significant change in both Rac1 and 
RhoA activity levels were detected. (Appendix 5.6) 
 
Figure 42: RhoA and Rac1 activity levels in podocytes transfected with control siRNA or 
vav1 siRNA. 
Activity levels of A) RhoA and B) Rac1 in podocytes transfected with control siRNA (negative 
control), IL-13 stimulated podocytes with siRNA transfection, and IL-13 stimulated vav1 knock 
down podocytes. *p<0.05, compared to negative control; and #p<0.05, compared to IL-13 




The hallmark of nephrotic syndrome in the glomerulus is podocyte FP 
effacement, the corollary of which in the in-vitro podocyte culture system is that 
of actin cytoskeleton rearrangement [77].  In healthy podocytes, distinct bundles 
of actin filament are characteristically seen to traverse the cells from one end to 
the other. On the other hand following podocyte injury, a cortical ring of F-actin 
is formed.  Our in vitro IL-13 stimulated podocytes displayed this characteristic 
feature of weak F-actin signal in the cell center with accumulation of F-actin at 
the cell periphery (Figure 28B), which was also reflected by the significantly 
increased cortical F-actin score index (Figure 29), suggesting that IL-13 could 
induce podocyte injury.  
 
This change in actin cytoskeleton arrangement was associated with increased 
Rac1 activity in the IL-13 stimulated podocytes. Rho family small GTPases, 
namely RhoA, Rac1 and CDC42, are known regulators of the actin 
cytoskeleton.  Activation of RhoA induces the assembly of contractile actin and 
stress fibres [286, 287].  Activation of Rac1 induces actin polymerization to 
form lamellipodia [287, 288], whereas activation of CDC42 stimulates the 
polymerization of actin to filopodia [287, 289].  Healthy, stationary podocytes 
with intact FP are generally thought to have predomoninat RhoA activity, 
whereas in injured, motile podocytes with retracted FP, Cdc42 or Rac1 activity 
is more prevalent [77].  
 
Several studies have implicated the role of RhoA and Rac1 in podocyte FP 
effacement.  Rho GDIα-/- mice developed massive proteinuria resembling 
nephrotic syndrome and died due to renal failure [290].  This was associated 
with increased Rac1 (but not RhoA) and mineralocorticoid receptor signaling 
in the kidney [291]. Pharmacological intervention with a Rac1-specific small-
molecule inhibitor diminished mineralocorticoid receptor hyperactivity and 
reduced proteinuria and renal damage in this mouse model of proteinuria.  
 
Tian, D., et al. have shown that TRPC5 and TRPC6 channels were antagonistic 
regulators of actin dynamics and cell motility in podocytes through the 
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regulation of Rac1 and RhoA, respectively [100].  TRPC5-mediated Ca2+ influx 
was shown to activate Rac1, promoting cell migration; whereas TRPC6-
mediated Ca2+ influx induced RhoA activity, inhibiting cell migration. 
 
Rac1 has either beneficial or deleterious effects depending on the context of 
podocyte injury.  Using the protamine sulfate model of acute podocyte injury, 
podocyte-specific deletion of Rac1 prevented podocyte FP effacement.  In a 
long-term model of chronic hypertensive glomerular damage, however, loss of 
Rac1 led to worsening of albuminuria and glomerulosclerosis [292]. 
 
To date, there have been no reports of the role of vav1 in actin cytoskeleton 
reorganization in podocytes.  However, in T-cells, reorganization of the 
cytoskeleton is needed for T cell activation and function [293-296] upon binding 
with co-receptors such as CD28, ICOS and CTLA-4 [297-299]. The full co-
stimulatory effect of CD28 on T-cells involves the vav1-MEKK1-JNK 
pathway, whereas the ICOS signaling pathway is less understood and probably 
involves the PI3K-PDK-PKB pathway [299].  The polarization of T-cells by 
CTLA-4 requires PI3K, vav1, Cdc42, and myosin L chain kinase, but protein 
kinase B, Rho kinase and RhoA are not required [266]. Regulation of the actin 
cytoskeleton is subsequently mediated via vav1 activation of Rac1 and Cdc42 
[275, 300]. 
 
The classical hematopoietic markers, CD80 (B7-1) [217, 218] and CTLA-4 
[267, 301], have also been shown to be expressed in podocytes.  Podocyte-
specific expression of B7-1 has been implicated as the final common pathway 
in the genesis of proteinuria in glomerulopathies [211, 212]. Following in vitro 
LPS stimulation, podocyte expression of B7-1 was shown to be increased with 
concurrent actin cytoskeleton reorganization.  B7-1 knockout mice were 
protected from LPS-induced proteinuria, suggesting a functional link between 
podocyte B7-1 expression and proteinuria.  Our in vitro IL-13-stimulated 
podocytes showed increased B7-1 expression as well as actin cytoskeleton 
rearrangement, suggesting that IL-13 could induce podocyte injury possibly 
through B7-1 upregulation, correlating with the findings of increased B7-1 
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glomerular expression and FP effacement in our IL-13 overexpression rat model 
of MCNS. 
 
In this chapter, we have demonstrated increased expression of IL-13Rα2, B7-1 
and phosphorylated vav1 following IL-13 stimulation of podocytes transfected 
with control siRNA. This was associated with activation of Rac1 and actin 
cytoskeleton rearrangement.  On the other hand, podocytes with vav1 siRNA 
transfection was protected from this IL-13 induced actin cytoskeleton 
rearrangement and Rac1 activation.  In our vav1 knock-down studies, B7-1 
expression remained upregulated following IL-13 stimulation, but no 
significant changes were seen in the actin-cytoskeleton, suggesting that B7-1 
activation could be the upstream event of vav1 activation in podocytes.  B7-1 
has been shown in previous knock-down studies to be responsible for 
involvement in actin cytoskeleton rearrangement [217, 218].   
 
In summary, we have demonstrated that vav1 plays a role in the IL-13 induced 
podocyte injury which could be mediated via Rac1 (Figure 43).  These findings 
are consistent with the hypothesis that the podocyte FP effacement seen in our 
IL-13 overexpression rat model of MCNS involves the activation of B7-1 and 
subsequent phosphorylation of vav1 and activation of Rac1 resulting in actin 
cytoskeleton rearrangement in podocytes. 
 
Figure 43: Proposed mechanism of IL-13 induced podocyte injury. 
IL-13-induced actin cytoskeleton rearrangement in podocytes through activation of B7-1, 
phosphorylation of vav1 and activation of Rac1. 
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Knowledge of the signaling pathways involved in the pathogenesis of this 
disease may provide us more targeted treatment at the molecular level, allowing 
us to design new therapeutic strategies. Therapeutic strategies could either target 
the source, or stabilize the end point. In our case of increase IL-13 levels in the 
plasma of MCNS patient in relapse which then acts on the IL-13 receptors on 
the podocytes when blood pass through kidney, drugs could be designed to 
sequester IL-13, increasing the level of the IL-13Rα2, or blocking the IL-13Rα1 
on the podocytes. The subsequent activation of B7-1 and vav1-Rac1 signaling 
pathway, could conceivably use Abatacept (CTLA-4-Ig) to block B7-1 
activation or Azathioprine which was shown to have antagonistic effect in the 
vav-Rac signaling pathway in T cells [302, 303]. The challenge, however, will 
be to selectively target these effects to the podocytes (i.e. not affecting the T 
cells). In addition, targeting IL-13 might not be effective if there is a “second 






CONCLUSION AND FUTURE DIRECTIONS 
6.1. Conclusion 
In this study, we have delineated the molecular signature of the glomerulopathy 
associated with our IL-13 overexpressed rat model of MCNS. This was defined 
by differential regulation of genes involved in immune responses, transcription 
regulation and actin cytoskeleton remodeling. In addition, more than 87% of 
genes known to be related to podocytes were significantly downregulated, 
suggesting extensive podocyte injury at the molecular level, whose phenotypic 
expression in this rat model translates to podocyte FP effacement and 
proteinuria.  Moreover, we have identified a possible role of vav1 in the 
regulation of actin cytoskeleton rearrangement seen in podocyte FP effacement.  
This role of vav1 in the regulation of podocyte actin cytoskeleton rearrangement 
is novel, and has not been previously described in kidneys.  We have further 
demonstrated protein expression of vav1 in the glomeruli and tubular epithelial 
cells of rat kidney and showed that vav1 co-localized with synaptopodin, 
confirming its location in podocytes.   
 
Using in vitro human podocyte cell culture, we showed that gene expression of 
vav1 was upregulated by IL-13. We have also demonstrated gene and protein 
expression of vav1 as well as the phosphorylated form of vav1 in pure podocyte 
cell culture systems.  Following IL-13 stimulation, expression levels of IL-
13Rα2, B7-1 and phosphorylated vav1 were significantly increased from the 
basal level, indicating the possible roles of B7-1 and vav1 in IL-13 mediated 
podocyte injury.  
 
IL-13 stimulated podocytes displayed the characteristic feature of actin 
cytoskeleton rearrangement consisting of weak central F-actin, but strong 
peripheral F-actin signal. This was associated with activation of Rac1, 
indicative of motile podocytes with retracted FP.  Vav1 knock-down podocytes 
were protected from IL-13 induced actin cytoskeleton changes and Rac1 
activity, suggesting that the podocyte injury caused by IL-13 via B7-1 involved 




In conclusion, the mechanism of IL-13 induced podocyte FP effacement seen 
in our rat model of MCNS was partly due to the direct action of IL-13 on 
podocytes through activation of B7-1-vav1-Rac1 mediated actin cytoskeleton 
rearrangement (Figure 44). 
 
Figure 44: Mechanism of IL-13 induced podocyte foot process effacement in the rat model 
of MCNS. 
IL-13 could act directly on podocytes, resulting in activation of B7-1 and phosphorylation of 
vav1, switching the Rac1 to the GTP-bound active state, resulting in actin cytoskeleton 
rearrangement.  The podocyte FP effacement in the rat model of MCNS thus could be the result 
of this direct effect of IL-13 induced podocyte injury (direct pathway) or the indirect effect of 
IL-13 on other immune mediators which caused the dysregulation of other podocytes proteins 
not seen in the direct effect of IL-13 on podocytes (accessory pathway). 
 
6.2. Future directions 
We have demonstrated that IL-13 stimulation in cultured human podocytes 
resulted in upregulation of B7-1 gene expression, leading to increased 
phosphorylation of vav1.  This was associated with increased level of activated 
Rac1, and subsequent actin cytoskeleton rearrangement. Though IL-13 was able 
to upregulate B7-1 gene expression in the podocyte cell cultures, the degree of 
upregulation was not as marked as that seen in the glomeruli of the IL-13 
overexpressed rats.  Therefore it is conceivable that a second signal could result 
in perpetuation of the glomerular B7-1 expression.  We have shown that 
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glomerular gene expression of TLR-4 was also significantly elevated in the IL-
13 overexpressed rats, however, this was not seen in IL-13 stimulated human 
podocyte cell cultures.  Stimulation of TLR-4 by specific ligands is a known 
potent inducer of B7-1 expression.  Therefore, we hypothesized that the IL-13 
induced podocyte FP effacement and subsequent proteinuria in our rat model 
could, in part, be due to the presence of an accessory pathway which augments 
and perpetuates the increased B7-1 expression with consequent actin 
cytoskeleton rearrangement.   
 
This is in contrast to the ‘Two-Hit’ hypothesis proposed by Garin et al. [301, 
304].  Reiser et al, in 2004 [217, 218], hypothesized that the initial hit is 
induction of B7-1 on the podocyte, and that this results in change in shape of 
the podocyte with actin rearrangement, leading to increase in glomerular 
permeability and proteinuria.  Induction of B7-1 may result from either direct 
binding of podocyte receptors by activated T-cell cytokines, such as IL-13, or 
by activation of podocyte TLR by viral products or allergens.  Garin et al. 
further hypothesized that under normal circumstances, B7-1 expression is only 
transiently expressed and proteinuria is minimal due to rapid autoregulatory 
response resulting in downregulation of B7-1 response.  The second ‘hit’ in 
MCNS therefore consists of abnormal censoring of podocyte B7-1 expression 
due to a defective autoregulatory response by Tregs or by defective upregulation 
of podocyte CTLA4, a negative regulator of B7-1, resulting in persistent 
podocyte expression of B7-1 and hence proteinuria [304].  Our current study 
could not demonstrate defective upregulation of podocyte CTLA4 in the IL-13 
overexpressed rat, instead, we showed significant upregulation of glomerular 
CTLA4, suggesting that this could be a positive feedback following 
upregulation of B7-1 in this model. 
  
In our model, we are proposing that perpetuation of B7-1 expression occurred 
due to a consequent summative effect of direct IL-13 stimulation as well as 
indirect signaling through TLR-4 mediated by other immune mediators, on B7-
1 (Figure 45).  The identity of the mediator(s) which, via the accessory pathway, 
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augments B7-1 expression with consequent actin cytoskeleton rearrangement 
is, however, unclear. 
 
As IL-13 is an important modulator of monocyte/macrophage function, it is 
plausible that the indirect action of IL-13 on podocyte may be mediated via 
monocyte polarization with consequent secretion of monokine(s) acting on the 
TLR-4/B7-1 danger signaling, resulting in podocyte actin cytoskeleton 
rearrangement. Therefore, we will be studying the monocyte transcription 
profile as well as cytokines/chemokines profile in our population of children 
with MCNS in order to identify the molecules which may be the crucial 
mediator(s) providing the “second hit” in the pathogenesis of MCNS in both 
humans and IL-13 overexpressed rats.   
 
Figure 45: Direct and accessory pathways in the pathogenesis of MCNS (‘Two-Hit’ 
Hypothesis). 
Perpetuation of B7-1 expression occurred due to a consequent summative effect of direct IL-13 
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Appendix 2.1: Protocol for rat urine albumin ELISA 
1. Coat 96 well microtiter plate (Corning, MA, USA) with 100μl of rabbit 
antiserum to rat albumin antibody (MP Biomedicals, CA, USA) diluted 
1/2000 in 0.1M carbonate buffer, 4°C, overnight. 
2. Thoroughly aspirate and discard the coating antibody and wash with 3 
changes of 400µl of 1X PBS.  
3. Blocking with 100μl of 1% BSA in 1X PBS with 0.05% Tween 20 for 45 
minutes, room temperature. 
4. Thoroughly aspirate and discard the blocking solution. Do not wash. 
5. Add 50μl of standards, diluted urine samples and diluent, as blank, to each 
well in triplicate. Incubate for 2 hours, 37°C. 
6. Thoroughly aspirate and discard the liquid and wash with 3 changes of 
400µl of 1X PBS. 
7. Incubate with 50μl of HRP-conjugated sheep polyclonal antibody to rat 
albumin (MP Biomedicals, CA, USA), diluted 1/20000 in 1% BSA in 1X 
PBS with 0.05% Tween 20, for 1 hour at 37°C.  
8. Thoroughly aspirate and discard the detecting antibody and wash with 4 
changes of 400µl of 1X PBS. 
9. Add 50μl of 0.05% OPD substrate (MP Biomedicals, CA, USA) in each 
well and incubate for 10 minutes at room temperature in dark. 
10. Stop reaction with 60μl of 4.5 N sulphuric acid. Gently mix and incubate for 
5 minutes. 
11. Read the absorbance at 490 nm using a microplate reader. 
 
Preparation of standards: 
• Rat albumin (MP Biomedicals, CA, USA) stock solution = 20mg/ml  
• Diluent = 0.05% Tween 20 in 1X PBS 
• Dilute the 20 mg/ml stock solution 1/100 to final concentration of 200μg/ml: 
10μl of stock solution + 990μl of diluent 
• Dilute the 200μg/ml rat albumin solution 1/100 to 2μg/ml: 50μl of 200μg/ml 
rat albumin solution + 4950μl of diluent 
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• Make a 2X standard serial dilutions from the 2μg/ml rat albumin solution  
• Concentration of standards: 2000, 1000, 500, 250, 125, 62.5, 31.25, 15.625 
ng/ml 
 
Dilution of urine samples: 
• Dilute the urine samples 1/10: 50μl of urine sample + 450μl of diluent. 
• Further serial dilute the urine samples ranging from 1/10 to 1/100 as shown 
in the table below. 
Dilution factor 
(Final dilution) Volume from first dilution/ μl Volume of diluent/ μl 
1/10 (1/100) 20 180 
1/20 (1/200) 15 285 
1/30 (1/300) 15 435 
1/40 (1/400) 15 585 
1/50 (1/500) 15 735 
1/60 (1/600) 15 885 
1/70 (1/700) 15 1035 
1/80 (1/800) 15 1185 
1/90 (1/900) 15 1335 
1/100 (1/1000) 15 1485 
 
 Reagent preparation: 
0.1M Sodium carbonate buffer, pH 9.6: 
0.2M Sodium carbonate (Na2CO3)   8ml 
0.2M Sodium bicarbonate (NaHCO3)  17ml 
ddH2O       25ml 
 
0.2M Sodium carbonate (Na2CO3): 
Sodium carbonate (Na2CO3)    21.2g 
ddH2O       1000ml 
 
0.2M Sodium bicarbonate (NaHCO3): 
Sodium bicarbonate (NaHCO3)   16.8g 






1X PBS      50ml 
BSA       0.5g 
Tween 20      25μl 
 
Diluent for standards and urine samples: 
1X PBS      500ml 
Tween 20      250μl 
  
OPD substrate: 
Phosphate-citrate buffer, pH 5.0   6ml 
OPD (o-Diphenylenediamine)   300μl 
30% H2O2*      3μl 
*Add the H2O2 just before use. 
 
Phosphate-Citrate buffer pH 5.0 for OPD substrate: 
0.1M Citrate buffer     24.3ml 
0.2M Phosphate buffer    25.7ml 
ddH2O       50ml 
 
0.1M Citrate buffer: 
Citric acid      3.84g 
ddH2O       200ml 
 
0.2M Phosphate buffer: 
Na2HPO4 (anhydrous)     5.68g 








Appendix 2.2: Protocol for RNA cleanup using RNeasy® Kit (RNeasy® Mini 
Handbook, 4th Edition, 09/2010) 
1. Adjust the sample to final volume of 100μl with RNase-free water.  
2. Add 350μl Buffer RLT, and mix well. 
3. Add 250μl absolute ethanol to the mixture and mix well by pipetting.  
4. Transfer all the sample to an RNeasy Mini spin column placed in a 2 ml 
collection tube supplied. Close the lid, and centrifuge for 15s at 13,000rpm. 
Discard the flow-through. 
5. Add 350μl of Buffer RW1 to the RNeasy spin column. Close the lid, and 
centrifuge for 15s at 13,000rpm. Discard the flow-through. 
6. Add 10μl of DNase I stock solution to 70μl Buffer RDD. Mix by gently 
inverting the tube, and centrifuge briefly to collect residual liquid from the 
sides of the tube. 
7. Add the DNase I incubation mix (80μl) directly to the RNeasy spin column 
membrane, and incubate at room temperature for 15 minutes. 
8. Add 350μl of Buffer RW1 to the RNeasy spin column. Close the lid, and 
centrifuge for 15s at 13,000rpm. Discard the flow-through. 
9. Add 500μl of Buffer RPE to the RNeasy spin column. Close the lid, and 
centrifuge for 15s at 13,000rpm. Discard the flow-through. 
10. Add 500μl of Buffer RPE to the RNeasy spin column. Close the lid, and 
centrifuge for 2 minutes at 13,000rpm. Discard the flow-through. 
11. Place the RNeasy spin column in a new 2ml collection tube (supplied) and 
discard the old collection tube with the flow-through. Close the lid gently, 
and centrifuge at 13,000rpm for 1 minute. 
12. Place the RNeasy spin column in a new 1.5ml collection tube (supplied). 
Add 30μl of RNase-free water directly to the spin column membrane. Close 
the lid gently, and centrifuge for 1 minute at 13,000rpm to elute the RNA. 
13. Repeat step 12 using the eluate from step 12 for high RNA concentration. 






Buffer RPE working solution: 
Buffer RPE is supplied as a concentrate. Before using for the first time, add 4 
volumes of absolute ethanol as indicated on the bottle to obtain a working 
solution. 
 
DNase I stock solution: 
Prepare DNase I stock solution before using the RNase-Free DNase Set for the 
first time. Dissolve the lyophilized DNase I (1500 Kunitz units) by injecting 
550μl of the RNase free water provided using RNase-free needle and syringe. 
Mix gently by inverting the vial. Do not vortex. Aliquot the stock solution into 




Appendix 2.3: Protocol for cRNA hybridization and array scanning 
(Illumina® Whole-Genome Expression for BeadStation) 
Hybridization: 
Preheat the oven (with rocking platform) to 58°C. 
 
Mix with Hyb Reagents: 
1. Add up to 5μl of RNase free water to 750ng cRNA, and mix. 
2. Incubate at room temperature for 10 minutes to resuspend cRNA. 
3. Place the HYB and HCB bottles in the 58°C oven for 10 minutes to dissolve 
any salt precipitation. Cool to room temperature and mix thoroughly before 
use. 
4. Add 10μl of HYB to each cRNA sample. 
 
Set up Hybridization: 
1. Place Illumina Hyb Chamber Gaskets into BeadChip Hyb Chamber. 
2. Dispense 200μl of HCB into each of the two humidifying buffer reservoirs 
in each Hyb Chamber. Only add buffer to chambers that will be used. 
3. Seal Hyb Chamber with lid and keep on bench at room temperature until 
ready to load BeadChips into Hyb Chamber. 
4. Remove all BeadChips from their packages. (3 fingers at the notches to 
release) 
5. Holding BeadChip by coverseal tab with tweezers using powder-free gloved 
hands, slide BeadChip into Hyb Chamber Insert such that the barcode lines 
up with barcode symbol on the Insert. 
6. Preheat the assay sample at 65°C for 5 minutes. 
7. Briefly vortex, then briefly centrifuge to collect the liquid in the bottom of 
the tube. Allow sample to cool to room temperature before using. Pipet 
sample immediately after cooling to room temperature. 
8. Dispense 15μl of assay sample onto the large sample port of each array, 
ensuring pipet tip does not touch array. 
9. Load Hyb Chamber Inserts containing BeadChips into the Hyb Chamber 
with rocker speed at 5. 
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10. Seal lid onto the Hyb Chamber by applying the back of the lid first and then 
bringing it down to the front to avoid dislodging the Hyb Chamber Insert(s). 
11. Incubate for 18.5 hours at 58°C. 
 
Prepare for High-Temp Wash & Overnight Incubation: 
1. Prepare 1X High-Temp Wash buffer by adding 50ml of 10X stock to 450ml 
of RNAse free water. 
2. Place waterbath insert into heat block, and add 500ml of 1X High-Temp 
Wash buffer. 
3. Set heat block temperature to 55°C and pre-warm High-Temp Wash buffer 
to that temperature overnight. 
 
Prepare Reagents: 
1. The next day, prepare Wash E1BC solution by adding 3ml of E1BC buffer 
to 1L of RNase free water. 
2. Pre-warm Block E1 buffer (4ml/chip) to room temperature.  
 
Room-Temperature Incubation: 
1. Remove Hyb Chamber from oven and disassemble. (Observe for bubbles, 
if any, and locate them on the tracking sheet). 
2. Remove coverseal in a zig-zag manner in a container with 1L of Wash E1BC 
solution. Using tweezers or powder-free gloved hands, place the BeadChip 
into the slide rack submerged in the staining dish containing 250ml of Wash 
E1BC solution. 
3. Using the slide rack handle, transfer the rack into the Hybex Waterbath 
insert containing High-Temp Wash buffer. 
 
High-Temp Wash: 





1st Room-Temp Wash: 
1. During the 10 minutes High-Temp Wash buffer incubation, add fresh 250ml 
of Wash E1BC solution to a clean staining dish. 
2. After the 10 minutes High-Temp Wash buffer incubation is complete, 
immediately transfer the slide rack into the above prepared staining dish. 




Transfer rack to a clean staining dish containing 250ml of absolute ethanol. 
Briefly agitate using rack handle, then shake on orbital shaker for 10 minutes at 
110rpm. 
 
2nd Room-Temp Wash: 
Transfer rack to a clean staining dish containing fresh 250ml of Wash E1BC 
solution. Briefly agitate using rack handle, then shake on orbital shaker for 2 
minutes at 110rpm. 
 
Block: 
1. Pipette 4ml of Block E1 buffer into the Wash Tray(s). 
2. Transfer the BeadChip, face up into BeadChip Wash Tray(s) on rocker. 
3. Rock at medium speed for 10 minutes.  
4. Prepare Block E1 buffer (cloudy looking, normal) (2 ml/chip) with 
streptavidin-Cy3 (2μl of 1mg/ml stock per chip). Use a single conical tube 
for all BeadChips. Store in dark until detection step. 
 
Detect: 
1. Pipette 2ml of Block E1 buffer + streptavidin-Cy3 into fresh Wash Tray(s). 
2. Transfer the BeadChip, face up into Wash Tray(s) on rocker. 
3. Place cover on tray and rock at medium speed for 10 minutes. 
 
3rd Room-Temp Wash: 
1. Add 250ml of Wash E1BC solution to a clean staining dish. 
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2. Transfer the BeadChip to the slide rack submerged in the staining dish. 
3. Briefly agitate using rack, and then shake at room temperature on orbital 
shaker for 5 minutes. 
 
Dry: 
1. Prepare centrifuge with plateholders, paper towels and balance rack. Set 
speed to 270rcf. 
2. Transfer rack of BeadChips from staining dish to centrifuge and spin at 
room temperature for 4 minutes. 
3. Store dry chips in slide box until scanned. 
 
Scanning: 
Scan the arrays with scan factor 1.5, PMT 551 using Illumina® BeadArray 
Reader. Ensure the signal is strong enough, i.e. green colour on the slot instead 
of red. Check that all the housekeeping genes and other parameters are normal. 
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Appendix 2.4: Protocol for single-stranded cDNA synthesis using 
Superscript III First-Strand Synthesis System for RT-PCR 
Single-stranded cDNA was synthesized from 150ng of total RNA using the 
Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen Life 
Technologies, CA, USA), according to the manufacturer’s instructions. The 
initial reaction mixture for cDNA conversion was prepared as shown below. 
Reagent Volume for 1 reaction 
50pmol Oligo(dT) 1µl 
10mM dNTP 1µl 
150ng total RNA  Variable 
DEPC-treated water Top up to 13µl 
Final Volume 13 µl 
 
The mixture was incubated at 65 ºC for 5 minutes followed by incubation at 4ºC 
for at least 1 minute. A second reaction mixture was prepared as shown in the 
table below and added to each tube and mixed by gentle pipetting. All tubes 
were incubated at 50ºC for 1 hour, followed by inactivation at 70 ºC for 15 
minutes and cooling at 4ºC. 
Reagent Volume for 1 reaction 
5X First Strand Buffer 4µl 
0.1M DTT 1µl 
RNaseOUT recombinant RNase Inhibitor (40U/µl) 1µl 
Superscript III Reverse Transcriptase (200U/µl) 1µl 
Final Volume 7 µl 
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Appendix 2.5: Protocol for plasmid standard curve generation 
Polymerase chain reaction (PCR) was carried out using podocyte cDNA and 
specific primer sequences as shown in the table below to obtain the genes of 
interest. The reactions were run at 95°C for 5 minutes, followed by 40 
amplification cycles of 95°C for 30 seconds, annealing temperature of 58°C for 
30 seconds and 72°C for 30 seconds. A final 9 minutes of extension at 72°C was 
performed after the last amplification cycle, followed by cooling at 4°C.  
Nucleotide sequence of primers for the respective genes of interest in rat glomeruli. 
Gene 
Accession no. Primers  Nucleotide sequence 5’ - 3’ bp 
Rat vav1 Forward 5’- GGGTGAAAGATACAGCGGAA -3’ 234 
NM_012759 Reverse 5’- GCTTGTTGATGGCTCTCCTC -3’  
Rat Kirrel2 Forward 5’- TCTGTGTCTCTGGTTGCTGG -3’ 169 
XM_218486 Reverse 5’- AGGTGTTTTCAACTGTCCCG -3’  
Rat Cdh11 Forward 5’- CTTTGCAGCAGAAATCCACA -3’ 299 
XM_001059464 Reverse 5’- CACGTCGGGCATATACTCCT -3’  
Rat Nck2 Forward 5’- TCCACAGATCAGCTACACCG -3’ 184 
NM_001108216 Reverse 5’- TGATGCTTTGAGAGACACGG -3’  
Rat Magi2 Forward 5’- CGAGAGTGTCATTGGCAGAA -3’ 228 
NM_053621 Reverse 5’- GGGTCCTTGCAGTGTTTGAT -3’  
Rat Actn4 Forward 5’- AGTGGGATAACCTGGGCTCT -3’ 227 
NM_031675 Reverse 5’- GGTGGACTTGAACTGGTCGT -3’  
Rat Ctnnal1 Forward 5’- GTGTGGAGGACTTCACCGAT -3’ 253 
NM_001106649 Reverse 5’- TGGAATTTTAACAGGTCGGC -3’  
Rat Itga3 Forward 5’- AGGGACCTTAGGGCACATCT -3’ 179 
NM_001108292 Reverse 5’- TTCACAGTCTTCATGGCAGC -3’  
Rat Ptpro Forward 5’- CTTGGAGAGGGAAGGGAAA -3’ 281 
NM_017336 Reverse 5’- GATCTGCAGCAAAGTGTGGA -3’  
Rat Ezr Forward 5’- AAGATGACAAGTTGACCCCG -3’ 187 
NM_019357 Reverse 5’- ATGTACAGCTCGTGGTTCCC -3’  
Rat Junb Forward 5’- GCAGCTACTTTTCGGGTCAG -3’ 247 
NM_021836 Reverse 5’- TGGTTCATCTTGTGCAGGTC -3’  
Rat GAPDH Forward 5’- GGTGATGCTGGTGCTGAGTA-3’ 273 






Nucleotide sequence of primers for the respective genes of interest in human podocytes. 
Gene 
Accession No. Primers Nucleotide sequence 5’ - 3’ bp 
GAPDH 
NM_002046.3 
Forward 5’ – CTGGCATGGCCTTCCGTGTC – 3’ 194 
Reverse 5’ – GGAGGAGTGGGTGTCGCTGT – 3’  
B7.1 
NM_005191.3 
Forward 5’ – CACGGAGGCAGGGAACATCA – 3’ 183 
Reverse 5’ – AGATGCGAGTTTGTGCCAGC – 3’  
Nephrin 
NM_004646.3 
Forward 5’ – GAGCACCCCACTCCCCTAAC – 3’ 212 
Reverse 5’ – GCAGACACGTTGGCAATGGT – 3’  
Podocin 
NM_014625.2 
Forward  5’ – CAGGACTCCGCACAAGGAGA – 3’ 159 
Reverse 5’ – ACCTCATCCACGTCCACCAC – 3’  
dystroglycan   
NM_004393.4 
Forward 5’ – AGGATGTCTGTGGGCCTCTC – 3’ 240 
Reverse 5’ – GGTCACTCGAAATGAGCGCC – 3’  
IL-4R 
NM_000418.2 
Forward  5’ – CCTGGAGCCAAGTCCTCCTG – 3’ 200 
Reverse 5’ – CACAGGGCATCTCGGGTTCT – 3’  
IL-13Rα1 
NM_001560.2 
Forward  5’ – GCTCCGGAAACTCGTCGTTC – 3’ 187 
Reverse 5’ – AGCTCAGGTTGTGCCAAATGC – 3’   
IL-13Rα2 
NM_000640.2     
Forward  5’ – CAATGGCAACCCCCACTGTC – 3’ 186 
Reverse 5’ – GCATTGCCATGGTAAAAGCGTG – 3’  
Vav1 
NM_005428.2     
Forward  5’ – CCCTGTCTGCTCTGTCCTGG  – 3’ 241 
Reverse 5’ – TCTGTCATCTTGGGCGGCAT – 3’  
ACTN4 
(NM_004924.4) 
Forward  5’ – CAGCTTCTACCATGCCTTTT – 3’ 195 
Reverse 5’ – TCCTGGATAGTCTTTTGGGG – 3’  
CDH11 
(NM_001797.2) 
Forward  5’ –  TTGTACCTTCTGCCCATAGT – 3’ 200 
Reverse 5’ – ATGACCAGGAGAATGACGAT – 3’  
CTNNAL1 
(NM_003798.2) 
Forward  5’ – AGCTCTTCGGGAGAATCTTT – 3’ 193 
Reverse 5’ – TTGAGCTTGAATCCACACAG – 3’  
EZR 
(NM_003379.4) 
Forward  5’ – ATGCCGAAACCAATCAATGT – 3’ 192 
Reverse 5’ – CTTCTTATCCAGCTTCAGCC – 3’  
ITGA3   
(NM_002204.2) 
Forward 5’ – GCCAAGCTAATGAGACCATC – 3’ 197 
Reverse 5’ – TGTATAGTCCACCAGCAGAG – 3’  
JUNB 
(NM_002229.2) 
Forward 5’ – ACACGACTACAAACTCCTGA – 3’ 200 
Reverse 5’ – TGCTGTTGGGGACAATCA – 3’  
KIRREL2 
(NM_199179.2) 
Forward 5’ – TCTCTGTGCTACACATTTCG – 3’ 188 
Reverse 5’ – CCCAGTGATGACCATAAGGA – 3’  
MAGI2 
(NM_012301.3) 
Forward  5’ – CGAAAAAGGCTAAACCTCCA – 3’ 192 
Reverse 5’ – TTGTTCCAAGTTCTGTGTGG – 3’  
NCK2 
(NM_003581.4) 
Forward 5’ – GACCAGAGGCAGCTCTTGGT – 3’ 198 
Reverse 5’ – GCAGCCAGCAAGAAGCATCA – 3’  
PTPRO 
(NM_030667.2) 
Forward 5’ – ACGGACAGGAACATTCATTG – 3’ 187 




The PCR products were cloned into pCR 2.1-TOPO vector using the TOPO® 
TA cloning kit (Invitrogen Life Technologies, CA, USA). The TA cloning 
reaction was set up as shown in the table below. 
Reagent Volume for 1 reaction 
Fresh PCR product 3µl 
Water 1µl 
Salt Solution 1µl 
TOPO vector 1µl 
Final Volume 6µl 
 
The reaction mixture for each gene was mixed gently and incubated at room 
temperature for 15 minutes. Two µl of the reaction mixture was then added to a 
vial of OneShot® TOP10 Chemically Competent E. coli cells and incubated for 
15 minutes on ice before being subjected to heat shock for 30 seconds at 42ºC 
without shaking. The vial was placed on ice for 2 minutes before adding 250µl 
of S.O.C. medium to each vial and incubated for 1 hour at 37ºC with shaking at 
250rpm. 
 
One hundred µl of the incubation mixture was spread onto a pre-warmed Luria-
Bertani (LB) agar plate containing 100µg/ml ampicillin and 40µg/ml 5-bromo-
4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal) (Promega, WI, USA) for 
blue-white selection. Plates were incubated overnight at 37ºC. Isolated white 
colonies were picked for sub-culturing. Each colony was grown in 3ml of LB 
broth containing 100µg/ml ampicillin at 37ºC with shaking at 250rpm. After 8 
hours, the bacterial culture was diluted by topping up the LB broth to 10ml and 
was incubated overnight under the same conditions but not more than 16 hours. 
Cells were then centrifuged at 6000g and 4ºC for 15 minutes. The supernatant 
was discarded and plasmids were extracted using the QIAprep Spin Miniprep 
Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer’s 
protocol. Concentration of the plasmid DNA stock was measured using 
NanoDrop 1000 Spectrophotometer (NanoDrop products, Thermo Scientific, 
DE, USA). Presence of gene inserts was confirmed by EcoRI restriction and 
agarose gel electrophoresis. Serial dilutions were done to get a series of plasmid 
standards, ranging from 109 copy number to 101 copy number. Plasmid 
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standards were run in triplicates in real-time PCR using LightCycler® 480 
SYBR Green I Master reagent (Roche, Germany). Good standard curves should 




Appendix 3.1: Biochemistry data of control and IL-13 overexpressed rats 
 
Biochemistry profile of rats used for the microarray analysis. 














(3)C2 C2 0 41 1.94 88.2 218 
(3)C3 C3 0 42.4 1.53 65.2 303 
(3)C4 C4 0 56.9 1.63 67.2 194 
(3)C5 C5 2 38.6 1.81 84.9 231 
(6)C3 C15 11 42.4 1.5 82.2 495 
(6)C5 C17 8 46.7 1.55 82.2 275 
(3)J2 J2 1578 27.9 7.8 69.7 2331 
(3)J4 J4 376 29.3 5.83 89.5 3098 
(4)J5 J11 28 29 4.3 70.5 2996 
(4)J9 J15 336 29.3 4.45 67.6 6846 
(4)J13 J19 1753 18.9 8.78 79.3 12087 
(4)J16 J22 657 15.5 12.2 56.8 32845 




Appendix 3.2: Full list of DEGs  
 
List of genes differentially expressed in the glomeruli of IL-13 overexpression rats versus 
control rats. 
GenBank 




NM_053394.2 Klf5 Kruppel-like factor 5 -4.09 
NM_031836.1 Vegfa vascular endothelial growth factor A -3.67 
XM_241275.4 Sema5a sema domain, seven thrombospondin 
repeats (type 1 and type 1-like), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 5A
-3.01 




XM_344806.3 Hey2 hairy/enhancer-of-split related with 
YRPW motif 2 -2.36 
NM_016991.2 Adra1b adrenergic, alpha-1B-, receptor -2.19 
XM_001070551.1 Reck reversion-inducing-cysteine-rich protein 
with kazal motifs -2.09 
NM_053356.1 Col1a2 collagen, type I, alpha 2 -2.08 
NM_133386.2 Sphk1 sphingosine kinase 1 -2.01 
XM_001079521.1 Fgfr2 fibroblast growth factor receptor 2 -1.97 
XM_001060648.1 Tiparp TCDD-inducible poly(ADP-ribose) 
polymerase -1.69 
NM_013151.2 Plat plasminogen activator, tissue -1.66 
NM_001024781.1 Sox18 SRY (sex determining region Y)-box 18 1.90 
NM_019386.2 Tgm2 transglutaminase 2, C polypeptide 1.77 
NM_022277.1 Casp8 caspase 8 1.64 
Cell adhesion 
XM_579693.1 Spon1 spondin 1, extracellular matrix protein -6.88 
NM_021682.1 Negr1 neuronal growth regulator 1 -4.93 
XM_229775.4 LOC317070 similar to nidogen 2 -4.28 
XM_342325.3 Col11a1 collagen, type XI, alpha 1 -3.62 
NM_013137.1 Ddr1 discoidin domain receptor tyrosine kinase 
1 -3.08 
NM_138525.1 Mucdhl mucin and cadherin like -3.02 
NM_031753.1 Alcam activated leukocyte cell adhesion 
molecule -2.93 
NM_053848.1 Opcml opioid binding protein/cell adhesion 
molecule-like -2.92 
NM_031716.1 Wisp1 WNT1 inducible signaling pathway 
protein 1 -2.77 
XM_213902.4 Lamc2 laminin, gamma 2 -2.76 
XM_213560.4 Pkp2 plakophilin 2 -2.76 
NM_019358.1 Pdpn podoplanin -2.72 
NM_019140.2 Ptprd protein tyrosine phosphatase, receptor 
type, D -2.59 
XM_241632.4 Col18a1 collagen, type XVIII, alpha 1 -2.53 
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XM_221337.3 LOC288010 LIM domain containing preferred 
translocation partner in lipoma -2.38 
XM_001076220.1 Celsr2 cadherin, EGF LAG seven-pass G-type 
receptor 2 (flamingo homolog, 
Drosophila) 
-2.38 
XM_223583.4 Aebp1 AE binding protein 1 -2.28 
NM_031521.1 Ncam1 neural cell adhesion molecule 1 -2.19 
XM_001072297.1 RGD1564327 similar to integrin alpha 8 -2.00 
XM_230950.4 Itgav integrin alpha V -1.97 
XM_235308.4 Col14a1 collagen, type XIV, alpha 1 -1.97 
XM_345584.3 Col16a1 collagen, type XVI, alpha 1 -1.96 
XM_227117.4 Pcdh18 protocadherin 18 -1.93 
NM_022944.1 Inppl1 inositol polyphosphate phosphatase-like 1 -1.91 
NM_013016.2 Sirpa signal-regulatory protein alpha -1.88 
NM_198747.1 Col27a1 collagen, type XXVII, alpha 1 -1.74 
XM_001076634.1 LOC686988 discoidin domain receptor tyrosine kinase 
2 -1.73 
NM_030842.1 Itga7 integrin alpha 7 -1.70 
NM_001004090.2 Tspan5 tetraspanin 5 -1.67 
XM_575373.2 RGD1564980 ribosomal protein L29; similar to 60S 
ribosomal protein L29 (P23); ribosomal 
protein L29, pseudogene 1; similar to 60S 
ribosomal protein L29
3.26 
NM_001025750.1 Plek pleckstrin 2.43 
XM_579351.1 LOC497761 Cd2 molecule 2.23 
XM_575338.2 RGD1562323 similar to CD36 antigen; similar to fatty 
acid translocase/CD36; CD36 molecule 
(thrombospondin receptor) 
2.19 
NM_020308.1 Adam15 a disintegrin and metallopeptidase 
domain 15 (metargidin) 2.07 
NM_019177.1 Sell selectin, lymphocyte 2.05 
NM_024360.2 Hes1 hairy and enhancer of split 1 (Drosophila) 2.01 
XM_575339.1 LOC499985 similar to fatty acid translocase/CD36 2.01 
NM_133306.1 Olr1 oxidized low density lipoprotein (lectin-
like) receptor 1 2.00 
NM_031691.1 Itgad integrin, alpha D 1.91 
XM_001067562.1 Itgb7 integrin, beta 7 1.88 
XM_342930.2 Ptpru protein tyrosine phosphatase, receptor 
type, U 1.69 
XM_219001.4 Xlkd1 lymphatic vessel endothelial hyaluronan 
receptor 1 1.63 
XM_001055526.1 Pcdhb10 protocadherin beta 10 1.61 
Intrinsic to plasma membrane 
XM_001055768.1 Tmeff1 transmembrane protein with EGF-like 
and two follistatin-like domains 1 -6.67 
NM_031739.1 Kcnd3 potassium voltage gated channel, Shal-
related family, member 3 -5.64 
NM_019214.1 Slc26a4 solute carrier family 26, member 4 -4.26 
NM_019276.2 Ugt8 UDP glycosyltransferase 8 -4.19 
NM_024376.1 Gja3 gap junction protein, alpha 3 -3.70 




NM_012813.1 St8sia1 ST8 alpha-N-acetyl-neuraminide alpha-
2,8-sialyltransferase 1 -3.68 
NM_173103.1 Clcnkb chloride channel Kb -3.48 
XM_234108.4 Prkcm protein kinase D1 -3.21 
XM_001075775.1 Mpv17l Mpv17 transgene, kidney disease mutant-
like -3.09 
NM_173293.1 Olr59 olfactory receptor 59 -2.96 
NM_152938.1 Slc4a9 solute carrier family 4, sodium 
bicarbonate cotransporter, member 9 -2.88 
NM_012799.1 Nmbr neuromedin B receptor -2.87 
NM_001014171.1 Veph1 ventricular zone expressed PH domain 
homolog 1 (zebrafish) -2.86 
NM_053981.1 Kcnj12 potassium inwardly-rectifying channel, 
subfamily J, member 12 -2.80 
NM_001025413.1 Tmem184a transmembrane protein 184A -2.71 
NM_053445.1 Fads1 fatty acid desaturase 1 -2.67 
NM_019243.1 Ptgfrn prostaglandin F2 receptor negative 
regulator -2.63 
XM_217033.4 LOC300191 solute carrier family 48 (heme 
transporter), member 1 -2.62 
NM_001034014.1 Accn1 amiloride-sensitive cation channel 1, 
neuronal -2.57 
XM_001057885.1 Atp2b3 ATPase, Ca++ transporting, plasma 
membrane 3 -2.56 
NM_031007.1 Adcy2 adenylate cyclase 2 (brain) -2.47 
NM_021688.2 Kcnk1 potassium channel, subfamily K, member 
1 -2.46 
NM_053570.1 Cxadr coxsackie virus and adenovirus receptor -2.45 
NM_022590.2 Slc5a2 solute carrier family 5 (sodium/glucose 
cotransporter), member 2 -2.45 
NM_198786.2 Mal2 mal, T-cell differentiation protein 2 -2.45 
NM_031841.1 Scd stearoyl-CoA desaturase (delta-9-
desaturase) -2.44 
NM_021266.2 Fzd1 frizzled homolog 1 (Drosophila) -2.41 
NM_001004282.1 Tmem178 transmembrane protein 178 -2.41 
NM_031034.1 Gna12 guanine nucleotide binding protein, alpha 
12 -2.40 
XM_225718.3 Kcng2 potassium voltage-gated channel, 
subfamily G, member 2 -2.38 
NM_031795.1 Ugcg UDP-glucose ceramide 
glucosyltransferase -2.34 
NM_053571.1 Sec16b SEC16 homolog B (S. cerevisiae) -2.33 
XM_344661.3 Reep5 receptor accessory protein 5 -2.31 
NM_031344.2 Fads2 fatty acid desaturase 2 -2.30 
NM_001005562.1 Creb3l1 cAMP responsive element binding 
protein 3-like 1 -2.24 
NM_017060.1 Hrasls3 phospholipase A2, group XVI -2.19 
NM_017049.1 Slc4a3 solute carrier family 4 (anion exchanger), 
member 3 -2.18 
NM_001013185.1 Cabc1 presenilin 2; chaperone, ABC1 activity of 
bc1 complex homolog (S. pombe) -2.16 
NM_172091.1 Gcgr glucagon receptor -2.15 
XM_342986.2 Tas1r1 taste receptor, type 1, member 1 -2.12 
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NM_001005558.1 Fam151a family with sequence similarity 151, 
member A -2.11 
NM_012507.2 Atp1b2 ATPase, Na+/K+ transporting, beta 2 
polypeptide -2.08 
NM_199105.1 MGC72614 hypothetical LOC310540 -2.08 
NM_130822.1 Lphn3 latrophilin 3 -2.07 
NM_053735.1 Pi4k2a phosphatidylinositol 4-kinase type 2 
alpha -2.06 
NM_001010958.1 Slc25a29 solute carrier family 25, member 29 -2.06 
NM_001007672.1 Tmem98 transmembrane protein 98 -2.05 
NM_031648.1 Fxyd1 FXYD domain-containing ion transport 
regulator 1 -2.04 
NM_181639.3 Slc29a3 solute carrier family 29 (nucleoside 
transporters), member 3 -1.99 
NM_001003705.1 LOC291840 solute carrier family 38, member 7 -1.99 
NM_017136.1 Sqle squalene epoxidase -1.97 
NM_184050.2 Ermp1 endoplasmic reticulum metallopeptidase 
1 -1.97 
NM_017206.1 Slc6a6 solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 -1.95 
NM_139325.1 Eno2 enolase 2, gamma, neuronal -1.94 
NM_017299.1 Slc19a1 solute carrier family 19 (folate 
transporter), member 1 -1.93 
NM_053485.2 S100a6 S100 calcium binding protein A6 -1.90 
NM_173145.1 Dlgap4 discs, large homolog-associated protein 4 
(Drosophila) -1.88 
NM_139082.2 Bambi BMP and activin membrane-bound 
inhibitor, homolog (Xenopus laevis) -1.88 
NM_022219.2 Fut4 fucosyltransferase 4 (alpha (1,3) 
fucosyltransferase, myeloid-specific) -1.87 
NM_022862.1 Unc13b unc-13 homolog B (C. elegans) -1.87 
NM_183332.1 Myadm myeloid-associated differentiation marker -1.87 
NM_012919.2 Cacna2d1 calcium channel, voltage-dependent, 
alpha2/delta subunit 1 -1.87 










NM_001007679.1 Tmem206 transmembrane protein 206 -1.82 
NM_001012345.1 Dgat2 diacylglycerol O-acyltransferase homolog 
2 (mouse) -1.82 
NM_001014209.1 LOC363060 similar to RIKEN cDNA 1600029D21 -1.81 
XM_574680.1 Cnnm2 cyclin M2 -1.81 
NM_001013903.1 Tmem171 transmembrane protein 171; proline rich 
protein 2 -1.77 
NM_080582.1 Abcb6 ATP-binding cassette, sub-family B 
(MDR/TAP), member 6 -1.77 
NM_001013126.1 Cyb5r1 cytochrome b5 reductase 1 -1.75 
NM_176861.1 Kcnmb2 potassium large conductance calcium-





NM_012716.1 Slc16a1 solute carrier family 16, member 1 
(monocarboxylic acid transporter 1) -1.74 
NM_134363.1 Slc12a5 solute carrier family 12 (potassium-
chloride transporter), member 5 -1.73 
NM_033352.1 Abcd2 ATP-binding cassette, sub-family D 
(ALD), member 2 -1.72 
NM_001012018.1 B4galt4 UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 4 -1.71 
NM_001008358.1 Tmem106c transmembrane protein 106C -1.69 
NM_001007002.1 Mxra8 matrix-remodelling associated 8 -1.68 
XM_001080929.1 RGD1565432 similar to hypothetical protein -1.66 
NM_001004204.2 MGC94190 similar to 0610007L01Rik protein -1.66 
NM_080480.1 Pip5k2c phosphatidylinositol-5-phosphate 4-
kinase, type II, gamma -1.66 
XM_220982.3 Ptrf polymerase I and transcript release factor -1.66 
NM_031559.1 Cpt1a carnitine palmitoyltransferase 1a, liver -1.64 
NM_012661.1 Sts steroid sulfatase -1.64 
NM_017223.2 Slc20a2 solute carrier family 20 (phosphate 
transporter), member 2 -1.62 
NM_001024897.1 Ehd2 similar to hypothetical protein; 
hypothetical gene supported by X51706; 
similar to ribosomal protein L9; similar to 
60S ribosomal protein L9; ribosomal 
protein L9; EH-domain containing 2 
-1.61 
NM_017037.1 Pmp22 peripheral myelin protein 22 2.85 
XM_001064152.1 Loc266761 cytochrome P450, family 4, subfamily v, 
polypeptide 3; family with sequence 
similarity 149, member A
2.51 
NM_030848.1 Bst1 bone marrow stromal cell antigen 1 2.45 
NM_031664.1 Slc28a2 similar to solute carrier family 28, 
member 2; solute carrier family 28 
(sodium-coupled nucleoside transporter), 
member 2 
2.24 
NM_020100.2 Ramp3 receptor (G protein-coupled) activity 
modifying protein 3 2.21 
XM_001071501.1 St8sia4 similar to CMP-N-acetylneuraminate-
poly-alpha-2,8-sialyltransferase (Alpha-





XM_001077664.1 LOC691312 cytochrome P450 4F5; cytochrome P450, 
family 4, subfamily f, polypeptide 37 2.11 
NM_001008843.1 RT1-CE5 RT1 class I, CE5 2.07 
NM_017054.1 Tbxa2r thromboxane A2 receptor 2.03 
NM_012800.1 P2ry1 purinergic receptor P2Y, G-protein 
coupled 1 1.96 
NM_019354.1 Ucp2 uncoupling protein 2 (mitochondrial, 
proton carrier) 1.96 
NM_053822.1 S100a8 S100 calcium binding protein A8 1.92 
NM_001024995.1 Lrrc33 leucine rich repeat containing 33 1.91 
NM_031684.2 Slc29a1 solute carrier family 29 (nucleoside 
transporters), member 1 1.91 
NM_031349.2 Aplnr apelin receptor 1.90 
NM_001005384.1 Osmr oncostatin M receptor 1.90 
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NM_001025415.1 Ch25h cholesterol 25-hydroxylase 1.90 
NM_173124.1 Cyp4f5 cytochrome P450 4F5; cytochrome P450, 
family 4, subfamily f, polypeptide 37 1.88 
NM_001024968.1 Slc46a3 solute carrier family 46, member 3 1.88 
XM_001069340.1 Prr7 proline rich 7 (synaptic) 1.88 
NM_001008306.1 Calhm2 calcium homeostasis modulator 2 1.87 
NM_139341.1 Slc15a3 solute carrier family 15, member 3 1.86 
NM_144758.1 Slc15a4 solute carrier family 15, member 4 1.85 
NM_001010964.1 Klrb1a killer cell lectin-like receptor subfamily 
B, member 1A 1.81 
NM_053607.1 Acsl5 acyl-CoA synthetase long-chain family 
member 5 1.80 
NM_023021.1 Kcnn4 potassium intermediate/small 
conductance calcium-activated channel, 
subfamily N, member 4 
1.78 
NM_053596.1 Ece1 endothelin converting enzyme 1 1.77 
NM_023099.1 Gpr27 G protein-coupled receptor 27 1.77 
NM_053951.1 Mcf2l MCF.2 cell line derived transforming 
sequence-like 1.77 
NM_198754.2 Cmtm8 CKLF-like MARVEL transmembrane 
domain containing 8 1.77 
NM_053827.1 Plod1 procollagen-lysine 1, 2-oxoglutarate 5-
dioxygenase 1 1.76 
NM_001002802.1 Bace2 beta-site APP-cleaving enzyme 2 1.75 
NM_031740.1 B4galt6 UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 6 1.75 
NM_031322.1 Lrp4 low density lipoprotein receptor-related 
protein 4 1.74 
NM_001013895.1 Prkd2 protein kinase D2 1.71 
NM_031079.1 Pde2a phosphodiesterase 2A, cGMP-stimulated 1.71 
XM_001078922.1 Gprc5b G protein-coupled receptor, family C, 
group 5, member B 1.71 
NM_020543.3 Cnr2 cannabinoid receptor 2 (macrophage) 1.70 
NM_173310.2 GalNAc4S6S
T 
B cell RAG associated protein 1.70 
NM_013091.1 Tnfrsf1a tumor necrosis factor receptor 
superfamily, member 1a 1.68 
NM_139110.1 Gpr116 G protein-coupled receptor 116 1.68 
NM_001008845.1 RT1-CE7 similar to RT1 class I, CE11; RT1 class I, 
CE11; RT1 class I, CE7 1.67 
XM_342524.3 Plcb1 phospholipase C, beta 1 
(phosphoinositide-specific) 1.66 
NM_053821.2 Ralb v-ral simian leukemia viral oncogene 
homolog B (ras related; GTP binding 
protein) 
1.66 
NM_001004269.1 Jam3 junctional adhesion molecule 3 1.66 
NM_145679.1 Lrrc3 leucine rich repeat containing 3 1.65 
NM_030844.1 Ica1 islet cell autoantigen 1 1.65 
NM_017292.1 Gabrr2 gamma-aminobutyric acid (GABA) 
receptor, rho 2 1.65 
NM_172040.1 Hyal2 hyaluronoglucosaminidase 2 1.65 
NM_173135.1 Accn3 amiloride-sensitive cation channel 3 1.64 
XM_344616.3 MGC112790 frizzled homolog 8 (Drosophila) 1.64 
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NM_001008834.1 RT1-CE11 similar to RT1 class I, CE11; RT1 class I, 
CE11; RT1 class I, CE7 1.63 
NM_053492.2 Cdw92 CDW92 antigen 1.62 
NM_001008840.1 RT1-CE2 RT1 class I, CE2 1.62 
NM_017071.1 Insr insulin receptor 1.62 
NM_031649.1 Klrg1 killer cell lectin-like receptor subfamily 
G, member 1 1.62 
NM_001007728.1 Mpzl1 myelin protein zero-like 1 1.62 
NM_001014059.1 RGD1304952 similar to RIKEN cDNA C530028O21 
gene 1.61 
XM_235609.4 Prickle1 prickle homolog 1 (Drosophila) 1.61 
NM_020086.1 Plvap plasmalemma vesicle associated protein 1.61 
NM_053321.2 Ptafr platelet-activating factor receptor 1.60 
NM_057201.1 Gpr37 G protein-coupled receptor 37 1.60 
Cell motion 
XM_217250.3 Ephb1 Eph receptor B1 -6.40 
NM_012648.1 Scnn1b sodium channel, nonvoltage-gated 1 beta -4.12 
NM_080778.1 Nr2f2 nuclear receptor subfamily 2, group F, 
member 2 -3.64 
NM_012807.1 Smo smoothened homolog (Drosophila) -3.27 
XM_222785.4 Astn1 astrotactin 1 -3.00 
XM_001070296.1 Plxna2 plexin A2 -2.73 
NM_012934.1 Dpysl3 dihydropyrimidinase-like 3 -2.57 
NM_031520.1 Myh10 myosin, heavy chain 10, non-muscle -2.47 
NM_053503.1 Jub jub, ajuba homolog (Xenopus laevis) -2.35 
NM_017003.2 Erbb2 v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog (avian)
-2.30 
NM_017195.1 Gap43 growth associated protein 43 -2.10 
NM_013040.2 Abcc9 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 9 -2.09 
NM_001033701.1 Zeb2 zinc finger E-box binding homeobox 2 -2.01 
XM_573530.1 Enah enabled homolog (Drosophila) -2.01 
NM_031022.1 Cspg4 chondroitin sulfate proteoglycan 4 -1.87 
NM_031321.1 Slit3 slit homolog 3 (Drosophila) -1.72 
NM_031056.1 Mmp14 matrix metallopeptidase 14 (membrane-
inserted) -1.62 
XM_215451.4 Cspg2 versican 2.28 
NM_013114.1 Selp selectin, platelet 2.20 
NM_017076.1 PVR poliovirus receptor 2.14 
NM_130411.2 Coro1a coronin, actin binding protein 1A 2.12 
NM_021759.1 Lypd3 Ly6/Plaur domain containing 3 2.09 
XM_227600.4 RGD1565941 vav 3 guanine nucleotide exchange factor 1.98 
NM_022206.1 Unc5a unc-5 homolog A (C. elegans) 1.75 
NM_201272.1 Plekhg5 pleckstrin homology domain containing, 
family G (with RhoGef domain) member 
5 
1.72 
NM_175756.1 Fcgr2b Fc fragment of IgG, low affinity IIb, 
receptor (CD32); Fc fragment of IgG, low 




NM_012945.1 Hbegf heparin-binding EGF-like growth factor 1.69 
NM_012967.1 Icam1 intercellular adhesion molecule 1 1.64 
XM_001057564.1 Csf3r colony stimulating factor 3 receptor 
(granulocyte) 1.62 
NM_001007729.1 Pf4 platelet factor 4 1.62 
Extracellular region 
NM_001012039.1 Efemp1 epidermal growth factor-containing 
fibulin-like extracellular matrix protein 1 -4.76 
NM_020071.1 Fgb fibrinogen beta chain -4.33 
XM_001060132.1 C1qtnf7 C1q and tumor necrosis factor related 
protein 7 -4.16 
NM_021586.1 Ltbp2 latent transforming growth factor beta 
binding protein 2 -3.52 
XM_001066152.1 Egfl6 EGF-like-domain, multiple 6 -3.47 
NM_001012225.1 Mgat4a mannoside acetylglucosaminyltransferase 
4, isoenzyme A -3.28 
NM_053385.1 Prelp proline arginine-rich end leucine-rich 
repeat protein -3.10 
NM_012559.2 Fgg fibrinogen gamma chain -2.92 
NM_031810.1 Defb1 defensin beta 1 -2.74 
NM_053856.1 Scg3 secretogranin III -2.64 
NM_032616.1 Lsr lipolysis stimulated lipoprotein receptor -2.64 
NM_017061.1 Lox lysyl oxidase -2.58 
XM_001064272.1 Crim1 cysteine rich transmembrane BMP 
regulator 1 (chordin like) -2.57 
NM_031609.1 Nbl1 neuroblastoma, suppression of 
tumorigenicity 1 -2.54 
NM_130741.1 Lcn2 lipocalin 2 -2.54 
XM_001056704.1 RGD1560408 similar to Mannoside 
acetylglucosaminyltransferase 4, 





NM_053606.1 Mmp23 matrix metallopeptidase 23 -2.43 
NM_013122.1 Igfbp2 insulin-like growth factor binding protein 
2 -2.41 
NM_019237.1 Pcolce procollagen C-endopeptidase enhancer 
protein -2.35 
NM_001014104.1 Metrnl meteorin, glial cell differentiation 
regulator-like -2.31 
NM_080698.1 Fmod fibromodulin -2.26 
NM_031826.1 Fbn2 fibrillin 2 -2.25 
NM_001007710.1 Acpl2 acid phosphatase-like 2 -2.24 
XM_001076441.1 Cilp cartilage intermediate layer protein, 
nucleotide pyrophosphohydrolase -2.22 
NM_013144.1 Igfbp1 insulin-like growth factor binding protein 
1 -2.20 
NM_001014140.1 RGD1309676 similar to RIKEN cDNA 5730469M10 -2.13 
NM_012880.1 Sod3 superoxide dismutase 3, extracellular -2.12 
NM_001006979.1 Matn1 matrilin 1, cartilage matrix protein -2.09 
XM_343607.3 Col4a3 collagen, type IV, alpha 3 -1.99 
NM_012590.1 Inha inhibin alpha -1.98 
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NM_133557.1 Cda08 integrin alpha FG-GAP repeat containing 
1 -1.94 
XM_001077795.1 Ltbp4 latent transforming growth factor beta 
binding protein 4 -1.89 
NM_172030.1 Entpd2 ectonucleoside triphosphate 
diphosphohydrolase 2 -1.87 
NM_023967.1 Gfra4 GDNF family receptor alpha 4 -1.83 
NM_053629.2 Fstl3 follistatin-like 3 -1.82 
NM_031697.1 St3gal3 ST3 beta-galactoside alpha-2,3-
sialyltransferase 3 -1.79 
NM_031640.1 Pgcp plasma glutamate carboxypeptidase -1.76 
XM_001070303.1 Gpld1 glycosylphosphatidylinositol specific 
phospholipase D1 -1.75 
NM_203493.2 Dmp1 dentin matrix acidic phosphoprotein 1 -1.72 
NM_021989.2 Timp2 tissue inhibitor of metalloproteinase 2 -1.71 
XM_001058647.1 Pappa pregnancy-associated plasma protein A -1.68 
XM_001060614.1 Olfml2a olfactomedin-like 2A -1.68 
NM_001004218.1 Fuca2 fucosidase, alpha-L- 2, plasma -1.61 
NM_031766.1 Cpz carboxypeptidase Z -1.60 
XM_001061784.1 Chit1 chitinase 1 (chitotriosidase) 3.18 
NM_022221.1 Mmp8 matrix metallopeptidase 8 3.07 
NM_001024240.1 RGD1310251 similar to RIKEN cDNA 2010001M09 2.59 
NM_031645.1 Ramp1 receptor (G protein-coupled) activity 
modifying protein 1 2.57 
NM_053373.1 Pglyrp1 peptidoglycan recognition protein 1 2.36 
NM_172328.2 Tac4 tachykinin 4 2.30 
NM_012908.1 Faslg Fas ligand (TNF superfamily, member 6) 2.24 
XM_001058441.1 RGD1565970 mast cell protease 8-like 2; similar to 
mast cell protease 8; mast cell protease 8 2.21 
NM_134361.1 Xcl1 chemokine (C motif) ligand 1 2.11 
NM_012636.1 Pthlh parathyroid hormone-like hormone 2.09 
NM_012548.1 Edn1 endothelin 1 2.08 
NM_001003403.1 Apold1 apolipoprotein L domain containing 1 2.02 
XM_239260.4 Sez6 seizure related 6 homolog (mouse) 2.00 
NM_012859.1 Lipe lipase, hormone sensitive 1.99 
NM_021664.1 Dnase2b deoxyribonuclease II beta 1.96 
NM_013092.1 Cma1 chymase 1, mast cell 1.94 
NM_017066.2 Ptn pleiotrophin 1.94 
XM_001074055.1 LOC690312 Fc receptor-like A; similar to Fc receptor-
like and mucin-like 1 1.89 
NM_017330.2 Prf1 perforin 1 (pore forming protein) 1.89 
NM_153721.1 Ppbp pro-platelet basic protein (chemokine (C-
X-C motif) ligand 7) 1.88 
NM_212507.2 Ltb lymphotoxin beta (TNF superfamily, 
member 3) 1.87 
NM_020074.2 Srgn serglycin 1.86 
NM_012762.2 Casp1 caspase 1 1.86 
NM_001012467.1 Rnase10 ribonuclease, RNase A family, 10 (non-
active) 1.85 
XM_001067964.1 Tgfbi transforming growth factor, beta induced 1.82 
NM_153294.1 Npw neuropeptide W 1.81 
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XM_001061982.1 Col5a2 collagen, type V, alpha 2 1.79 
NM_022534.1 Tcn2 transcobalamin 2 1.77 
NM_139104.1 Egfl7 EGF-like-domain, multiple 7 1.76 
NM_020082.2 Rnase4 ribonuclease, RNase A family 4 1.76 
XM_235461.3 Apol3 similar to apolipoprotein L, 3; 
apolipoprotein L, 3 1.71 
XM_001063886.1 LOC685462 EMI domain containing 1 1.71 
XM_236642.3 Camp cathelicidin antimicrobial peptide 1.66 
NM_030988.1 Tg thyroglobulin 1.66 
NM_021587.1 Ltbp1 latent transforming growth factor beta 
binding protein 1 1.64 
NM_138882.1 Pla1a phospholipase A1 member A 1.62 
Immune response 
NM_013163.1 Il2ra interleukin 2 receptor, alpha -2.83 
NM_012752.2 Cd24 CD24 molecule -2.51 
NM_052807.1 Igf1r insulin-like growth factor 1 receptor -2.48 
NM_181086.2 Tnfrsf12a tumor necrosis factor receptor 
superfamily, member 12a -2.45 
NM_001002805.1 C4-2 complement component 4, gene 2 -2.43 
NM_019165.1 Il18 interleukin 18 -2.42 
NM_145765.1 Tnfsf15 tumor necrosis factor (ligand) 
superfamily, member 15 -2.03 
NM_012671.1 Tgfa transforming growth factor alpha -1.82 
NM_012895.3 Adk adenosine kinase -1.69 
NM_053858.1 Ccl4 chemokine (C-C motif) ligand 4 3.12 
XM_001059278.1 LOC301133 tumor necrosis factor (ligand) 
superfamily, member 14 2.93 
NM_031539.1 Cd8b CD8b molecule 2.71 
NM_053953.1 Il1r2 interleukin 1 receptor, type II 2.67 
NM_053647.1 Cxcl2 chemokine (C-X-C motif) ligand 2 2.63 
NM_017124.1 Cd37 CD37 molecule 2.57 
NM_031512.1 Il1b interleukin 1 beta 2.39 
NM_022205.3 Cxcr4 chemokine (C-X-C motif) receptor 4 2.37 
NM_017079.1 Cd1d1 CD1d1 molecule 2.22 
NM_053983.1 Cd52 CD52 antigen 2.17 
NM_134327.1 Cd69 Cd69 molecule 2.17 
NM_053634.1 Fcnb ficolin B 2.14 
NM_013169.1 Cd3d CD3 molecule delta polypeptide 2.14 
NM_013127.1 Cd38 CD38 molecule 2.12 
NM_019311.1 Inpp5d inositol polyphosphate-5-phosphatase D 2.12 
NM_030845.1 Cxcl1 chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating activity, 
alpha) 
2.09 
XM_001059172.1 RGD1562408 SH2 domain protein 1A 2.07 
NM_130399.2 Ada adenosine deaminase 2.04 
XM_218851.4 Il16_mapped interleukin 16 2.01 
NM_053390.1 Il12a interleukin 12a 2.00 




NM_031561.2 Cd36 similar to CD36 antigen; similar to fatty 
acid translocase/CD36; CD36 molecule 
(thrombospondin receptor) 
1.99 
NM_212466.2 Cfb complement factor B 1.99 
NM_031116.2 Ccl5 chemokine (C-C motif) ligand 5 1.96 
NM_145672.3 Cxcl9 chemokine (C-X-C motif) ligand 9 1.95 
NM_031518.1 Cd200 Cd200 molecule 1.95 
NM_145680.3 Gimap5 GTPase, IMAP family member 1; 
GTPase, IMAP family member 5 1.92 
NM_012745.2 Klrd1 killer cell lectin-like receptor, subfamily 
D, member 1; killer cell lectin-like 
receptor, family E, member 1 
1.92 
NM_170789.1 Cd247 Cd247 molecule 1.91 
NM_133534.1 Cx3cr1 chemokine (C-X3-C motif) receptor 1 1.85 
NM_022303.1 Card9 caspase recruitment domain family, 
member 9 1.84 
XM_343800.2 Il2rg interleukin 2 receptor, gamma 1.83 
NM_001008839.1 RT1-CE16 RT1 class I, CE14; RT1 class I, CE16; 
RT1 class Ia, locus A2; RT1 class Ib, 
locus Cl; RT1 class Ia, locus A1; RT1 
class I, A3
1.83 
NM_138880.2 Ifng interferon gamma 1.72 
NM_001012164.1 Cd97 CD97 molecule 1.70 
NM_001017478.1 Cxcl16 chemokine (C-X-C motif) ligand 16 1.66 
XM_344184.3 Hlx1 H2.0-like homeobox 1.65 
NM_207604.1 Tlr6 toll-like receptor 6 1.63 
XM_341509.3 Cd83 CD83 molecule 1.60 
Cytoskeletal component/process 
XM_001054365.1 Arhgap28 Rho GTPase activating protein 28 -4.83 
XM_215469.4 Map1b microtubule-associated protein 1B -3.55 
NM_031613.1 Tmod2 tropomodulin 2 -3.46 
XM_225259.4 Dsp desmoplakin -3.33 
XM_214338.3 LOC290704 similar to palladin -3.18 
NM_053309.1 Homer2 homer homolog 2 (Drosophila) -3.16 
XM_223229.4 Shroom3 shroom family member 3 -3.02 
NM_001009645.1 Kif22 kinesin family member 22 -2.97 
XM_230774.4 Myh7b myosin, heavy chain 7B, cardiac muscle, 
beta -2.96 
NM_001034105.1 Tnnc1 troponin C type 1 (slow) -2.74 
NM_024396.1 Abca2 ATP-binding cassette, sub-family A 
(ABC1), member 2 -2.72 
NM_024127.2 Gadd45a growth arrest and DNA-damage-
inducible 45 alpha -2.67 
NM_133545.1 Ptpn21 protein tyrosine phosphatase, non-
receptor type 21 -2.67 
NM_001034075.1 Tpm1 tropomyosin 1, alpha -2.55 
XM_342179.3 Rgnef Rho-guanine nucleotide exchange factor -2.47 
NM_013082.2 Sdc2 syndecan 2 -2.46 
XM_216688.4 Arhgap5 Rho GTPase activating protein 5 -2.43 
NM_145682.1 Filip1 filamin A interacting protein 1 -2.41 
XM_237042.4 Dst dystonin -2.39 
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XM_220031.4 Myof myoferlin -2.38 
XM_001064622.1 Itgb5 integrin beta 5 -2.37 
XM_001065955.1 Ttn titin -2.34 
XM_238004.3 RGD1309427 tubulin, beta 2b -2.32 
XM_238004.3 Tubb2b tubulin, beta 2B -2.32 
NM_032071.1 Synj2 synaptojanin 2 -2.28 
XM_574117.2 RGD1561153 myosin VIIb -2.26 
NM_183054.1 Rhbg Rh family, B glycoprotein -2.25 
NM_001013246.1 Arhgef12 Rho guanine nucleotide exchange factor 
(GEF) 12 -2.21 
NM_012909.2 Aqp2 aquaporin 2 (collecting duct) -2.19 
NM_017327.1 Gnao1 guanine nucleotide binding protein (G 
protein), alpha activating activity 
polypeptide O 
-2.19 
NM_022178.1 Myo5a myosin Va -2.18 
NM_138921.1 Eml2 echinoderm microtubule associated 
protein like 2 -2.18 
NM_012604.1 Myh3 myosin, heavy chain 3, skeletal muscle, 
embryonic -2.18 
XM_235213.3 Srgap1 SLIT-ROBO Rho GTPase activating 
protein 1 -2.17 
NM_017137.1 Clcn2 chloride channel 2 -2.16 
NM_017032.1 Pde4d phosphodiesterase 4D, cAMP-specific 
(phosphodiesterase E3 dunce homolog, 
Drosophila) 
-2.14 
XM_240464.3 Ank1 ankyrin 1, erythrocytic -2.13 
NM_017083.1 Myo5b myosin Vb -2.08 
NM_017180.1 Phlda1 pleckstrin homology-like domain, family 
A, member 1 -2.06 
XM_001058944.1 RGD1565118 actin binding LIM protein family, 
member 3 -2.06 
NM_012606.1 Myl3 myosin, light chain 3, alkali; ventricular, 
skeletal, slow -2.06 
NM_001007150.1 Stau2 staufen, RNA binding protein, homolog 2 
(Drosophila) -2.05 
XM_227658.3 Fnbp1l formin binding protein 1-like -2.03 
XM_217035.4 Krt7 keratin 7 -2.01 
NM_001002798.1 Top1mt DNA topoisomerase 1, mitochondrial -2.01 
XM_001078859.1 Farp1 FERM, RhoGEF (Arhgef) and pleckstrin 
domain protein 1 (chondrocyte-derived) -2.00 
NM_019167.1 Sptbn2 spectrin, beta, non-erythrocytic 2 -1.98 
NM_053326.1 Pdlim5 PDZ and LIM domain 5 -1.91 
NM_012935.2 Cryab crystallin, alpha B -1.90 
XM_341538.2 Kif5b kinesin family member 5B -1.87 
NM_031552.1 Add3 adducin 3 (gamma) -1.85 
NM_080689.3 Dnm1 dynamin 1 -1.81 
NM_012676.1 Tnnt2 troponin T type 2 (cardiac) -1.81 
XM_001080795.1 LOC366669 similar to mKIAA1011 protein -1.80 
XM_001074984.1 Bbs4 Bardet-Biedl syndrome 4 homolog 
(human) -1.77 
XM_573030.2 Myh11 myosin, heavy chain 11, smooth muscle -1.75 
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XM_345195.3 Tbl1xr1 transducin (beta)-like 1 X-linked receptor 
1 -1.75 
NM_001024341.1 Fam110b family with sequence similarity 110, 
member B -1.74 
XM_001072750.1 RGD1308350 similar to hypothetical protein 
MGC13251 -1.72 
XM_001061392.1 Myo6 myosin VI -1.72 
NM_139231.1 Nexn nexilin (F actin binding protein) -1.72 
NM_017155.1 Adora1 adenosine A1 receptor -1.72 
XM_573863.2 RGD1564875 LIM domain binding 3 -1.71 
XM_343248.3 Mtss1 metastasis suppressor 1 -1.71 
NM_001009966.2 Pacsin3 protein kinase C and casein kinase 
substrate in neurons 3 -1.69 
NM_001014070.1 LOC313672 kazrin -1.68 
XM_218858.4 Cpeb1 cytoplasmic polyadenylation element 
binding protein 1 -1.68 
NM_024368.1 Frk fyn-related kinase -1.66 
NM_001033987.1 Map2k5 mitogen activated protein kinase kinase 5 -1.65 
XM_001066467.1 RGD1310722 ubinuclein 2 -1.65 
XM_001081714.1 Evpl envoplakin -1.63 
XM_236367.4 RGD1565416 similar to talin 2 -1.63 
XM_001080622.1 Myh14 myosin, heavy chain 14 -1.63 
NM_053603.1 Clic5 chloride intracellular channel 5 -1.62 
XM_576473.1 LOC367171 microtubule-associated protein 4 -1.61 
XM_226175.4 Mib1 mindbomb homolog 1 (Drosophila) -1.61 
NM_130894.2 Mfn2 mitofusin 2 -1.60 
NM_001008384.1 Rac2 ras-related C3 botulinum toxin substrate 2 
(rho family, small GTP binding protein 
Rac2) 
2.52 
NM_012759.1 Vav1 vav 1 guanine nucleotide exchange factor 2.40 
NM_019169.2 Snca synuclein, alpha (non A4 component of 
amyloid precursor) 2.28 
NM_021909.1 Fxyd5 FXYD domain-containing ion transport 
regulator 5 2.12 
XM_232763.4 Lck_mapped similar to lymphocyte protein tyrosine 
kinase; lymphocyte-specific protein 
tyrosine kinase
1.99 
NM_001012044.1 Lcp1 lymphocyte cytosolic protein 1 1.98 
NM_001013430.1 Rhoh ras homolog gene family, member H 1.97 
NM_022542.1 Rhob ras homolog gene family, member B 1.86 
XM_219517.3 Map3k11 mitogen-activated protein kinase kinase 
kinase 11 1.82 
NM_017317.2 Rab27a RAB27A, member RAS oncogene family 1.80 
NM_030857.1 Lyn v-yes-1 Yamaguchi sarcoma viral related 
oncogene homolog 1.80 
XM_001059351.1 Hist1h2bc histone cluster 1, H2bc 1.77 
NM_030863.1 Msn moesin 1.76 
XM_217152.3 Pstpip1 proline-serine-threonine phosphatase-
interacting protein 1 1.75 
XM_219540.4 RGD1310168 fermitin family homolog 3 (Drosophila) 1.75 




NM_001025680.1 Gpr4 G protein-coupled receptor 4 1.74 
NM_133392.1 Stk17b serine/threonine kinase 17b 1.74 
XM_001070203.1 Itga5_mappe
d 
integrin alpha 5 (fibronectin receptor 
alpha) 1.72 
NM_138520.1 Klc3 kinesin light chain 3 1.71 
XM_221956.3 LOC288515 MICAL-like 2 1.71 
NM_017280.2 Psma3 proteasome (prosome, macropain) 
subunit, alpha type 3; proteasome subunit 
alpha type 3-like; similar to Proteasome 
subunit alpha type 3 (Proteasome 
component C8) (Macropain subunit C8) 
(Multicatalytic endopeptidase complex 
subunit C8) (Proteasome subunit K)
1.68 
XM_001054737.1 Adam10 ADAM metallopeptidase domain 10 1.67 
NM_001025733.2 Procr protein C receptor, endothelial 1.67 
NM_198787.1 Sgsm3 small G protein signaling modulator 3 1.66 
XM_001060919.1 Dapk1 death associated protein kinase 1 1.64 
NM_053484.1 Gas7 growth arrest specific 7 1.63 
NM_001011965.1 Stom stomatin; ABO-family member 5 1.61 
NM_053783.1 Ifngr1 interferon gamma receptor 1 1.61 
NM_053920.1 Trip10 thyroid hormone receptor interactor 10 1.60 
NM_001039207.1 Narf nuclear prelamin A recognition factor 1.60 
Neuron development 
XM_001062426.1 Sema3g sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3G 
-3.98 
NM_001033757.1 Cdkn1c cyclin-dependent kinase inhibitor 1C 
(P57) -3.26 
XM_231354.4 Sema3e sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3E 
-3.24 
XM_236640.4 Plxnb1 plexin B1 -2.78 
NM_022589.1 Tspan2 tetraspanin 2 -2.74 
XM_001063804.1 Hoxd10 homeo box D10 -2.72 
NM_012827.1 Bmp4 bone morphogenetic protein 4 -2.41 
NM_013088.1 Ptpn11 protein tyrosine phosphatase, non-
receptor type 11 -2.26 
XM_001056831.1 LOC681886 acyl-CoA synthetase short-chain family 
member 1; visual system homeobox 1 -2.05 
XM_001068573.1 Hoxc10 homeo box C10 -2.00 
NM_053896.1 Aldh1a2 aldehyde dehydrogenase 1 family, 
member A2 -1.88 
NM_017129.1 Ctf1 cardiotrophin 1 -1.83 
NM_052803.1 Atp7a ATPase, Cu++ transporting, alpha 
polypeptide -1.79 
NM_019284.1 Cspg5 chondroitin sulfate proteoglycan 5 -1.71 
NM_017259.1 Btg2 B-cell translocation gene 2, anti-
proliferative 2.91 
NM_012566.1 Gfi1 growth factor independent 1 transcription 
repressor 2.34 
XM_001069879.1 Bcl11b B-cell CLL/lymphoma 11B (zinc finger 
protein) 1.90 
NM_013058.2 Id3 inhibitor of DNA binding 3 1.90 
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NM_053594.1 Ptprr protein tyrosine phosphatase, receptor 
type, R 1.79 
XM_220712.4 Scarf1 scavenger receptor class F, member 1 1.67 
NM_022673.1 Mecp2 methyl CpG binding protein 2 1.64 
Motif/Domain 
XM_222763.4 Tdrd5 tudor domain containing 5 -3.84 
XM_001073627.1 Plekha5 pleckstrin homology domain containing, 
family A member 5 -3.79 
XM_001055725.1 Kank1 KN motif and ankyrin repeat domains 1 -2.88 
XM_001069410.1 Hoxc6 homeobox C6 -2.87 
XM_001058167.1 Sgip1 SH3-domain GRB2-like (endophilin) 
interacting protein 1 -2.78 
NM_019316.1 Mafb v-maf musculoaponeurotic fibrosarcoma 
oncogene family, protein B -2.71 
XM_001053668.1 Rc3h2 ring finger and CCCH-type zinc finger 
domains 2 -2.66 
XM_001062112.1 Sh3bgrl2 SH3 domain binding glutamic acid-rich 
protein like 2 -2.44 
XM_342682.3 Mpp6 membrane protein, palmitoylated 6 
(MAGUK p55 subfamily member 6) -2.39 
NM_001012048.1 Sh2d4a SH2 domain containing 4A -2.28 
NM_001014268.1 Lrrc1 leucine rich repeat containing 1 -2.11 
NM_001011922.1 Nedd9 neural precursor cell expressed, 
developmentally down-regulated gene 9 -1.84 
NM_012828.1 Cacnb3 calcium channel, voltage-dependent, beta 
3 subunit -1.76 
NM_001007148.1 Btrc beta-transducin repeat containing protein -1.73 
NM_001002277.1 Ahi1 Abelson helper integration site 1 -1.66 
XM_233830.4 Plekhh2 pleckstrin homology domain containing, 
family H (with MyTH4 domain) member 
2 
-1.65 
XM_001081287.1 Ankrd40 ankyrin repeat domain 40 -1.61 
NM_130821.1 Samsn1 SAM domain, SH3 domain and nuclear 
localization signals, 1 2.75 
XM_576306.2 LOC500904 neutrophil cytosolic factor 4 2.52 
NM_001013118.1 Abi3 ABI family, member 3 2.23 
NM_017168.1 Plcg2 phospholipase C, gamma 2 1.98 
NM_031238.1 Sh3gl3 SH3-domain GRB2-like 3 1.96 
NM_001024260.1 Nostrin nitric oxide synthase trafficker 1.92 
NM_001024255.1 Txk TXK tyrosine kinase 1.92 
NM_053851.1 Cacnb2 calcium channel, voltage-dependent, beta 
2 subunit 1.86 
NM_001011961.1 Srms src-related kinase lacking C-terminal 
regulatory tyrosine and N-terminal 
myristylation sites 
1.83 
XM_340911.3 Mpp3 membrane protein, palmitoylated 3 
(MAGUK p55 subfamily member 3) 1.77 
NM_130413.1 Skap2 src family associated phosphoprotein 2 1.75 
AMD protein complexes 
NM_017336.1 Ptpro protein tyrosine phosphatase, receptor 
type, O -2.42 
NM_019357.1 Ezr ezrin -1.82 
BMD protein complexes 
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XM_342410.3 Aif1l allograft inflammatory factor 1-like -3.43 
NM_012649.1 Sdc4 syndecan 4 -2.79 
NM_001012032.1 Arhgap24 Rho GTPase activating protein 24 -2.48 
NM_012983.2 Myo1d myosin ID -2.28 
XM_340884.2 Itga3 integrin alpha 3 -2.23 
XM_343483.3 Dag1 dystroglycan 1 -2.07 
XM_001066264.1 Tenc1 tensin like C1 domain-containing 
phosphatase -2.00 
NM_012904.1 Anxa1 annexin A1 -1.91 
XM_001078155.1 Parvb parvin, beta 1.65 
SD protein complexes 
NM_053621.1 Magi2 membrane associated guanylate kinase, 
WW and PDZ domain containing 2 -3.93 
NM_021695.1 Synpo synaptopodin -3.62 
XM_218486.3 Kirrel2 kin of IRRE like 2 (Drosophila) -3.47 
XM_001059464.1 Cdh11 cadherin 11 -3.16 
NM_022628.1 Nphs1 nephrosis 1 homolog, nephrin -3.06 
NM_130828.2 Nphs2 nephrosis 2 homolog, podocin -3.02 
NM_001012055.1 Cdh16 cadherin 16 -2.73 
XM_001059679.1 Ctnnal1 catenin (cadherin associated protein), 
alpha-like 1 -2.42 
NM_031005.2 Actn1 actinin, alpha 1 -2.30 
XM_001059817.1 Nck2 NCK adaptor protein 2 -2.10 
XM_237115.1 Nck2 NCK adaptor protein 2 -1.62 
XM_226213.4 Cdh5 cadherin 5 1.88 
Cell junction 
XM_236385.4 Cgnl1 cingulin-like 1 -2.54 
NM_012528.1 Chrnb1 cholinergic receptor, nicotinic, beta 
polypeptide 1 (muscle) -2.40 
NM_017198.1 Pak1 p21 protein (Cdc42/Rac)-activated kinase 
1 -2.19 
NM_012663.2 Vamp2 vesicle-associated membrane protein 2 -1.60 
Tight junction 
NM_031699.1 Cldn1 claudin 1 -3.19 
XM_001080868.1 Mpp5 membrane protein, palmitoylated 5 
(MAGUK p55 subfamily member 5) -2.33 
NM_031675.2 Actn4 actinin alpha 4 -1.72 
NM_017093.1 Akt2 thymoma viral proto-oncogene 2 -1.68 
XM_342223.3 Prkci protein kinase C, iota -1.61 
Cell morphogenesis 
XM_216679.4 Lamb1 laminin, beta 1 -2.84 
NM_031235.1 Pard3 par-3 (partitioning defective 3) homolog 
(C. elegans) -2.64 
NM_012715.1 Adm adrenomedullin -2.10 
XM_242297.4 Ntng2 netrin G2 -1.93 
NM_024159.1 Dab2 disabled homolog 2 -1.74 
NM_017089.2 Efnb1 ephrin B1 -1.65 
Ion transport 
NM_001033693.1 Slc31a2 solute carrier family 31, member 2 -2.15 
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NM_022269.1 Cd55 CD55 antigen -1.95 
NM_139332.3 Tpcn1 two pore channel 1 -1.81 
Kidney development 
XM_213677.3 Robo2 roundabout homolog 2 -4.77 
NM_031534.1 Wt1 Wilms tumor 1 homolog -4.05 
NM_001032397.1 Tcf21 transcription factor 21 -3.54 
NM_053758.1 Plce1 phospholipase C, epsilon 1 -3.29 
XM_001053727.1 Bmp7 bone morphogenetic protein 7 -2.68 
NM_012774.1 Gpc3 glypican 3 -2.37 
NM_030849.1 Bmpr1a bone morphogenetic protein receptor, 
type 1A -2.13 
XM_213954.4 Nid1 nidogen 1 -2.12 
NM_173101.1 Myo1e myosin IE -2.03 
NM_053566.1 Ptch1 patched homolog 1 -1.99 
NM_053698.2 Cited2 Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 2 -1.68 
XM_001070482.1 Cutl1 similar to CCAAT displacement protein 
isoform b; cut-like homeobox 1 -1.67 
XM_340765.2 Pkd1 polycystic kidney disease 1 homolog 
(human) -1.65 
NM_001002827.1 Notch4 Notch homolog 4 (Drosophila) 1.76 
XM_001054314.1 Tek TEK tyrosine kinase, endothelial 1.71 
Protein modification 
XM_001057269.1 Mgat5 mannoside acetylglucosaminyltransferase 
5 -3.21 
XM_219805.4 Prkg1 protein kinase, cGMP-dependent, type I -3.02 
XM_001076056.1 Uck2 uridine-cytidine kinase 2 -2.70 
XM_001080770.1 Cpd carboxypeptidase D -2.30 
XM_236687.4 Oxsr1 oxidative-stress responsive 1 -1.89 
XM_227618.4 Cdc14a CDC14 cell division cycle 14 homolog A -1.66 
Regulation of transcription 
NM_012760.1 Plagl1 pleiomorphic adenoma gene-like 1 -3.08 
XR_007660.1 Zfp462 zinc finger protein 462 -2.29 
NM_133560.2 Trak2 trafficking protein, kinesin binding 2 -2.26 
NM_031346.1 Rod1 ROD1 regulator of differentiation 1 -2.04 
NM_053583.1 Zfp423 zinc finger protein 423 -1.72 
NM_021597.1 Eif2c2 eukaryotic translation initiation factor 2C, 
2 -1.67 
NM_021836.2 Junb jun B proto-oncogene 3.85 
XM_001076072.1 Lmcd1 LIM and cysteine-rich domains 1 1.96 
NM_021835.3 Jun Jun 1.88 
NM_012855.1 Jak3 Janus kinase 3 1.63 
Signal transduction 
NM_001002829.1 Rasl11a RAS-like, family 11, member A -2.31 
XM_001073244.1 Plxdc2 plexin domain containing 2 -2.31 
NM_080904.2 Arf3 ADP-ribosylation factor 3 -1.92 
NM_032076.2 Ptger4 prostaglandin E receptor 4 (subtype EP4) -1.78 




NM_022251.1 Enpep glutamyl aminopeptidase -2.92 
NM_145081.3 Optn optineurin -2.84 
XM_341428.2 Clcn3 chloride channel 3 -2.14 
XM_342271.3 Lrba LPS-responsive beige-like anchor -1.83 
Miscellaneous (podocyte related) 
NM_022943.1 Mertk c-mer proto-oncogene tyrosine kinase -3.12 
XM_217192.4 Rora RAR-related orphan receptor alpha -2.70 
XM_236376.4 Fam81a family with sequence similarity 81, 
member A -2.65 
NM_017031.2 Pde4b phosphodiesterase 4B, cAMP specific -2.49 
NM_133569.1 Angptl2 angiopoietin-like 2 -2.45 
XM_221276.3 Arvcf armadillo repeat gene deleted in velo-
cardio-facial syndrome -2.39 
XM_575387.2 Thsd7a thrombospondin, type I, domain 
containing 7A -2.38 
XM_219201.4 Ppfibp2 PTPRF interacting protein, binding 
protein 2 (liprin beta 2) -2.37 
XM_001053270.1 Ccpg1 cell cycle progression 1 -2.34 
NM_013220.1 Ankrd1 ankyrin repeat domain 1 -2.32 
XM_226988.4 Fndc3b fibronectin type III domain containing 3B -2.30 
XM_001061817.1 Erlin2 ER lipid raft associated 2 -2.26 
XM_001075785.1 Fam65a family with sequence similarity 65, 
member A -2.26 
XM_340875.3 Rnft1 ring finger protein, transmembrane 1 -2.04 
XM_340886.3 Nfe2l1 nuclear factor, erythroid derived 2,-like 1 -2.01 
NM_133601.1 Cblb Casitas B-lineage lymphoma b -1.94 
NM_001013882.1 Dctd dCMP deaminase -1.92 
NM_021850.2 Bcl2l2 Bcl2-like 2; poly(A) binding protein, 
nuclear 1 -1.89 
NM_001005888.1 Galc galactosylceramidase -1.85 
NM_001014102.1 Spats2l spermatogenesis associated, serine-rich 2-
like -1.80 
NM_001007654.1 Agtrap angiotensin II receptor-associated protein -1.80 
NM_001025627.1 Leprel1 leprecan-like 1 -1.77 
XM_343420.3 Fam63b family with sequence similarity 63, 
member B -1.75 
XM_230036.4 Ssfa2 sperm specific antigen 2 -1.68 
XM_001070133.1 Nbeal1 neurobeachin like 1 -1.65 
NM_033485.2 Pawr PRKC, apoptosis, WT1, regulator -1.64 
NM_012868.1 Npr3 natriuretic peptide receptor 3 -1.61 
NM_199412.1 Cbara1 calcium binding atopy-related 
autoantigen 1 -1.61 
NM_031970.1 Hspb1 heat shock protein 1 2.42 
NM_053704.1 Bik BCL2-interacting killer (apoptosis-
inducing) 2.15 
NM_173153.2 Gimap4 GTPase, IMAP family member 4 2.02 
NM_012938.1 Ctse cathepsin E 2.01 
XM_001067588.1 Tm6sf1 transmembrane 6 superfamily member 1 1.83 




NM_057138.2 Cflar CASP8 and FADD-like apoptosis 
regulator 1.80 
XM_215117.4 Ifitm1 interferon induced transmembrane protein 
1 1.74 
XM_001059368.1 Ldb2 LIM domain binding 2 1.74 
NM_001025141.1 Ccnb1ip1 cyclin B1 interacting protein 1 1.67 
Miscellaneous (functional annotation enrichment scores <4.46) 
NM_145093.1 Aard alanine and arginine rich domain 
containing protein -6.02 
XM_001056569.1 RGD1312005 similar to DD1 -5.88 
XM_347233.3 LOC368066 indolethylamine N-methyltransferase -5.10 
NM_001012475.1 Rxfp2 relaxin/insulin-like family peptide 
receptor 2 -4.83 
XM_573676.1 LOC498427 similar to ubiquitin specific protease 34 -4.81 
XR_008037.1 RGD1561455 similar to Ras GTPase-activating-like 
protein IQGAP2 -4.53 
NM_153300.1 Aldh1a3 aldehyde dehydrogenase 1 family, 
member A3 -4.26 
NM_017081.1 Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 -4.17 
XM_001081892.1 Ngfg kallikrein 1-related peptidase b3 -4.14 
XM_575542.1 LOC500190 similar to IgM kappa chain variable 
region -4.14 
XM_001072453.1 RGD1560652 RGD1560652; hypothetical protein 
LOC690830 -4.07 
XM_575706.1 LOC500353 RGD1566261 -4.06 
XM_576597.1 LOC501170 similar to adaptor-related protein complex 
AP-1, sigma 3 -3.95 
XM_238042.4 RGD1564108 Hedgehog-interacting protein -3.85 
XM_001062343.1 Marveld2 MARVEL domain containing 2 -3.84 
XM_001065454.1 Elovl7 ELOVL family member 7, elongation of 
long chain fatty acids (yeast) -3.83 
XM_344015.3 RGD1562717 similar to ABI gene family, member 3 
(NESH) binding protein -3.82 
XM_001060350.1 Large like-glycosyltransferase -3.82 
XM_342632.3 Pftk1 PFTAIRE protein kinase 1 -3.81 
XM_001054726.1 RGD1561985 dystrobrevin alpha -3.79 
NM_001034160.1 Apeg3 antisense paternally expressed gene 3 -3.78 
XM_001067936.1 RGD1561090 protein tyrosine phosphatase, receptor 
type, D -3.75 
XM_238275.3 LOC295976 RGD1560837 -3.73 
XM_575380.2 RGD1563612 similar to testhymin -3.67 
XM_575721.2 RGD1559723 sarcospan -3.64 
NM_001014244.1 Cyb5r2 cytochrome b5 reductase 2 -3.64 
XM_001063197.1 RGD1559717 RPE-spondin -3.56 
XM_574931.1 LOC499605 similar to LRRGT00057 -3.54 
XM_219909.4 RGD1307524 similar to Friedreich ataxia region gene 
X123 -3.53 
XM_001069399.1 LOC684205 similar to MIC2 like 1 -3.44 
XM_001053430.1 RGD1559891 similar to synaptonemal complex protein 
3 -3.40 
XM_573889.1 LOC498611 similar to LRRGT00176 -3.38 
NM_012593.1 Klk1l kallikrein 1-like peptidase; kallikrein-
related peptidase 7 -3.36 
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XM_001079138.1 RGD1563574 similar to Hypothetical protein 
MGC30332 -3.36 
XM_001078963.1 Usp43 ubiquitin specific peptidase 43 -3.33 
XM_213993.4 Abhd7 epoxide hydrolase 4 -3.33 
XM_215016.3 Sox6 SRY (sex determining region Y)-box 6 -3.31 
NM_001024297.1 Spz1 spermatogenic leucine zipper 1 -3.29 
XM_001059530.1 RGD1305809 Na+/K+ transporting ATPase interacting 
4 -3.28 
XM_224841.4 Odz3 odz, odd Oz/ten-m homolog 3 
(Drosophila) -3.26 
XM_001053329.1 RGD1311196 tudor and KH domain containing -3.26 
XM_577046.1 LOC501651 similar to LRRGT00057 -3.25 
XM_573435.1 LOC498217 similar to LRRG00135 -3.19 
XM_001070775.1 Sorcs1 sortilin-related VPS10 domain containing 
receptor 1 -3.19 
NM_053352.1 Cxcr7 chemokine (C-X-C motif) receptor 7 -3.18 
XM_575335.1 LOC499981 similar to lamin B3 -3.10 
XM_574804.1 LOC499481 similar to LRRGT00057 -3.05 
NM_175759.2 Klks3 kallikrein, submaxillary gland S3 -3.04 
XM_574907.1 LOC499582 similar to LRRGT00176 -3.02 
XM_001059696.1 LOC498331 protein tyrosine phosphatase, non-
receptor type 13 -3.02 
XM_575738.1 LOC500380 similar to LRRGT00008 -2.99 
XM_575195.1 LOC499854 similar to putative RNA binding protein 1 -2.98 
XM_575790.1 LOC500428 similar to putative RNA binding protein 1 -2.97 
XM_577047.1 LOC501652 similar to LRRGT00194 -2.96 
XM_574687.1 LOC499372 similar to ORF1 -2.96 
XM_575071.1 LOC499737 similar to LRRGT00057 -2.95 
XM_574880.1 LOC499555 similar to LRRGT00082 -2.94 
XM_342147.2 LOC361853 family with sequence similarity 184, 
member A -2.94 
XM_575748.1 LOC500389 similar to LRRGT00176 -2.92 
XM_233266.3 Ttc22 tetratricopeptide repeat domain 22 -2.92 
XM_574484.1 LOC499197 similar to LRRGT00057 -2.90 
XM_221497.4 Bbx bobby sox homolog (Drosophila) -2.89 
NM_001004278.2 Tsga10ip testis specific 10 interacting protein -2.88 
XM_576800.1 LOC501387 similar to LRRGT00173 -2.87 
XM_001079607.1 RGD1560542 proline rich Gla (G-carboxyglutamic 
acid) 4 (transmembrane) -2.87 
XM_574888.1 LOC499564 similar to LRRGT00057 -2.86 
XM_576360.1 LOC500949 similar to LRRGT00176 -2.85 
XM_573538.2 RGD1564105 vasohibin 2 -2.85 
XM_342182.2 LOC361885 similar to LRRGT00194 -2.83 
XM_341843.2 Ankrd27 ankyrin repeat domain 27 (VPS9 domain) -2.83 
XM_576325.1 LOC500916 similar to LRRGT00176 -2.82 
XR_009191.1 RGD1309847 similar to peptidylglycine alpha-
amidating monooxygenase COOH-
terminal interactor; peptidylglycine 
alpha-amidating monooxygenase COOH-




XM_001062695.1 RGD1562954 aldo-keto reductase family 1, member 
C19 -2.81 
XM_574855.1 LOC499531 similar to LRRGT00176 -2.81 
NM_017058.1 Vdr vitamin D (1,25- dihydroxyvitamin D3) 
receptor -2.81 
XM_575541.1 LOC500189 similar to Ig kappa chain -2.79 
NM_001002830.2 Rasl11b RAS-like family 11 member B -2.76 
NM_001024265.1 RGD1311251 similar to RIKEN cDNA 4930550C14 -2.76 
NM_001030024.1 Slc19a2 solute carrier family 19 (thiamine 
transporter), member 2 -2.76 
XM_234454.4 Ston2 stonin 2 -2.76 
XM_213964.4 Disp1 dispatched homolog 1 (Drosophila) -2.75 
XM_001059200.1 LOC681982 tuftelin 1 -2.75 
XM_574260.1 LOC498973 similar to LRRGT00176 -2.74 
XM_575869.1 LOC500507 similar to LRRGT00194 -2.74 
XM_574084.1 LOC498799 similar to LRRGT00057 -2.74 
XM_573613.1 LOC498378 similar to LRRGT00176 -2.74 
XM_576530.1 LOC501112 similar to putative RNA binding protein 1 
(LOC501112) -2.73 
NM_001024888.1 Gatad2b GATA zinc finger domain containing 2B -2.73 
XM_001079075.1 Ppl periplakin -2.72 
XM_573829.1 LOC498553 similar to putative RNA binding protein 1 
(LOC498553) -2.72 
XM_574081.1 LOC498795 coiled-coil domain containing 3 -2.72 
NM_001013863.1 Ydjc YdjC homolog (bacterial) -2.71 
XM_574492.1 LOC499206 similar to LRRGT00057 -2.70 
XM_573952.1 LOC498669 similar to LRRGT00176 -2.70 
XM_576174.1 LOC500788 similar to LRRGT00176 -2.70 
XM_575859.1 LOC500495 similar to LRRGT00176 -2.69 
NM_019249.1 Ptprf protein tyrosine phosphatase, receptor 
type, F -2.69 
NM_177426.1 Gstm2 glutathione S-transferase mu 2 -2.69 
XM_579642.1 LOC497701 hypothetical gene supported by 
NM_134459 -2.69 
XM_225733.4 Pard6g par-6 partitioning defective 6 homolog 
gamma (C. elegans) -2.68 
XM_574023.1 LOC498745 similar to LRRGT00057 -2.68 
XM_001067343.1 Arhgef17 Rho guanine nucleotide exchange factor 
(GEF) 17 -2.68 
XM_001060502.1 RGD1566180 RGD1566180 -2.67 
XM_576284.1 LOC500883 similar to LRRGT00082 -2.67 
XM_340961.2 LOC360690 similar to LRRGT00194 -2.66 
XM_579538.1 LOC497706 hypothetical gene supported by 
NM_031819 -2.66 
XM_001056810.1 RGD1309701 family with sequence similarity 114, 
member A1; similar to RIKEN cDNA 
9130005N14 
-2.65 
XM_575567.1 LOC500216 similar to LRRGT00194 -2.64 
XM_001064705.1 RGD1564709 similar to ATP-binding cassette, sub-
family G (WHITE), member 3 -2.63 
XM_342428.2 LOC362127 similar to putative RNA binding protein 1 -2.63 
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NM_130738.1 Snurf similar to small nuclear 
ribonucleoparticle-associated protein; 
SNRPN upstream reading frame 
-2.62 
XM_001054725.1 Ogn osteoglycin -2.62 
XM_001069683.1 RGD1565408 SERTA domain containing 4 -2.61 
XM_001069787.1 Snx12 sorting nexin 12 -2.61 
XM_001070222.1 Dcdc2 doublecortin domain containing 2 -2.60 
XM_573579.1 LOC498346 similar to putative RNA binding protein 1 -2.59 
XR_009111.1 RGD1311309 similar to 2510002A14Rik protein -2.58 
XM_343130.2 LOC362803 similar to putative RNA binding protein 1 -2.56 
NM_001007645.1 MGC95152 similar to B230212L03Rik protein -2.56 
XM_227030.4 Ttc14 tetratricopeptide repeat domain 14 -2.55 
NM_053573.1 Olfm1 olfactomedin 1 -2.55 
NM_031745.2 Clip1 CAP-GLY domain containing linker 
protein 1 -2.55 
XM_574188.1 LOC498901 similar to LRRGT00176 -2.55 
XM_343479.3 Sema3b sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3B 
-2.53 
XM_001061697.1 Susd1 sushi domain containing 1 -2.53 
XM_345984.2 LOC501057 similar to Mtap4 protein -2.51 
XM_237064.4 RGD1310819 similar to putative protein (5S487) -2.50 
NM_001015017.1 Olfm2 olfactomedin 2 -2.50 
XM_576950.1 LOC501548 similar to LRRG00135 -2.49 
NM_133402.2 Nap1l3 nucleosome assembly protein 1-like 3 -2.49 
XM_001074148.1 Piwil4 piwi-like 4 (Drosophila) -2.49 
XM_215728.4 Smarca3 helicase-like transcription factor -2.49 
XM_577034.1 LOC501637 similar to LRRG00135 -2.49 
XM_573309.1 LOC498105 similar to LRRGT00176 -2.48 
XM_342281.3 Muc1 mucin 1, cell surface associated -2.47 
NM_001024791.1 Epn3 epsin 3 -2.47 
NM_001011984.1 Asb2 ankyrin repeat and SOCS box-containing 
2 -2.46 
XM_576904.1 LOC501503 nucleic acid binding protein; hypothetical 
protein LOC689117 -2.46 
XM_218462.4 RGD1310942 similar to R27328_1 -2.45 
XM_579778.1 LOC498061 RGD1564312 -2.45 
XM_574001.2 Elovl2 elongation of very long chain fatty acids 
(FEN1/Elo2, SUR4/Elo3, yeast)-like 2; 
similar to Elongation of very long chain 
fatty acids protein 2 
-2.44 
XM_001071030.1 Kbtbd9 kelch-like 29 (Drosophila) -2.44 
XM_226397.2 RGD1308358 similar to 2210023G05Rik protein -2.44 
XM_001065428.1 Ccbe1 collagen and calcium binding EGF 
domains 1 -2.44 
XM_579677.1 LOC497785 hypothetical gene supported by 
NM_147211 -2.43 
XM_574960.1 LOC499638 similar to LRRGT00057 -2.43 
XM_573611.1 LOC498376 similar to ORF4 -2.42 
XM_341405.2 LOC361117 similar to Rb1-inducible coiled coil 
protein 1 -2.41 
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XM_001063544.1 LOC362564 BEN domain containing 5 -2.41 
XM_232253.3 LOC312683 similar to KIAA0819 protein -2.40 
XM_576977.1 LOC501573 similar to LRRGT00194 -2.40 
XM_001062086.1 RGD1564964 similar to WD repeat domain 11 protein -2.40 
XM_001067324.1 RGD1564560 similar to RCK -2.40 
XM_575756.1 LOC500397 similar to LRRGT00176 -2.40 
XM_575955.1 LOC500586 similar to LRRGT00057 -2.40 
XM_226455.4 Zfp612 zinc finger protein 23 (KOX 16) -2.39 
XM_217293.4 Ctdspl CTD (carboxy-terminal domain, RNA 
polymerase II, polypeptide A) small 
phosphatase-like 
-2.38 
NM_001014095.1 Dzip1l DAZ interacting protein 1-like -2.38 
XM_574268.1 LOC498979 similar to LRRGT00194 -2.37 
XM_579762.2 RGD1562012 RGD1562012 -2.37 
XM_345970.3 Chst2 carbohydrate sulfotransferase 2 -2.36 
XR_005694.1 LOC680293 similar to developmental pluripotency 
associated 4 isoform 1 -2.35 
XM_575695.1 LOC500343 similar to LRRGT00176 -2.35 
XM_573278.1 LOC498076 similar to RIKEN cDNA 2410116I05 -2.35 
NM_001008364.1 Snx24 sorting nexin 24 -2.35 
XM_573468.1 LOC498245 similar to LRRGT00176 -2.34 
XM_221263.4 Slc7a4 solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 4 -2.34 
XM_579843.1 LOC498652 RGD1562341 -2.34 
XM_001059291.1 Klhdc8a kelch domain containing 8A -2.34 
XM_578457.1 LOC502952 similar to alpha-2u globulin PGCL4 -2.32 
XM_576350.1 LOC500940 similar to LRRGT00126 -2.31 
XM_579720.1 LOC497836 hypothetical gene supported by 
NM_181475 -2.29 
XM_001063318.1 Xpo4 exportin 4 -2.29 
XM_001061729.1 RGD1565886 RGD1565886 -2.29 
XM_001054590.1 LOC679075 similar to l(3)mbt-like 3 -2.29 
XM_573902.1 LOC498623 similar to LRRGT00176 -2.28 
XM_575635.1 LOC500285 similar to LRRGT00176 -2.28 
XM_213921.3 Creg cellular repressor of E1A-stimulated 
genes 1 -2.27 
XM_001071978.1 RGD1306151 similar to hypothetical protein 
DKFZp761D0211 -2.27 
NM_001025063.1 Scrn1 secernin 1 -2.26 
XM_575503.1 LOC500151 similar to RIKEN cDNA 2410116I05 -2.26 
XM_001076815.1 RGD1310958 similar to RIKEN cDNA C130090K23 -2.24 
XM_578934.1 LOC503396 similar to Ac1147 -2.24 
XM_342055.3 Sema4g sema domain, immunoglobulin domain 
(Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 
4G 
-2.23 
NM_001014199.1 Atp6v1c2 ATPase, H+ transporting, lysosomal V1 
subunit C2 -2.23 
XM_001056150.1 LOC362068 G protein-coupled receptor 98 -2.23 
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XM_001071508.1 Sema5b sema domain, seven thrombospondin 
repeats (type 1 and type 1-like), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 5B 
-2.22 
XM_576443.1 LOC501032 similar to LRRGT00176 -2.22 
XM_344817.2 LOC365104 similar to hypothetical protein cgd4_1450 -2.21 
XM_234584.3 LOC299356 similar to RIKEN cDNA 4831426I19 -2.18 
XM_576580.1 LOC501156 similar to LRRGT00176 -2.17 
XM_001078792.1 RGD1309576 transmembrane protein 220 -2.17 
XM_577983.2 RGD1565105 small EDRK-rich factor 1 -2.16 
XM_576265.1 LOC500867 similar to LRRG00116 -2.16 
NM_172038.1 Gstm5 glutathione S-transferase, mu 5 -2.16 
XM_577051.1 LOC501656 similar to LRRGT00057 -2.15 
XM_573248.1 LOC498048 similar to ORF4 -2.15 
NM_017303.2 Kcnab1 potassium voltage-gated channel, shaker-
related subfamily, beta member 1 -2.14 
XM_001078124.1 Arhgap8 proline rich 5 (renal) -2.14 
XM_223428.4 RGD1307468 RELT-like 1 -2.13 
XM_001055013.1 RGD1561255 leucine-rich repeats and immunoglobulin-
like domains 3 -2.13 
XM_230024.4 RGD1562244 SEC14 and spectrin domains 1 -2.13 
XM_001071349.1 Lrp6 low density lipoprotein receptor-related 
protein 6 -2.12 
XM_001068317.1 RGD1563354 similar to hypothetical protein 
D630003M21 -2.12 
XM_001068586.1 RGD1564808 ubiquitin specific peptidase 46 -2.12 
NM_001014240.2 LOC364773 aldo-keto reductase family 1, member 
C13 -2.11 
XM_001076292.1 RGD1565496 similar to Butyrate-induced transcript 1 -2.11 
XM_001070748.1 Lrrc16 leucine rich repeat containing 16A -2.11 
XM_213633.4 Hoxd3_mapp
ed 
homeo box D3 -2.10 
XM_573616.1 LOC498381 similar to ORF1 -2.10 
XM_576615.1 LOC501187 hypothetical protein LOC501187 -2.10 
XM_215524.4 Tpd52 tumor protein D52 -2.09 
XM_345665.2 LOC366608 similar to mKIAA0716 protein -2.09 
XM_220693.4 RGD1307222 similar to mKIAA0664 protein -2.09 
XM_342631.2 LOC362315 similar to Retrovirus-related POL 
polyprotein -2.09 
XM_237794.3 LOC287564 transmembrane protein 132E -2.08 
XR_009616.1 LOC498759 hypothetical protein LOC685873; 
LRRGT00094 -2.08 
XM_342241.2 LOC361942 similar to ORF4 -2.08 
XM_342864.2 LOC362543 similar to LRRG00116 -2.08 
NM_019363.2 Aox1 aldehyde oxidase 1 -2.08 
XM_227657.4 Bcar3 breast cancer anti-estrogen resistance 3 -2.07 
NM_177425.3 Csrp2 cysteine and glycine-rich protein 2 -2.07 
XM_576501.1 LOC501087 similar to LRRGT00057 -2.07 
XM_576860.1 LOC501449 similar to ORF2 consensus sequence 
encoding endonuclease and reverse 




NM_017226.1 Padi2 peptidyl arginine deiminase, type II -2.06 
XM_574702.1 LOC499388 similar to LRRGT00082 -2.05 
XM_001063599.1 Odz4 odz, odd Oz/ten-m homolog 4 
(Drosophila) -2.05 
XM_001059473.1 Lysmd2 LysM, putative peptidoglycan-binding, 
domain containing 2 -2.04 
XM_001057514.1 Fcmd fukutin -2.04 
XM_343815.2 LOC363492 similar to Ac1262 -2.04 
NM_001031660.1 Msrb2 methionine sulfoxide reductase B2 -2.04 
XM_575847.1 LOC500480 similar to ORF1 -2.04 
XM_001058156.1 Lrpap1 low density lipoprotein receptor-related 
protein associated protein 1 -2.03 
XM_001058239.1 Syngr3 synaptogyrin 3 -2.03 
XM_575569.1 LOC500218 similar to LRRGT00173 -2.03 
XM_001072062.1 Wdr35 WD repeat domain 35; WD repeat 
domain 35-like -2.03 
XM_001080610.1 Nxn nucleoredoxin -2.02 
XM_224972.3 LOC306577 similar to expressed sequence BB049667 -2.02 
NM_031117.1 Snrpn small nuclear ribonucleoprotein 
polypeptide N; small nuclear 
ribonucleoprotein polypeptides B and B1 
-2.02 
NM_001025402.1 Umps uridine monophosphate synthetase -2.01 
XM_342067.3 RGD1307158 similar to oocyte-testis gene 1 -2.01 
XM_001054328.1 RGD1564930 similar to novel protein similar to Tensin 
Tns -2.01 
XM_238787.4 Rhpn2 rhophilin, Rho GTPase binding protein 2 -2.01 
NM_001024978.1 RGD1305844 hypothetical LOC294883 -2.00 
XM_222679.4 RGD1560834 zinc finger and BTB domain containing 
41 -2.00 
XM_573943.2 LOC498662 similar to RIKEN cDNA 2610019F03 -2.00 
XM_574144.2 RGD1561942 coiled-coil domain containing 112 -2.00 
XM_579646.1 LOC497726 hypothetical gene supported by 
NM_138518 -2.00 
XM_343907.3 Gtlf3b gene trap locus F3b -2.00 
XM_342331.3 Agl amylo-1,6-glucosidase, 4-alpha-
glucanotransferase -1.99 
XR_008124.1 RGD1565779 similar to hypothetical protein 
E230025N22 -1.98 
NM_031141.2 Pax8 paired box 8 -1.98 
XM_001074613.1 RGD1311980 family with sequence similarity 20, 
member C -1.97 
XM_225864.4 Spire1 spire homolog 1 (Drosophila) -1.96 
XM_227409.4 Ash1l ash1 (absent, small, or homeotic)-like 
(Drosophila) -1.96 
XM_243652.4 Plxnb2 plexin B2 -1.95 
NM_001012091.1 Foxs1 forkhead box S1 -1.94 
XM_001073019.1 Zfp521 zinc finger protein 521 -1.94 
XM_577516.1 LOC502081 similar to LRRGT00049 -1.94 
XR_008228.1 RGD1566399 similar to MYST histone 
acetyltransferase monocytic leukemia 4; 
similar to Histone acetyltransferase 




YBF2/SAS3, SAS2 and TIP60 protein 4) 
(Querkopf protein) 
XR_007788.1 RGD1309368 crumbs homolog 2 (Drosophila) -1.93 
NM_001004246.1 Ttc12 tetratricopeptide repeat domain 12 -1.93 
XM_238219.2 RGD1562890 RGD1562890 -1.93 
XM_001076726.1 RGD1561651 similar to zinc finger protein 609; zinc 
finger protein 609 -1.93 
XM_234092.4 RGD1311444 patatin-like phospholipase domain 
containing 8 -1.93 
XM_343313.3 RGD1308012 family with sequence similarity 116, 
member B -1.91 
XR_009418.1 LOC688018 similar to SH3-domain binding protein 3 -1.91 
NM_134398.1 P34 p34 protein; similar to Alpha- and 
gamma-adaptin-binding protein p34 -1.91 
XM_574161.2 Nedd4l neural precursor cell expressed, 
developmentally down-regulated 4-like -1.91 
XM_233953.3 LOC313940 similar to Hypothetical protein 
KIAA1240 -1.91 
XM_001060542.1 LOC681153 hypothetical protein LOC681153 -1.90 
XM_579502.1 LOC497745 hypothetical gene supported by 
NM_031049 -1.90 
NM_001013132.1 Fbxo16 F-box protein 16 -1.89 
XM_342207.2 LOC361912 similar to LRRG00116 -1.89 
XM_225526.4 Larp5 La ribonucleoprotein domain family, 
member 5 -1.89 
NM_001013984.1 Npl N-acetylneuraminate pyruvate lyase -1.89 
XM_575855.1 LOC500490 similar to Retrovirus-related POL 
polyprotein -1.89 
XM_341148.3 Pou2f1 POU domain, class 2, transcription factor 
1 -1.88 
NM_133586.1 Ces2 carboxylesterase 2 (intestine, liver) -1.88 
XM_347084.2 LOC362870 RGD1566301 -1.88 
XM_001079241.1 LOC687582 outer dense fiber of sperm tails 2-like -1.87 
XM_215939.4 Pltp phospholipid transfer protein -1.87 
XM_580203.1 LOC501498 LOC501498 -1.87 
XM_001066967.1 Kctd3 potassium channel tetramerisation 
domain containing 3 -1.87 
XM_341918.2 LOC361639 similar to CG14182-PA -1.87 
XM_579486.1 LOC497780 hypothetical gene supported by 
NM_024353 -1.87 
NM_022400.1 Bcat2 branched chain aminotransferase 2, 
mitochondrial -1.87 
NM_001025772.1 MGC114440 similar to RIKEN cDNA 4930555I21 -1.86 
XM_222190.3 LOC304500 similar to acetyl-coA dehydrogenase -
related (111.6 kD) (5G231) -1.86 
NM_031347.1 Ppargc1a peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha -1.85 
XM_236411.4 Myo5c myosin VC -1.85 
XM_001072989.1 Sulf2 sulfatase 2 -1.85 
XM_001074860.1 RGD1559432 RGD1559432 -1.84 
XM_225941.4 Dmxl1 Dmx-like 1 -1.84 
XM_001067729.1 Mll_mapped myeloid/lymphoid or mixed-lineage 
leukemia 1 -1.84 
XM_575799.1 LOC500437 similar to LRRGT00094 -1.84 
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NM_001007628.1 Cxxc5 CXXC finger 5 -1.84 
XM_575015.2 RGD1560967 G-protein signaling modulator 2 (AGS3-
like, C. elegans) -1.83 
XM_001061692.1 Pus7 pseudouridylate synthase 7 homolog (S. 
cerevisiae) -1.83 
XM_574879.1 LOC499554 similar to ORF2 consensus sequence 
encoding endonuclease and reverse 
transcriptase minus RNaseH 
-1.83 
NM_001013979.1 LOC304131 similar to C21ORF7 -1.82 
XM_001067414.1 Phldb1 pleckstrin homology-like domain, family 
B, member 1 -1.82 
NM_181362.1 Cand2 cullin-associated and neddylation-
dissociated 2 (putative) -1.82 
XM_574477.1 LOC499184 similar to LRRGT00082 -1.82 
NM_199376.1 Sil1 SIL1 homolog, endoplasmic reticulum 
chaperone (S. cerevisiae) -1.81 
XM_001081128.1 Zc3h6 zinc finger CCCH type containing 6 -1.80 
XM_573393.1 LOC498177 zinc finger protein ZFOC1 -1.80 
NM_001008861.2 Usp11 ubiquitin specific peptidase 11 -1.80 
XM_001071113.1 RGD1562920 androgen-induced 1 -1.80 
XM_579872.1 LOC498813 LOC498813 -1.79 
XR_009136.1 LOC360932 ATPase, class V, type 10D -1.79 
XM_574910.1 LOC499585 similar to LRRG00135 -1.79 
NM_001009537.1 MGC72997 zinc finger protein 799 -1.79 
XM_221043.4 Tex2 testis expressed 2 -1.79 
XM_236938.4 RGD1310693 radial spoke head 9 homolog 
(Chlamydomonas) -1.78 
XM_218816.4 Man2a2 mannosidase 2, alpha 2 -1.78 
XM_576459.2 Ppp2r3a protein phosphatase 2 (formerly 2A), 
regulatory subunit B'', alpha -1.78 
XM_574735.1 Pcbp3 poly(rC) binding protein 3 -1.78 
XM_001062225.1 Kctd1 potassium channel tetramerisation 
domain containing 1 -1.78 
XM_222685.3 Hrpt2 cell division cycle 73, Paf1/RNA 
polymerase II complex component, 
homolog (S. cerevisiae) 
-1.77 
XM_222288.3 LOC304592 similar to olf186-F CG11430-PB, isoform 
B; ORAI calcium release-activated 
calcium modulator 2 
-1.77 
XM_235064.4 Eea1 early endosome antigen 1 -1.76 
XM_579655.1 LOC497844 hypothetical gene supported by 
NM_138846 -1.76 
NM_001005906.1 Chpf chondroitin polymerizing factor -1.76 
XM_341029.3 RGD1307396 similar to RIKEN cDNA 6330406I15 -1.76 
XM_001054836.1 LOC300472 vacuolar protein sorting 26 homolog B 
(S. pombe) -1.76 
NM_053642.2 Sc5dl sterol-C5-desaturase (ERG3 delta-5-
desaturase homolog, S. cerevisiae)-like -1.76 
NM_001008316.1 Plag1 pleiomorphic adenoma gene 1 -1.75 
XM_573911.2 RGD1559427 WW and C2 domain containing 2 -1.75 
XM_573735.1 LOC498477 similar to Spetex-2C protein -1.75 
XM_341877.3 Iqgap1 IQ motif containing GTPase activating 
protein 1 -1.75 
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NM_139330.1 Sipa1l1 signal-induced proliferation-associated 1 
like 1 -1.75 
XM_579393.1 LOC497757 guanylate cyclase 1, soluble, alpha 3 -1.75 
NM_001007646.1 Fkbp9 FK506 binding protein 9, 63 kDa -1.75 
XM_573448.1 LOC498228 major facilitator superfamily domain 
containing 4 -1.75 
XM_576133.1 LOC500755 similar to LRRGT00008 -1.75 
XM_225213.4 Aof1 amine oxidase (flavin containing) domain 
1 -1.75 
NM_080899.1 Ikbkap inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase complex-
associated protein 
-1.74 
XM_234923.4 RGD1304737 similar to KIAA1086 protein -1.74 
XM_001070228.1 Braf v-raf murine sarcoma viral oncogene 
homolog B1 -1.74 
XM_001055328.1 Fign fidgetin -1.74 
XM_575991.1 LOC500617 similar to LRRGT00014 -1.74 
XM_001071417.1 Gpr126 G protein-coupled receptor 126 -1.73 
NM_032074.1 Irs3 insulin receptor substrate 3 -1.73 
XM_001080455.1 Klk1c10 T-kininogenase -1.73 
NM_184046.1 Rtkn rhotekin -1.73 
NM_001013071.1 Tm7sf2 transmembrane 7 superfamily member 2 -1.73 
XM_001069309.1 RGD1562848 RGD1562848 -1.73 
XM_238063.4 Ibrdc1 ring finger protein 217 -1.73 
XM_228042.3 RGD1309887 potassium channel tetramerisation 
domain containing 20 -1.72 
NM_001033656.1 Man1a mannosidase, alpha, class 1A, member 1 -1.72 
XM_232620.3 Mybl1 myeloblastosis oncogene-like 1 -1.72 
XM_236192.2 Ddx6 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 6 (Ddx6) -1.72 
XM_001063707.1 Msc musculin -1.72 
XM_573061.2 Rgs11 regulator of G-protein signaling 11 -1.72 
NM_053456.1 Plcl1 phospholipase C-like 1 -1.72 
XM_579620.1 LOC497747 hypothetical gene supported by 
NM_133395 -1.72 
XM_580006.1 LOC499701 RGD1563244 -1.72 
XM_001057150.1 Ptpdc1 protein tyrosine phosphatase domain 
containing 1 -1.72 
XM_001060543.1 RGD1560335 phosphatidylinositol glycan anchor 
biosynthesis, class G -1.71 
XM_343376.2 Znf500 zinc finger protein 500 -1.71 
XM_227769.2 LOC310926 hypothetical protein LOC310926 -1.71 
NM_031503.1 Ascl2 achaete-scute complex homolog 2 
(Drosophila) -1.71 
XM_577031.1 LOC501634 similar to LRRGT00176 -1.71 
NM_001014165.1 RGD1310039 similar to hypothetical protein FLJ10058 -1.70 
XM_001073363.1 Chst9 carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 9 -1.70 
NM_017220.1 Pts 6-pyruvoyl-tetrahydropterin synthase -1.70 
XM_342286.3 Slc39a1 solute carrier family 39 (zinc transporter), 
member 1 -1.70 
NM_001014131.1 RGD1309708 similar to RIKEN cDNA 4930455F23 -1.70 
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XM_001079385.1 Jmjd3 jumonji domain containing 3 -1.70 
XM_001069011.1 RGD1566359 similar to RIKEN cDNA B230219D22 -1.70 
NM_001024315.1 LOC499949 similar to hypothetical protein FLJ90166 -1.70 
NM_012736.1 Gpd2 glycerol-3-phosphate dehydrogenase 2, 
mitochondrial -1.70 
XM_342731.2 Sumf1 sulfatase modifying factor 1 -1.70 
XM_222315.4 Baz2a bromodomain adjacent to zinc finger 
domain, 2A -1.69 
XM_576928.1 LOC501527 similar to LRRGT00057 -1.69 
NM_133541.1 Gtf3c1 general transcription factor III C 1 -1.69 
XM_575347.1 LOC499992 similar to Retrovirus-related POL 
polyprotein -1.69 
XM_001071807.1 RGD1566054 tetratricopeptide repeat domain 15 -1.69 
XM_001070393.1 RGD1307696 fat storage-inducing transmembrane 
protein 2 -1.68 
XM_001061189.1 RGD1306493 WD repeat domain 60 -1.68 
XM_574587.2 RGD1562983 HCCA2 protein -1.68 
XM_001053950.1 RGD1566050 similar to hypothetical protein FLJ32745 -1.68 
XM_001056091.1 LOC499337 dedicator of cytokinesis 8 -1.68 
NM_022857.1 N5 DNA binding protein N5 -1.68 
NM_133421.1 Lkap hypothetical gene supported by 
AB012133; NM_133421; similar to 
limkain b1; limkain b1
-1.68 
XM_578786.2 RGD1565095 similar to hypothetical protein 
MGC52110 -1.68 
XM_001056385.1 Ptchd1 patched domain containing 1 -1.68 
NM_001024975.1 Morn4 MORN repeat containing 4 -1.68 
XM_575480.2 RGD1564419 similar to hypothetical gene supported by 
BC025338 -1.67 
XM_342548.3 Snta1 syntrophin, acidic 1 -1.67 
XM_001055537.1 LOC679271 rhomboid, veinlet-like 2 (Drosophila) -1.67 
XM_341106.3 Fvt1 3-ketodihydrosphingosine reductase -1.67 
XM_001071547.1 LOC689581 eukaryotic translation initiation factor 5B, 
pseudogene 1; eukaryotic translation 
initiation factor 5B 
-1.67 
XM_234373.4 Ttc8 tetratricopeptide repeat domain 8 -1.67 
XM_579510.1 LOC497724 hypothetical gene supported by 
NM_031525 -1.67 
XM_001060860.1 LOC685778 pyruvate dehydrogenase E1 alpha 1 
pseudogene; pyruvate dehydrogenase 
(lipoamide) alpha 1
-1.66 
XM_001058768.1 Thoc2 similar to THO complex subunit 2 
(Tho2); THO complex 2 -1.66 
XM_001072660.1 Chchd6 coiled-coil-helix-coiled-coil-helix domain 
containing 6 -1.66 
XM_220933.3 Arf4l ADP-ribosylation factor 4-like -1.66 
XM_001071249.1 Kcnq5 potassium voltage-gated channel, 
subfamily Q, member 5-like -1.66 
NM_001012075.1 Tspyl4 TSPY-like 4 -1.66 
XM_232064.4 Tcf3 transcription factor 3 -1.66 
XM_342683.3 RGD1564287 oxysterol binding protein-like 3 -1.66 
XM_217443.3 Glb1l galactosidase, beta 1-like -1.66 
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XM_579478.2 Gucy1a2 guanylate cyclase 1, soluble, alpha 2 -1.66 
NM_001015012.1 Rab30 RAB30, member RAS oncogene family -1.66 
NM_153302.1 Dcps decapping enzyme, scavenger -1.66 
XM_001060916.1 RGD1308290 similar to RIKEN cDNA 5730454B08; 
similar to Zinc finger CCCH-type 
domain-containing protein 11A 
-1.66 
XM_345130.1 LOC365612 similar to putative aminopeptidase Fxna -1.65 
XM_347115.2 LOC363240 RGD1565696 -1.65 
NM_012988.1 Nfia nuclear factor I/A -1.65 
XM_001053119.1 LOC360728 hypothetical protein LOC678704; 
ATPase type 13A3 -1.64 
XM_223592.3 Zfp278 zinc finger protein 278 -1.64 
NM_147145.1 Dclre1c DNA cross-link repair 1C, PSO2 
homolog (S. cerevisiae) -1.64 
XM_224461.3 Klf12 Kruppel-like factor 12 -1.64 
XM_576559.1 LOC501139 similar to Ormdl1 protein -1.64 
NM_021581.1 Sc65 synaptonemal complex protein SC65 -1.64 
XR_009288.1 RGD1564206 synapse defective 1, Rho GTPase, 
homolog 2 (C. elegans) -1.64 
XM_223945.4 Samd4 sterile alpha motif domain containing 4A -1.63 
NM_001004095.1 S100a11 S100 calcium binding protein A11 
(calizzarin) -1.63 
XM_214734.4 RGD1311558 similar to 4930506M07Rik protein -1.63 
NM_001003957.1 Dnmt3a DNA (cytosine-5-)-methyltransferase 3 
alpha -1.63 
NM_182672.1 Cbr4 carbonyl reductase 4 -1.63 
XM_216149.3 LOC297099 homeobox A9-like -1.63 
NM_022268.1 Pygl phosphorylase, glycogen, liver -1.63 
NM_001014065.1 Zcchc12 zinc finger, CCHC domain containing 12 -1.63 
NM_053718.1 Mllt3 myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, 
Drosophila); translocated to, 3 
-1.63 
XM_001078585.1 RGD1564019 similar to GTPase activating RANGAP 
domain-like 3 -1.62 
XM_340870.3 RGD1305547 integrator complex subunit 2 -1.62 
XM_001075851.1 RGD1309779 similar to ENSANGP00000021391 -1.62 
XM_236292.4 Npat nuclear protein, ataxia-telangiectasia 
locus -1.62 
XM_579481.1 LOC497728 hypothetical gene supported by 
NM_024137 -1.62 
XM_574868.1 Pip3ap myotubularin related protein 12 -1.61 
XM_343923.2 Kctd11 potassium channel tetramerisation 
domain containing 11 -1.61 
XM_228708.4 RGD1563226 ubiquitin-conjugating enzyme E2Q 
family member 2-like -1.61 
XM_001055855.1 Mtf1 metal-regulatory transcription factor 1 -1.61 
XM_575067.1 LOC499732 leucine-rich repeats and IQ motif 
containing 3 -1.61 
XM_236739.4 Fyco1 FYVE and coiled-coil domain containing 
1 -1.61 
NM_001025755.1 MGC116197 similar to RIKEN cDNA 1700001E04 -1.60 
XM_001060093.1 RGD1561059 methyltransferase like 8 -1.60 
XM_579986.1 LOC499614 RGD1559718 -1.60 
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XM_214751.3 Mrpl18 mitochondrial ribosomal protein L18 15.19 
XM_575546.1 LOC500194 similar to immunoglobulin kappa-chain 3.48 
NM_001013063.1 Raet1l retinoic acid early transcript 1L 3.36 
XR_009489.1 Cd300le CD300 molecule-like family member E 3.28 
XM_575513.1 LOC500161 similar to Immunoglobulin kappa-chain 
VJ precursor 3.18 
XM_578288.1 LOC502789 similar to Immunoglobulin kappa-chain 
VJ precursor 3.14 
NM_001014132.1 Traf3ip3 TRAF3 interacting protein 3 3.09 
XM_221094.3 LOC303666 similar to dendritic cell-derived 
immunoglobulin(Ig)-like receptor 1, 
DIgR1 - mouse 
2.93 
NM_001009541.1 Ier2 immediate early response 2 2.76 
XM_234930.2 Edg6 sphingosine-1-phosphate receptor 4 2.74 
XM_001072477.1 Sema7a sema domain, immunoglobulin domain 
(Ig), and GPI membrane anchor, 
(semaphorin) 7A 
2.73 
XM_236646.2 Ngp neutrophilic granule protein 2.72 
XM_345752.2 LOC366765 similar to Ig H-chain 2.71 
XM_001070786.1 Stfa2 stefin A2-like 2; stefin A2-like 3 2.70 
XM_573293.1 RGD1560676 stefin A2-like 2; stefin A2-like 3 2.70 
XM_341195.2 Igj immunoglobulin joining chain 2.69 
XM_217791.4 Tagap T-cell activation GTPase activating 
protein 2.65 
NM_138547.1 LOC191574 aldo-keto reductase family 1, member 
C14 2.61 
XM_577145.1 LOC501744 similar to Immunoglobulin superfamily, 
member 7 2.59 
XM_343664.2 LOC363326 hypothetical LOC363326 2.57 
XM_575732.1 LOC500374 Ig kappa chain V region S211 2.57 
XM_578343.1 LOC502843 similar to immunoglobulin kappa-chain 2.55 
XM_341534.2 Tcrg T cell receptor gamma locus 2.53 
XM_001075162.1 LOC690672 similar to Discs large homolog 5 
(Placenta and prostate DLG) (Discs large 
protein P-dlg) 
2.52 
XM_575512.1 LOC500160 similar to Immunoglobulin light chain 2.48 
XM_576812.2 LOC501399 similar to Discs large homolog 5 
(Placenta and prostate DLG) (Discs large 
protein P-dlg) 
2.46 
XM_575930.2 RGD1564994 glycine/arginine rich protein 1 2.43 
XM_575544.1 LOC500192 similar to Ig kappa chain V-IV region 
precursor 2.42 
XM_222692.4 Rgs18 regulator of G-protein signaling 18 2.42 
XM_001061476.1 Tcf15 transcription factor 15 2.38 
XM_575525.1 LOC500173 similar to immunoglobulin light chain 
precursor 2.38 
XM_217546.3 LOC302210 similar to RIKEN cDNA 4930555G01 2.37 
NM_001009681.1 Oasl 2'-5'-oligoadenylate synthetase-like 2.35 
XM_579453.1 Gcnt1 glucosaminyl (N-acetyl) transferase 1, 
core 2 2.35 
XM_236658.4 Ccrl2 chemokine (C-C motif) receptor-like 2 2.35 
NM_001014125.1 Pdia5 protein disulfide isomerase family A, 
member 5 2.35 
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XM_575524.1 LOC500172 similar to immunoglobulin kappa-chain 2.35 
XM_576305.1 LOC500903 similar to RIKEN cDNA 2210421G13 2.32 
NM_001024289.1 Ptprcap protein tyrosine phosphatase, receptor 
type, C-associated protein 2.31 
XM_001061883.1 LOC363181 similar to RIKEN cDNA 1700001E04 2.31 
NM_001025115.1 Stap1 signal transducing adaptor family 
member 1 2.31 
NM_001014039.1 Tnfaip8l2 tumor necrosis factor, alpha-induced 
protein 8-like 2 2.30 
XM_579388.1 LOC497767 hypothetical gene supported by 
BC081816; NM_017043 2.30 
NM_053713.1 Klf4 Kruppel-like factor 4 (gut) 2.29 
NM_181087.2 Cyp26b1 cytochrome P450, family 26, subfamily 
b, polypeptide 1 2.28 
XM_575447.1 LOC500096 similar to T cell receptor variable 
region:SUBUNIT=beta:ISOTYPE=8.3 2.27 
XM_225319.3 RGD1306939 similar to mKIAA0386 protein 2.27 
XM_576504.1 LOC501089 similar to Discs large homolog 5 
(Placenta and prostate DLG) (Discs large 
protein P-dlg) 
2.26 
XM_224344.3 Dok2 docking protein 2 2.25 
XM_345803.3 Ankrd47 KN motif and ankyrin repeat domains 3 2.25 
XM_580254.1 LOC502542 RGD1565497 2.25 
XM_001059693.1 RGD1311960 transmembrane and coiled-coil domain 
family 2 2.25 
NM_001009717.1 Lrg1 leucine-rich alpha-2-glycoprotein 1 2.21 
XM_001059284.1 RGD1560455 similar to RIKEN cDNA A630033H20 
gene 2.21 
XM_579438.1 LOC497816 hypothetical gene supported by 
NM_019371 2.20 
XM_228320.4 Prdm1 PR domain containing 1, with ZNF 
domain 2.19 
NM_001012469.1 Il21r interleukin 21 receptor 2.17 
NM_001009489.1 Oas1k 2 ' -5 ' oligoadenylate synthetase 1K 2.17 
NM_001008518.1 MGC105649 hypothetical LOC302884 2.16 
XM_001073723.1 Kif23 kinesin family member 23 2.16 
XM_001059303.1 RGD1560293 SAM and SH3 domain containing 3 2.15 
XM_234747.2 LOC314521 similar to BWK3 2.15 
XM_214825.3 Nova2 neuro-oncological ventral antigen 2 2.15 
NM_133540.1 Nkg7 natural killer cell group 7 sequence 2.15 
NM_001030043.1 RGD1311300 similar to T cell receptor V delta 6 2.13 
XM_579551.1 LOC497748 hypothetical gene supported by 
NM_053313 2.13 
XM_573856.2 RGD1561145 similar to novel protein 2.12 
XM_574335.1 LOC499056 similar to KRAB-zinc finger protein; 
similar to 3110052M02Rik protein; zinc 
finger protein 53; zinc finger protein 51 
2.11 
XM_001078162.1 Dapp1 dual adaptor of phosphotyrosine and 3-
phosphoinositides 2.11 
XM_001062861.1 Akr1cl1 aldo-keto reductase family 1, member C-
like 1 2.11 
XR_009153.1 RGD1559899 similar to mannose receptor precursor-
like isoform 4 2.10 
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XM_216745.3 Batf basic leucine zipper transcription factor, 
ATF-like 2.10 
XM_220513.4 Cias1 NLR family, pyrin domain containing 3 2.08 
XM_222017.3 Hrbl ArfGAP with FG repeats 2 2.07 
NM_024356.1 Gch1 GTP cyclohydrolase 1 2.07 
XM_001055834.1 LOC680128 similar to phospholipase C-like 2 2.05 
XM_213490.4 RGD1307288 similar to Protein C21orf58 2.05 
XM_234419.4 Rps6kl1 ribosomal protein S6 kinase-like 1 2.05 
XM_578684.1 LOC503160 similar to Ly6-C antigen gene 2.03 
NM_053847.1 Map3k8 mitogen-activated protein kinase kinase 
kinase 8 2.03 
NM_001030025.1 Upp1 uridine phosphorylase 1 2.02 
XM_001058249.1 LOC680665 Fc receptor-like 1 2.01 
XM_001060043.1 Ptk9l protein tyrosine kinase 9-like (A6-related 
protein) 2.01 
XM_001058119.1 Mcpt10 mast cell protease 8-like 3; mast cell 
protease 10 2.00 
XM_221216.4 Cd7 Cd7 molecule 2.00 
NM_017016.1 Hdc histidine decarboxylase 1.98 
XM_213365.3 Centb1 ArfGAP with coiled-coil, ankyrin repeat 
and PH domains 1 1.98 
NM_001012226.1 Stat4 signal transducer and activator of 
transcription 1; signal transducer and 
activator of transcription 4 
1.96 
NM_145683.1 Ptpn7 protein tyrosine phosphatase, non-
receptor type 7 1.96 
XR_008288.1 RGD1565895 kelch-like 35 (Drosophila) 1.95 
XM_573119.2 RGD1560850 phosphoinositide-3-kinase, regulatory 
subunit 6 1.95 
XM_219476.3 Ifitm6 interferon induced transmembrane protein 
6 1.95 
XM_001078275.1 RGD1563164 G-2 and S-phase expressed 1 1.95 
XM_223423.4 Klf3_mapped Kruppel-like factor 3 (basic) 1.94 
XM_001067912.1 LOC684490 similar to methylenetetrahydrofolate 
dehydrogenase (NAD) (EC 
1.5.1.15)/methenyltetrahydrofolate 
cyclohydrolase (EC 3.5.4.9) precursor; 
methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
1.94 
XM_001055140.1 Dscr6 Down syndrome critical region homolog 
6 (human) 1.93 
XM_344042.2 LOC363828 similar to immunoglobulin light chain 
variable region 1.93 
XM_342673.2 LOC362350 similar to T-cell receptor beta-2 chain C 
region 1.92 
XM_228821.3 RGD1561019 G protein-coupled receptor associated 
sorting protein 2 1.92 
XM_001068004.1 Ap1s2 adaptor-related protein complex 1, sigma 
2 subunit 1.92 
XM_343880.2 Itk IL2-inducible T-cell kinase 1.92 
NM_172044.1 Mcpt2 mast cell protease 2 1.91 
NM_053769.2 Dusp1 dual specificity phosphatase 1 1.91 
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NM_199110.1 Mfng MFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase 1.90 
NM_001024776.1 Hipk4 homeodomain interacting protein kinase 4 1.90 
XM_230610.4 Hspa12b heat shock protein 12B 1.89 
XM_573745.2 RGD1565031 REST corepressor 2; similar to REST 
corepressor 2 1.89 
XM_001063436.1 RGD1566325 similar to regulator of sex-limitation 
candidate 16 1.89 
XM_001069146.1 RGD1311012 sterile alpha motif domain containing 5 1.89 
XM_576127.1 LOC500748 similar to Rap guanine nucleotide 
exchange factor 5 (Guanine nucleotide 
exchange factor for Rap1) (M-Ras-
regulated Rap GEF) (MR-GEF) 
1.88 
NM_053502.1 Abcg1 ATP-binding cassette, sub-family G 
(WHITE), member 1 1.88 
XR_000311.1 LOC501207 similar to 2810022L02Rik protein 1.88 
XM_224699.3 LOC306324 tetraspanin 14; SH2 domain containing 
4B 1.87 
XM_001071145.1 RGD1311490 TBC1 domain family, member 10C 1.87 
XM_220639.3 Nek8 NIMA (never in mitosis gene a)- related 
kinase 8 1.87 
XM_579446.1 LOC497690 hypothetical gene supported by 
NM_021684 1.87 
XM_214592.4 Stard4 StAR-related lipid transfer (START) 
domain containing 4 1.86 
NM_133290.2 Zfp36 zinc finger protein 36 1.86 
XM_577148.2 RGD1562974 glutamine rich 2 1.86 
XM_578296.1 LOC502797 similar to immunoglobulin kappa-chain 1.86 
NM_001009662.1 Car8 carbonic anhydrase 8 1.86 
XM_224403.4 RGD1304929 similar to chromosome 13 open reading 
frame 18 1.86 
XM_001072042.1 RGD1311475 similar to FLJ00354 protein 1.85 
XM_576264.2 RGD1564335 Golgi-localized protein 1.85 
XM_235398.4 RGD1311559 DENN/MADD domain containing 3 1.85 
XM_341876.3 RGD1564385 feline sarcoma oncogene 1.83 
XM_579397.1 LOC497811 xanthine dehydrogenase 1.83 
XM_580072.1 LOC500488 LOC500488 1.83 
NM_031821.1 Plk2 polo-like kinase 2 (Drosophila) 1.83 
XM_001072174.1 RGD1311132 exocyst complex component 3-like 1.82 
XM_231388.4 RGD1305854 DBF4 homolog (S. cerevisiae) 1.82 
XM_580016.1 LOC499785 RGD1564003 1.82 
NM_001039204.1 LOC290071 similar to RIKEN cDNA A430107P09 
gene 1.81 
NM_053391.1 Hs3st1 heparan sulfate (glucosamine) 3-O-
sulfotransferase 1 1.81 
XM_001076779.1 LOC499828 copine VIII; similar to copine VIII 
isoform 1 1.81 
XM_001078315.1 Def6 differentially expressed in FDCP 6 
homolog (mouse) 1.80 
XM_343579.2 Raph1 Ras association (RalGDS/AF-6) and 
pleckstrin homology domains 1 1.80 
NM_001024316.1 Gata5 GATA binding protein 5 1.80 
NM_001025693.1 Cdca7 cell division cycle associated 7 1.80 
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XM_001071550.1 Arrdc1 arrestin domain containing 1 1.79 
NM_175761.2 Hsp90aa1 similar to heat shock protein 1, alpha; 
heat shock protein 90, alpha (cytosolic), 
class A member 1 
1.79 
XM_001054586.1 RGD1565985 tetratricopeptide repeat domain 9 1.79 
XM_341832.2 LOC361546 similar to mKIAA0841 protein 1.79 
XM_219594.3 LOC293746 membrane-spanning 4-domains, 
subfamily A, member 4C 1.79 
XM_575036.1 LOC499708 similar to 60S ribosomal protein L7a 1.79 
XM_001071725.1 RGD1560608 similar to novel protein 1.78 
XM_217350.4 Mrpl14 mitochondrial ribosomal protein L14 1.78 
NM_001025688.1 Palmd palmdelphin 1.78 
XM_342414.3 Sh2d3c SH2 domain containing 3C 1.78 
XM_001072688.1 Mmp17 matrix metallopeptidase 17 1.78 
NM_012964.2 Hmmr hyaluronan mediated motility receptor 
(RHAMM) 1.78 
NM_001011968.1 Gimap6 GTPase, IMAP family member 6 1.77 
XM_576214.1 LOC500824 FYVE, RhoGEF and PH domain 
containing 6 1.77 
XM_340854.3 RGD1564005 similar to novel protein 1.77 
XM_001068254.1 RGD1561783 StAR-related lipid transfer (START) 
domain containing 5 1.77 
NM_207605.3 Sh2d2a SH2 domain protein 2A 1.77 
NM_001008398.2 Gimap9 GTPase, IMAP family member 9 1.76 
XM_340836.3 RGD1308747 hypothetical protein LOC680565; family 
with sequence similarity 64, member A 1.76 
XM_578149.1 LOC502655 similar to heat shock 90kDa protein 1, 
beta 1.76 
XM_001055379.1 Arhgef3 Rho guanine nucleotide exchange factor 
(GEF) 3 1.76 
XM_001067802.1 Pcdh19 protocadherin 19 1.76 
NM_031085.2 Prkch protein kinase C, eta 1.76 
XM_001065725.1 RGD1565540 cytotoxic T lymphocyte-associated 
protein 2 alpha 1.76 
XM_001079575.1 RGD1310788 similar to RIKEN cDNA 0610039P13 1.76 
XM_233480.3 RGD1309802 defects in morphology 1 homolog (S. 
cerevisiae) 1.75 
XM_001066862.1 Nalp12 NACHT, leucine rich repeat and PYD 
containing 12 1.75 
NM_001007694.1 Ifit3 interferon-induced protein with 
tetratricopeptide repeats 3 1.75 
NM_199491.1 Fut7 fucosyltransferase 7 (alpha (1,3) 
fucosyltransferase) 1.75 
XM_573480.1 LOC498256 immediate early response 5 1.75 
NM_001033963.1 Prkx protein kinase, X-linked 1.75 
NM_001025708.1 Ogfrl1 opioid growth factor receptor-like 1 1.75 
XM_216334.3 Hspcal3 heat shock 90kDa protein 1, alpha-like 3 1.75 
NM_153468.1 Gzma granzyme A 1.74 
XM_216310.4 Casc1 cancer susceptibility candidate 1 1.74 
NM_001014050.1 Fam110a family with sequence similarity 110, 
member A 1.73 
XM_001079908.1 Ifi44 interferon-induced protein 44 1.73 
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XM_227546.3 LOC295340 similar to Acidic ribosomal 
phosphoprotein P0 1.73 
NM_001007684.1 Klf2 Kruppel-like factor 2 (lung) 1.73 
XM_216547.4 Sh3bgrl3 SH3 domain binding glutamic acid-rich 
protein-like 3 1.73 
XM_001081251.1 RGD1561062 family with sequence similarity 117, 
member A 1.72 
XM_001062502.1 RGD1564040 similar to methylenetetrahydrofolate 
dehydrogenase (NAD) (EC 
1.5.1.15)/methenyltetrahydrofolate 
cyclohydrolase (EC 3.5.4.9) precursor; 
methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
1.72 
NM_172021.2 Tbkbp1 TBK1 binding protein 1 1.72 
XM_001061125.1 RGD1564160 solute carrier family 37 (glycerol-3-
phosphate transporter), member 2 1.70 
XM_235547.4 RGD1560783 family with sequence similarity 118, 
member A 1.70 
XM_001053661.1 Stim2 stromal interaction molecule 2 1.69 
XM_213896.2 LOC289084 similar to RIKEN cDNA 1700025G04 
gene 1.69 
XM_001065344.1 RGD1560731 G protein-coupled receptor 146 1.69 
NM_001014236.1 Ssbp4 single stranded DNA binding protein 4 1.69 
XM_001058176.1 RGD1563721 OTU domain containing 7A 1.69 
NM_017119.1 Gzmk granzyme K 1.69 
XM_001068837.1 RGD1563517 C-type lectin domain family 1, member b 1.69 
XM_230560.2 LOC311382 similar to ribosomal protein S2 1.68 
XM_346339.2 LOC367874 similar to 60S ribosomal protein L29 
(P23) 1.68 
XM_343921.3 Sox15 SRY (sex determining region Y)-box 15 1.68 
NM_053857.1 Eif4ebp1 eukaryotic translation initiation factor 4E 
binding protein 1 1.68 
NM_001024299.1 Zfp458 zinc finger protein 458 1.68 
XM_579288.1 Ly49s4 Ly49 stimulatory receptor 4; Ly-49 
stimulatory receptor 3 1.68 
NM_001006998.1 Aldh3b1 aldehyde dehydrogenase 3 family, 
member B1 1.68 
NM_001024361.1 LOC501110 similar to Glutathione S-transferase A1 
(GTH1) (HA subunit 1) (GST-epsilon) 
(GSTA1-1) (GST class-alpha) 
1.68 
XM_213626.4 Pvrl3 poliovirus receptor-related 3 1.67 
XR_008282.1 RGD1565661 similar to RIKEN cDNA 3110001I22 1.67 
NM_053826.2 Pdk1 pyruvate dehydrogenase kinase, isozyme 
1 1.67 
NM_053736.1 Casp11 caspase 4, apoptosis-related cysteine 
peptidase 1.67 
XM_577892.1 LOC502411 similar to Mature alpha chain of major 
histocompatibility complex class I 
antigen 
1.67 
NM_213561.2 Tcf19 transcription factor 19 1.66 
XM_234898.4 Hmha1 histocompatibility (minor) HA-1 1.66 
XM_001053269.1 Asah3l alkaline ceramidase 2 1.65 
NM_206815.1 Rnase6 ribonuclease, RNase A family, 6 1.65 
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XM_575130.1 LOC499794 ribosomal protein L10; similar to 
ribosomal protein L10; ribosomal protein 
L10-like 
1.65 
NM_001007667.1 Sat1 spermidine/spermine N1-acetyl 
transferase 1 1.65 
XM_212694.3 LOC288178 similar to extracellular signal-related 





XR_009158.1 RGD1565520 similar to 60S ribosomal protein L7a 1.64 
NM_001007144.1 Adfp adipose differentiation related protein 1.64 
XR_008840.1 RGD1564580 similar to ribosomal protein S10 1.64 
XM_575291.1 LOC366258 similar to 60S ribosomal protein L7a 1.64 
NM_001013880.1 Isyna1 inositol-3-phosphate synthase 1 1.64 
XM_001054287.1 Rnpc1 RNA binding motif protein 38 1.64 
XM_001072744.1 RGD1309543 similar to 2310014H01Rik protein 1.63 
NM_001008876.1 Rsl1d1 ribosomal L1 domain containing 1 1.63 
XM_001061369.1 Luzp5 leucine zipper protein 5 1.63 
XM_234471.4 Rin3 Ras and Rab interactor 3 1.63 
XM_001080759.1 Rasip1 Ras interacting protein 1 1.63 
NM_001037775.1 Chst12 carbohydrate sulfotransferase 12 1.63 
XR_009032.1 RGD1565356 similar to RIKEN cDNA 2210421G13 1.63 
NM_199089.2 Tcirg1 T-cell, immune regulator 1, ATPase, H+ 
transporting, lysosomal V0 subunit A3 1.63 
NM_020103.1 Ly6c Ly6-C antigen 1.62 
XM_574285.2 RGD1566426 nuclear receptor coactivator 7 1.62 
XM_001081011.1 RGD1562705 Src homology 2 domain containing F 1.62 
XM_341842.3 Cebpg CCAAT/enhancer binding protein 
(C/EBP), gamma 1.62 
XM_226529.3 LOC307907 similar to RIKEN cDNA 6430548M08 1.62 
XR_007676.1 RGD1560557 similar to minichromosome maintenance 
protein 8 isoform 1 1.62 
NM_019339.1 Rgs12 regulator of G-protein signaling 12 1.61 
XM_578590.1 LOC503070 similar to immunoglobulin heavy chain 
variable region 1.61 
XM_001064856.1 Thsd1 thrombospondin, type I, domain 
containing 1 1.61 
XM_001060148.1 RGD1306498 zinc finger and SCAN domain containing 
20; zinc finger protein 362 1.61 
XM_342643.3 Mdfic MyoD family inhibitor domain 
containing 1.61 
XM_233741.2 Tyk2 tyrosine kinase 2 1.60 
XM_001062249.1 LOC685088 Src homology 2 domain containing E 1.60 
XR_008462.1 RGD1305138 similar to expressed sequence AW556797 1.60 
Each gene is given a representative GenBank accession number, gene symbol, gene description, 
and fold change (relative to control rats; negative values indicate down regulation). Genes are 
grouped according to the functional annotation cluster analysed using DAVID and arranged by 




Appendix 3.3: Differentially expressed podocyte related genes 
 





Symbol Gene Description 
Fold 
Change 
AMD protein complexes 
NM_017336.1 Ptpro protein tyrosine phosphatase, receptor type, O -2.42 
NM_019357.1 Ezr ezrin -1.82 
BMD protein complexes 
XM_342410.3 Aif1l allograft inflammatory factor 1-like -3.43 
NM_012649.1 Sdc4 syndecan 4 -2.79 
NM_001012032.1 Arhgap24 Rho GTPase activating protein 24 -2.48 
NM_012983.2 Myo1d myosin ID -2.28 
XM_340884.2 Itga3 integrin alpha 3 -2.23 
XM_343483.3 Dag1 dystroglycan 1 -2.07 
XM_001066264.1 Tenc1 tensin like C1 domain-containing phosphatase -2.00 
NM_012904.1 Anxa1 annexin A1 -1.91 
XM_001078155.1 Parvb parvin, beta 1.65 
SD protein complexes 
NM_053621.1 Magi2 membrane associated guanylate kinase, WW 
and PDZ domain containing 2 -3.93 
NM_021695.1 Synpo synaptopodin -3.62 
XM_218486.3 Kirrel2 kin of IRRE like 2 (Drosophila) -3.47 
XM_001059464.1 Cdh11 cadherin 11 -3.16 
NM_022628.1 Nphs1 nephrosis 1 homolog, nephrin -3.06 
NM_130828.2 Nphs2 nephrosis 2 homolog, podocin -3.02 
NM_001012055.1 Cdh16 cadherin 16 -2.73 
XM_001059679.1 Ctnnal1 catenin (cadherin associated protein), alpha-
like 1 -2.42 
NM_031005.2 Actn1 actinin, alpha 1 -2.30 
XM_001059817.1 Nck2 NCK adaptor protein 2 -2.10 
XM_237115.1 Nck2 NCK adaptor protein 2 -1.62 
XM_226213.4 Cdh5 cadherin 5 1.88 
Cell junction 
XM_236385.4 Cgnl1 cingulin-like 1 -2.54 
NM_012528.1 Chrnb1 cholinergic receptor, nicotinic, beta 
polypeptide 1 (muscle) -2.40 
NM_017198.1 Pak1 p21 protein (Cdc42/Rac)-activated kinase 1 -2.19 
NM_012663.2 Vamp2 vesicle-associated membrane protein 2 -1.60 
Tight junction 
NM_031699.1 Cldn1 claudin 1 -3.19 
XM_001080868.1 Mpp5 membrane protein, palmitoylated 5 (MAGUK 
p55 subfamily member 5) -2.33 
NM_031675.2 Actn4 actinin alpha 4 -1.72 
NM_017093.1 Akt2 thymoma viral proto-oncogene 2 -1.68 




NM_001012039.1 Efemp1 epidermal growth factor-containing fibulin-
like extracellular matrix protein 1 -4.76 
XM_001060132.1 C1qtnf7 C1q and tumor necrosis factor related protein 
7 -4.16 
NM_001012225.1 Mgat4a mannoside acetylglucosaminyltransferase 4, 
isoenzyme A -3.28 
XM_001064272.1 Crim1 cysteine rich transmembrane BMP regulator 1 
(chordin like) -2.57 
NM_031609.1 Nbl1 neuroblastoma, suppression of tumorigenicity 
1 -2.54 
NM_053606.1 Mmp23 matrix metallopeptidase 23 -2.43 
NM_019237.1 Pcolce procollagen C-endopeptidase enhancer protein -2.35 
XM_343607.3 Col4a3 collagen, type IV, alpha 3 -1.99 
NM_053629.2 Fstl3 follistatin-like 3 -1.82 
NM_031697.1 St3gal3 ST3 beta-galactoside alpha-2,3-
sialyltransferase 3 -1.79 
NM_031640.1 Pgcp plasma glutamate carboxypeptidase -1.76 
NM_021989.2 Timp2 tissue inhibitor of metalloproteinase 2 -1.71 
NM_001004218.1 Fuca2 fucosidase, alpha-L- 2, plasma -1.61 
Intrinsic to plasma membrane 
NM_053570.1 Cxadr coxsackie virus and adenovirus receptor -2.45 
NM_017206.1 Slc6a6 solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 -1.95 
NM_183332.1 Myadm myeloid-associated differentiation marker -1.87 
NM_001007002.1 Mxra8 matrix-remodelling associated 8 -1.68 
NM_139110.1 Gpr116 G protein-coupled receptor 116 1.68 
NM_173135.1 Accn3 amiloride-sensitive cation channel 3 1.64 
Cell adhesion 
NM_031753.1 Alcam activated leukocyte cell adhesion molecule -2.93 
NM_019358.1 Pdpn podoplanin -2.72 
NM_019140.2 Ptprd protein tyrosine phosphatase, receptor type, D -2.59 
XM_223583.4 Aebp1 AE binding protein 1 -2.28 
XM_230950.4 Itgav integrin alpha V -1.97 
NM_013016.2 Sirpa signal-regulatory protein alpha -1.88 
NM_001004090.2 Tspan5 tetraspanin 5 -1.67 
Cell morphogenesis 
XM_216679.4 Lamb1 laminin, beta 1 -2.84 
NM_031235.1 Pard3 par-3 (partitioning defective 3) homolog (C. 
elegans) -2.64 
NM_012715.1 Adm adrenomedullin -2.10 
XM_242297.4 Ntng2 netrin G2 -1.93 
NM_024159.1 Dab2 disabled homolog 2 -1.74 
NM_017089.2 Efnb1 ephrin B1 -1.65 
Cytoskeletal component/process 
XM_214338.3 Palld similar to palladin -3.18 
XM_001054365.1 Arhgap28 Rho GTPase activating protein 28 -4.83 
XM_223229.4 Shroom3 shroom family member 3 -3.02 




NM_133545.1 Ptpn21 protein tyrosine phosphatase, non-receptor 
type 21 -2.67 
NM_001034075.1 Tpm1 tropomyosin 1, alpha -2.55 
NM_013082.2 Sdc2 syndecan 2 -2.46 
XM_216688.4 Arhgap5 Rho GTPase activating protein 5 -2.43 
XM_237042.4 Dst dystonin -2.39 
XM_220031.4 Myof myoferlin -2.38 
XM_001064622.1 Itgb5 integrin beta 5 -2.37 
XM_238004.3 Tubb2b tubulin, beta 2B -2.32 
NM_001013246.1 Arhgef12 Rho guanine nucleotide exchange factor 
(GEF) 12 -2.21 
XM_235213.3 Srgap1 SLIT-ROBO Rho GTPase activating protein 1 -2.17 
NM_017180.1 Phlda1 pleckstrin homology-like domain, family A, 
member 1 -2.06 
XM_227658.3 Fnbp1l formin binding protein 1-like -2.03 
XM_217035.4 Krt7 keratin 7 -2.01 
NM_001002798.1 Top1mt DNA topoisomerase 1, mitochondrial -2.01 
NM_053326.1 Pdlim5 PDZ and LIM domain 5 -1.91 
NM_012935.2 Cryab crystallin, alpha B -1.90 
XM_341538.2 Kif5b kinesin family member 5B -1.87 
NM_080689.3 Dnm1 dynamin 1 -1.81 
XM_573030.2 Myh11 myosin, heavy chain 11, smooth muscle -1.75 
XM_001061392.1 Myo6 myosin VI -1.72 
XM_343248.3 Mtss1 metastasis suppressor 1 -1.71 
NM_053603.1 Clic5 chloride intracellular channel 5 -1.62 
XM_001059351.1 Hist1h2bc histone cluster 1, H2bc 1.77 
NM_030863.1 Msn moesin 1.76 
XM_001070203.1 Itga5 integrin alpha 5 (fibronectin receptor alpha) 1.72 
NM_053783.1 Ifngr1 interferon gamma receptor 1 1.61 
Ion transport 
NM_001033693.1 Slc31a2 solute carrier family 31, member 2 -2.15 
NM_022269.1 Cd55 CD55 antigen -1.95 
NM_139332.3 Tpcn1 two pore channel 1 -1.81 
Kidney development 
XM_213677.3 Robo2 roundabout homolog 2 -4.77 
NM_031534.1 Wt1 Wilms tumor 1 homolog -4.05 
NM_001032397.1 Tcf21 transcription factor 21 -3.54 
NM_053758.1 Plce1 phospholipase C, epsilon 1 -3.29 
XM_001053727.1 Bmp7 bone morphogenetic protein 7 -2.68 
NM_012774.1 Gpc3 glypican 3 -2.37 
NM_030849.1 Bmpr1a bone morphogenetic protein receptor, type 1A -2.13 
XM_213954.4 Nid1 nidogen 1 -2.12 
NM_173101.1 Myo1e myosin IE -2.03 
NM_053566.1 Ptch1 patched homolog 1 -1.99 
NM_053698.2 Cited2 Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 2 -1.68 
XM_001070482.1 Cutl1 similar to CCAAT displacement protein 
isoform b; cut-like homeobox 1 -1.67 
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XM_340765.2 Pkd1 polycystic kidney disease 1 homolog (human) -1.65 
NM_001002827.1 Notch4 Notch homolog 4 (Drosophila) 1.76 
XM_001054314.1 Tek TEK tyrosine kinase, endothelial 1.71 
Neuron development 
XM_001062426.1 Sema3g sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3G -3.98 
NM_001033757.1 Cdkn1c cyclin-dependent kinase inhibitor 1C (P57) -3.26 
XM_231354.4 Sema3e sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3E -3.24 
XM_236640.4 Plxnb1 plexin B1 -2.78 
NM_022589.1 Tspan2 tetraspanin 2 -2.74 
NM_017259.1 Btg2 B-cell translocation gene 2, anti-proliferative 2.91 
Protein modification 
XM_001057269.1 Mgat5 mannoside acetylglucosaminyltransferase 5 -3.21 
XM_219805.4 Prkg1 protein kinase, cGMP-dependent, type I -3.02 
XM_001076056.1 Uck2 uridine-cytidine kinase 2 -2.70 
XM_001080770.1 Cpd carboxypeptidase D -2.30 
XM_236687.4 Oxsr1 oxidative-stress responsive 1 -1.89 
XM_227618.4 Cdc14a CDC14 cell division cycle 14 homolog A -1.66 
Regulation of transcription 
NM_012760.1 Plagl1 pleiomorphic adenoma gene-like 1 -3.08 
XR_007660.1 Zfp462 zinc finger protein 462 -2.29 
NM_133560.2 Trak2 trafficking protein, kinesin binding 2 -2.26 
NM_031346.1 Rod1 ROD1 regulator of differentiation 1 -2.04 
NM_053583.1 Zfp423 zinc finger protein 423 -1.72 
NM_021597.1 Eif2c2 eukaryotic translation initiation factor 2C, 2 -1.67 
NM_021836.2 Junb jun B proto-oncogene 3.85 
XM_001076072.1 Lmcd1 LIM and cysteine-rich domains 1 1.96 
NM_021835.3 Jun Jun 1.88 
NM_012855.1 Jak3 Janus kinase 3 1.63 
Signal transduction 
NM_001002829.1 Rasl11a RAS-like, family 11, member A -2.31 
XM_001073244.1 Plxdc2 plexin domain containing 2 -2.31 
NM_080904.2 Arf3 ADP-ribosylation factor 3 -1.92 
NM_032076.2 Ptger4 prostaglandin E receptor 4 (subtype EP4) -1.78 
NM_001009405.1 Arhgap29 Rho GTPase activating protein 29 -1.61 
Vasculature development 
NM_031836.1 Vegfa vascular endothelial growth factor A -3.67 
XM_241275.4 Sema5a sema domain, seven thrombospondin repeats 
(type 1 and type 1-like), transmembrane 
domain (TM) and short cytoplasmic domain, 
(semaphorin) 5A 
-3.01 
XM_001070551.1 Reck reversion-inducing-cysteine-rich protein with 
kazal motifs -2.09 
NM_053356.1 Col1a2 collagen, type I, alpha 2 -2.08 
NM_013151.2 Plat plasminogen activator, tissue -1.66 
Vesicle 
NM_022251.1 Enpep glutamyl aminopeptidase -2.92 
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NM_145081.3 Optn optineurin -2.84 
XM_341428.2 Clcn3 chloride channel 3 -2.14 
XM_342271.3 Lrba LPS-responsive beige-like anchor -1.83 
Motif/Domain 
XM_222763.4 Tdrd5 tudor domain containing 5 -3.84 
XM_001073627.1 Plekha5 pleckstrin homology domain containing, 
family A member 5 -3.79 
XM_001055725.1 Kank1 KN motif and ankyrin repeat domains 1 -2.88 
XM_001069410.1 Hoxc6 homeobox C6 -2.87 
XM_001058167.1 Sgip1 SH3-domain GRB2-like (endophilin) 
interacting protein 1 -2.78 
NM_019316.1 Mafb v-maf musculoaponeurotic fibrosarcoma 
oncogene family, protein B -2.71 
XM_001053668.1 Rc3h2 ring finger and CCCH-type zinc finger 
domains 2 -2.66 
XM_001062112.1 Sh3bgrl2 SH3 domain binding glutamic acid-rich 
protein like 2 -2.44 
NM_001012048.1 Sh2d4a SH2 domain containing 4A -2.28 
NM_001014268.1 Lrrc1 leucine rich repeat containing 1 -2.11 
NM_001011922.1 Nedd9 neural precursor cell expressed, 
developmentally down-regulated gene 9 -1.84 
NM_001007148.1 Btrc beta-transducin repeat containing protein -1.73 
XM_233830.4 Plekhh2 pleckstrin homology domain containing, 
family H (with MyTH4 domain) member 2 -1.65 
XM_001081287.1 Ankrd40 ankyrin repeat domain 40 -1.61 
NM_130413.1 Skap2 src family associated phosphoprotein 2 1.75 
Miscellaneous 
NM_022943.1 Mertk c-mer proto-oncogene tyrosine kinase -3.12 
XM_217192.4 Rora RAR-related orphan receptor alpha -2.70 
XM_236376.4 Fam81a family with sequence similarity 81, member A -2.65 
NM_017031.2 Pde4b phosphodiesterase 4B, cAMP specific -2.49 
NM_133569.1 Angptl2 angiopoietin-like 2 -2.45 
XM_221276.3 Arvcf armadillo repeat gene deleted in velo-cardio-
facial syndrome -2.39 
XM_575387.2 Thsd7a thrombospondin, type I, domain containing 
7A -2.38 
XM_219201.4 Ppfibp2 PTPRF interacting protein, binding protein 2 
(liprin beta 2) -2.37 
XM_001053270.1 Ccpg1 cell cycle progression 1 -2.34 
NM_013220.1 Ankrd1 ankyrin repeat domain 1 -2.32 
XM_226988.4 Fndc3b fibronectin type III domain containing 3B -2.30 
XM_001061817.1 Erlin2 ER lipid raft associated 2 -2.26 
XM_001075785.1 Fam65a family with sequence similarity 65, member A -2.26 
XM_340875.3 Rnft1 ring finger protein, transmembrane 1 -2.04 
XM_340886.3 Nfe2l1 nuclear factor, erythroid derived 2,-like 1 -2.01 
NM_133601.1 Cblb Casitas B-lineage lymphoma b -1.94 
NM_001013882.1 Dctd dCMP deaminase -1.92 
NM_021850.2 Bcl2l2 Bcl2-like 2; poly(A) binding protein, nuclear 
1 -1.89 
NM_001005888.1 Galc galactosylceramidase -1.85 
NM_001014102.1 Spats2l spermatogenesis associated, serine-rich 2-like -1.80 
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NM_001007654.1 Agtrap angiotensin II receptor-associated protein -1.80 
NM_001025627.1 Leprel1 leprecan-like 1 -1.77 
XM_343420.3 Fam63b family with sequence similarity 63, member B -1.75 
XM_230036.4 Ssfa2 sperm specific antigen 2 -1.68 
XM_001070133.1 Nbeal1 neurobeachin like 1 -1.65 
NM_033485.2 Pawr PRKC, apoptosis, WT1, regulator -1.64 
NM_012868.1 Npr3 natriuretic peptide receptor 3 -1.61 
NM_199412.1 Cbara1 calcium binding atopy-related autoantigen 1 -1.61 
NM_031970.1 Hspb1 heat shock protein 1 2.42 
NM_053704.1 Bik BCL2-interacting killer (apoptosis-inducing) 2.15 
NM_173153.2 Gimap4 GTPase, IMAP family member 4 2.02 
NM_012938.1 Ctse cathepsin E 2.01 
XM_001067588.1 Tm6sf1 transmembrane 6 superfamily member 1 1.83 
NM_023962.2 Pdgfd platelet-derived growth factor, D polypeptide 1.80 
NM_057138.2 Cflar CASP8 and FADD-like apoptosis regulator 1.80 
XM_215117.4 Ifitm1 interferon induced transmembrane protein 1 1.74 
XM_001059368.1 Ldb2 LIM domain binding 2 1.74 
NM_001025141.1 Ccnb1ip1 cyclin B1 interacting protein 1 1.67 
Each gene is given a representative GenBank accession number, gene symbol, gene description, 
and fold change (relative to control rats; negative values indicate down regulation). Genes are 





Appendix 3.4: Gene expression index of TLR4, CTLA4 and CD28 in control 
and IL-13 overexpression rats. 
 
Glomerular gene expression index normalized against GAPDH. 
Code Sample TLR-4 CTLA-4 CD28
(3)C1 C1 6.84E-04 3.16E-04 1.62E-02
(3)C2 C2 6.81E-04 1.94E-04 5.18E-03 
(3)C3 C3 7.12E-04 7.16E-05 5.72E-03
(3)C4 C4 5.32E-04 4.79E-05 6.64E-03 
(3)C5 C5 6.97E-04 5.27E-05 4.90E-03 
(3)C6 C6 5.70E-04 2.19E-05 2.98E-03 
(6)C4 C16 9.27E-04 6.47E-05 5.23E-03 
(6)C5 C17 1.04E-03 3.72E-05 3.42E-03 
(3)J1 J1 7.96E-04 3.62E-05 4.07E-03 
(3)J2 J2 1.65E-03 6.50E-05 4.71E-03 
(3)J3 J3 1.23E-03 9.51E-05 4.70E-03 
(3)J4 J4 1.15E-03 4.73E-04 8.58E-03 
(3)J5 J5 9.07E-04 5.87E-05 7.52E-03 
(3)J6 J6 5.57E-04 8.97E-05 6.26E-03 
(4)J1 J7 6.80E-04 2.84E-04 3.08E-02
(4)J2 J8 1.15E-03 1.90E-04 1.38E-02 
(4)J3 J9 1.17E-03 2.02E-04 2.21E-02
(4)J4 J10 1.19E-03 4.66E-04 2.57E-02 
(4)J5 J11 9.04E-04 5.45E-04 1.76E-02 
(4)J6 J12 1.18E-03 1.86E-04 1.40E-02 
(4)J7 J13 1.69E-03 2.64E-04 1.97E-02 
(4)J8 J14 8.26E-04 1.92E-04 6.76E-03 
(4)J9 J15 9.07E-04 2.46E-04 3.86E-03 
(6)J1 J25 1.04E-03 2.91E-04 1.71E-02 
(6)J2 J26 1.12E-03 1.62E-04 1.24E-02 
(6)J6 J30 1.36E-03 9.93E-05 1.17E-02 
(6)J7 J31 1.35E-03 1.78E-04 1.23E-02
(6)J8 J32 1.32E-03 1.83E-04 1.60E-02 
(6)J9 J33 1.26E-03 2.67E-04 1.64E-02
(6)J13 J37 9.89E-04 2.42E-04 1.04E-02 
(6)J16 J40 1.26E-03 1.02E-04 1.10E-02 





Appendix 4.1: Gene expression index of B7-1, IL-13 receptors, vav1, 
dystroglycan, nephrin and podocin in unstimulated and IL-13 stimulated 
podocytes. 
 
Human podocytes gene expression index normalized against GAPDH (Part I).  
Group B7-1 IL13Rα2 IL13Rα1 IL4Rα vav1 dystro nephrin podocin 
1 1.27E-04 8.51E-04 7.96E-03 1.06E-02 6.54E-06 1.55E-02 2.36E-05 3.47E-05 
1 2.00E-04 6.34E-04 1.05E-02 1.56E-02 2.03E-05 1.41E-02 1.30E-05 2.85E-05 
1 5.26E-05 3.03E-04 8.56E-03 9.32E-03 1.42E-05 8.14E-03 2.74E-05 5.77E-05 
1 1.77E-05 8.97E-04 4.14E-03 4.80E-03 2.29E-05 4.84E-03 2.57E-04 7.48E-06 
1 2.30E-05 4.88E-04 3.34E-03 3.47E-03 5.20E-06 1.86E-03 7.20E-06 3.73E-05 
1 9.21E-05 1.35E-03 1.27E-02 1.56E-02 7.69E-06 1.21E-02 6.43E-05 4.35E-05 
1 3.47E-05 7.91E-04 1.09E-02 1.43E-02 1.06E-05 1.25E-02 2.05E-05 2.54E-05 
1 1.89E-04 1.17E-03 1.55E-02 1.42E-02 2.95E-05 2.05E-02 5.26E-04 1.83E-04 
1 1.70E-04 4.52E-04 1.73E-02 1.30E-02 4.77E-06 1.73E-02 1.89E-04 9.14E-05 
1 1.74E-04 1.40E-04 3.95E-03 3.88E-03 1.68E-05 5.59E-03 3.93E-06 2.07E-06
1 1.10E-04 4.57E-04 1.57E-02 8.92E-03 4.31E-06 1.52E-02 2.32E-05 4.26E-05 
1 6.94E-05 4.66E-04 1.26E-02 1.95E-02 2.46E-05 2.85E-02 3.01E-05 3.57E-05
1 3.44E-05 2.99E-04 1.76E-02 1.57E-02 4.76E-06 2.92E-02 8.83E-05 1.57E-05 
2 1.46E-04 1.63E-03 1.03E-02 1.77E-02 9.50E-06 1.58E-02 1.31E-05 3.04E-05
2 2.47E-04 9.45E-04 1.13E-02 1.96E-02 1.83E-05 1.80E-02 1.38E-05 2.44E-05 
2 1.37E-04 6.37E-04 1.43E-02 1.55E-02 1.95E-05 1.25E-02 2.41E-05 1.09E-04
2 4.45E-05 1.08E-03 5.63E-03 1.17E-02 2.61E-05 5.44E-03 1.34E-03 6.94E-06 
2 1.08E-04 4.94E-03 1.45E-02 1.57E-02 1.89E-05 9.82E-03 7.93E-05 3.59E-05 
2 2.77E-04 2.96E-03 1.43E-02 1.90E-02 2.72E-05 1.42E-02 1.01E-04 5.11E-05 
2 6.27E-05 1.55E-03 1.22E-02 1.88E-02 2.00E-05 1.69E-02 1.70E-05 4.08E-05 
2 3.52E-04 1.76E-03 1.53E-02 1.72E-02 3.54E-05 1.71E-02 5.46E-04 1.29E-04 
2 2.52E-04 8.12E-04 2.06E-02 1.57E-02 8.25E-06 2.44E-02 4.39E-04 5.60E-06 
2 1.83E-04 3.98E-04 5.44E-03 7.21E-03 3.06E-05 1.05E-02 6.88E-06 2.18E-06 
2 1.80E-04 5.91E-04 1.68E-02 9.58E-03 9.13E-06 8.93E-03 2.05E-05 3.02E-05 
2 9.01E-05 8.64E-04 1.02E-02 1.14E-02 3.05E-05 2.41E-02 7.69E-05 3.57E-05 
2 1.80E-04 7.14E-04 1.32E-02 1.69E-02 3.39E-05 2.62E-02 1.72E-04 1.98E-05 














Human podocytes gene expression index normalized against GAPDH (Part II). 
group TLR4 CTLA4 CD28 
1 1.60E-02 3.51E-03 2.49E-04 
1 2.13E-02 4.38E-04 4.04E-04 
1 1.86E-02 3.13E-04 2.81E-04 
1 1.72E-02 9.54E-04 1.18E-03 
1 2.04E-02 3.78E-03 3.07E-04 
1 1.40E-02 5.39E-03 1.76E-03 
1 2.04E-02 3.13E-04 5.51E-04 
1 9.81E-03 2.18E-04 6.54E-04 
1 1.35E-02 5.02E-04 9.01E-04 
1 1.34E-02 1.54E-03 3.64E-04 
1 1.46E-02 3.95E-04 1.25E-04 
1 1.83E-02 6.39E-04 1.57E-04 
1 ND 5.96E-04 ND 
1 ND 3.28E-04 ND 
2 1.27E-02 5.63E-04 1.91E-04 
2 1.70E-02 2.56E-04 4.66E-04 
2 1.79E-02 4.36E-04 3.40E-04 
2 6.71E-03 7.98E-04 8.73E-04 
2 2.55E-02 4.67E-03 2.27E-04 
2 1.14E-02 5.12E-04 1.10E-03 
2 1.39E-02 1.85E-04 2.28E-04 
2 1.51E-02 3.39E-04 2.65E-04 
2 1.20E-02 4.74E-04 9.68E-04 
2 1.56E-02 1.07E-03 2.51E-04 
2 1.06E-02 5.70E-04 1.57E-04 
2 1.27E-02 3.35E-04 2.33E-04 
2 ND 1.09E-04 ND 
2 ND 1.38E-03 ND 
Group 1 represents unstimulated podocytes; Group 2 represents IL-13 stimulated podocytes. 




Appendix 4.2: Protein expression index of B7-1, IL-13Rα2, vav1, 
phosphorylated vav1 and phosphor-vav1/vav1 in unstimulated and IL-13 
stimulated podocytes. 
 
Human podocytes protein expression index normalized against GAPDH. 
Group B7-1 IL-13Rα2 vav1 p-vav1 p-vav1/vav1 
1 0.36 1.00 1.76 0.56 0.32 
1 0.19 0.58 1.16 1.03 0.89 
1 0.89 0.49 2.13 2.39 1.12 
1 0.11 0.61 0.64 1.64 2.57 
1 1.03 0.41 1.21 3.63 3.00 
1 0.42 0.66 0.63 1.56 2.48 
1 0.60 0.77 1.02 5.57 5.46 
1 1.06 0.49 1.32 1.76 1.33 
1 1.03 0.49 0.31 0.38 1.24 
1 0.59 0.27 0.31 0.38 1.24 
2 0.38 1.22 0.77 0.68 0.88 
2 0.73 0.72 0.75 2.32 3.09 
2 1.11 0.60 1.86 2.44 1.31 
2 0.37 1.09 1.10 4.51 4.10 
2 1.26 0.61 0.47 1.52 3.24 
2 1.43 0.77 0.60 1.79 2.99 
2 1.04 0.98 1.38 10.93 7.92 
2 1.23 1.56 1.12 3.02 2.70 
2 1.23 1.00 0.68 2.01 2.96 
2 0.88 0.58 0.76 4.01 5.27 
Group 1 represents unstimulated podocytes; Group 2 represents IL-13 stimulated podocytes. 
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Appendix 5.1: Cortical F-actin scores in unstimulated and IL-13 stimulated 
podocytes. 
 
Cortical F-actin scores in podocytes. 
Batch Group Total no. of cells 
Number of cells Scores sum of 
score 0 1 2 3 0 1 2 3 
H30 1 3 0 2 1 0 0 2 2 0 4 
H30 1 10 0 6 2 2 0 6 4 6 16 
H30 1 12 0 7 5 0 0 7 10 0 17 
H30 1 6 1 5 0 0 0 5 0 0 5 
H30 1 1 0 1 0 0 0 1 0 0 1 
H30 Total 32 1 21 8 2 0 21 16 6 43 
H29 1 7 1 6 0 0 0 6 0 0 6 
H29 1 8 0 2 4 2 0 2 8 6 16 
H29 1 1 0 1 0 0 0 1 0 0 1 
H29 Total 16 1 9 4 2 0 9 8 6 23 
H23 1 3 0 2 1 0 0 2 2 0 4 
H23 1 2 1 0 0 1 0 0 0 3 3 
H23 1 6 0 1 2 3 0 1 4 9 14 
H23 1 5 0 0 4 1 0 0 8 3 11 
H23 1 3 0 0 2 1 0 0 4 3 7 
H23 1 3 0 1 0 2 0 1 0 6 7 
H23 1 2 0 1 0 1 0 1 0 3 4 
H23 1 2 0 0 2 0 0 0 4 0 4 
H23 1 3 0 2 1 0 0 2 2 0 4 
H23 Total 29 1 7 12 9 0 7 24 27 58 
H22 1 5 0 4 1 0 0 4 2 0 6 
H22 1 4 0 3 0 1 0 3 0 3 6 
H22 1 1 0 1 0 0 0 1 0 0 1 
H22 1 3 0 0 3 0 0 0 6 0 6 
H22 1 2 0 1 1 0 0 1 2 0 3 
H22 1 4 0 1 2 1 0 1 4 3 8 
H22 Total 19 0 10 7 2 0 10 14 6 30 
H30 2 2 0 1 0 1 0 1 0 3 4 
H30 2 1 0 0 0 1 0 0 0 3 3 
H30 2 2 0 0 2 0 0 0 4 0 4 
H30 2 5 0 1 0 4 0 1 0 12 13 
H30 2 3 0 0 2 1 0 0 4 3 7 
H30 2 7 0 2 2 3 0 2 4 9 15 
H30 2 9 0 1 3 5 0 1 6 15 22 
H30 2 3 0 1 0 2 0 1 0 6 7 
H30 2 12 0 1 8 3 0 1 16 9 26 
H30 Total 44 0 7 17 20 0 7 34 60 101 
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H29 2 1 0 0 0 1 0 0 0 3 3 
H29 2 1 0 0 0 1 0 0 0 3 3 
H29 2 8 0 6 2 0 0 6 4 0 10 
H29 2 8 0 0 3 5 0 0 6 15 21 
H29 Total 18 0 6 5 7 0 6 10 21 37 
H23 2 4 0 0 1 3 0 0 2 9 11 
H23 2 6 0 1 0 5 0 1 0 15 16 
H23 2 6 0 0 1 5 0 0 2 15 17 
H23 2 1 0 0 0 1 0 0 0 3 3 
H23 2 3 0 0 0 3 0 0 0 9 9 
H23 2 2 0 0 0 2 0 0 0 6 6 
H23 2 3 0 0 2 1 0 0 4 3 7 
H23 2 3 0 0 3 0 0 0 6 0 6 
H23 2 1 0 0 0 1 0 0 0 3 3 
H23 Total 29 0 1 7 21 0 1 14 63 78 
H22 2 4 0 0 4 0 0 0 8 0 8 
H22 2 3 0 0 2 1 0 0 4 3 7 
H22 2 7 0 1 6 0 0 1 12 0 13 
H22 2 1 0 0 0 1 0 0 0 3 3 
H22 2 1 0 0 1 0 0 0 2 0 2 
H22 2 6 0 0 0 6 0 0 0 18 18 
H22 2 10 0 1 9 0 0 1 18 0 19 
H22 Total 32 0 2 22 8 0 2 44 24 70 
Group 1 represents unstimulated podocytes; Group 2 represents IL-13 stimulated podocytes. 
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Appendix 5.2: RhoA and Rac1 activities in unstimulated and IL-13 
stimulated podocytes. 
 
Normalized RhoA and Rac1 activities in podocytes. 
 Normalized RhoA Normalized Rac1 
Group 5 mins 10 mins 20 mins 30 mins 5 mins 10 mins 20 mins 30 mins 
1 3.99 3.76 0.98 1.63 0.31 0.88 0.72 0.59 
1 3.58 3.99 1.66 1.44 1.37 1.08 1.18 1.15 
1 4.23 4.53 1.81 2.57 0.72 0.58 0.74 0.53 
1 1.23 4.02 1.14 1.34 2.43 2.16 0.85 2.31 
1 3.81 1.99 2.41 1.88 1.22 1.08 1.17 1.15 
1 4.79 5.50 3.61 3.06 0.28 0.32 0.78 0.71 
1 1.94 2.71 2.32 3.23 0.16 0.30 1.51 1.11 
1 0.97 1.36 2.03 1.62 0.26 0.29 1.00   
2 3.27 4.27 1.35 1.14 0.38 0.64 1.28 0.69 
2 3.35 2.92 1.20 1.39 1.53 1.51 2.05 1.56 
2 4.28 3.96 2.13 2.09 0.64 0.63 0.98 0.64 
2 1.33 3.33 0.85 1.09 3.22 4.32 1.06 2.28 
2 2.84 3.42 1.46 2.15 2.76 2.41 1.51 1.14 
2 4.98 6.23 3.46 3.52 0.23 0.24 1.57 0.61 
2 2.23 1.80 2.35 1.92 0.18 0.18 1.66 0.87 
2 1.26 1.32 1.37 1.06 0.29 0.29 2.51   




Appendix 5.3: Gene expression index of B7-1, IL-13 receptors, vav1, 
dystroglycan, nephrin and podocin in podocyte siRNA experiments. 
 
Human podocytes gene expression index normalized against GAPDH.  
Group B7-1 IL-13Rα2 IL-13Rα1 IL-4Rα dystro nephrin podocin vav1 
3 2.24E-04 8.21E-04 1.47E-02 1.19E-02 1.79E-02 2.63E-05 3.21E-05 1.62E-05 
3 6.03E-05 1.10E-03 3.19E-02 4.15E-02 6.17E-02 4.62E-05 1.18E-04 3.86E-05 
3 7.74E-05 7.45E-04 1.28E-02 1.73E-02 2.11E-02 3.67E-05 2.29E-05 1.57E-04 
3 1.83E-04 6.44E-04 2.01E-02 2.87E-02 4.37E-02 1.16E-04 6.88E-05 6.72E-05 
3 8.86E-05 2.24E-03 1.59E-02 2.50E-02 3.12E-02 2.28E-04 2.48E-05 5.66E-05 
3 2.12E-04 8.76E-04 2.21E-02 2.71E-02 3.76E-02 2.67E-04 6.81E-05 4.57E-05 
3 1.77E-05 1.92E-03 1.31E-02 2.40E-02 2.95E-02 3.97E-05 1.42E-05 2.78E-05 
3 7.28E-05 1.50E-03 1.68E-02 2.58E-02 3.46E-02 5.27E-05 6.79E-05 8.73E-05 
3 2.16E-04 1.71E-03 1.59E-02 3.33E-02 3.62E-02 8.36E-05 1.27E-05 1.40E-04 
4 3.83E-04 2.44E-02 2.00E-02 5.23E-02 2.83E-02 2.53E-03 3.45E-05 6.65E-04 
4 1.19E-03 2.77E-03 2.06E-02 3.37E-02 2.09E-02 5.91E-05 5.72E-05 1.96E-04 
4 1.25E-04 3.22E-03 3.30E-02 3.53E-02 3.57E-02 6.42E-05 7.69E-05 4.71E-04 
4 2.05E-04 6.50E-03 2.10E-02 2.96E-02 4.05E-02 5.20E-04 4.86E-05 3.16E-04 
4 2.91E-04 2.68E-03 1.67E-02 2.83E-02 3.67E-02 8.14E-05 1.84E-05 2.00E-04 
4 1.15E-04 8.13E-03 3.27E-02 4.85E-02 3.58E-02 2.31E-04 5.76E-05 1.16E-04 
4 1.76E-04 2.11E-03 2.64E-02 2.95E-02 2.97E-02 2.92E-04 2.40E-05 2.14E-04 
4 1.08E-03 2.60E-03 1.61E-02 3.05E-02 3.23E-02 3.27E-05 6.44E-05 3.30E-05 
4 3.59E-04 3.29E-03 1.58E-02 3.04E-02 3.60E-02 1.23E-04 2.46E-05 2.39E-05 
5 5.71E-04 1.18E-02 3.34E-02 8.24E-02 3.86E-02 5.39E-04 3.86E-05 1.30E-05 
5 6.85E-04 1.05E-03 2.07E-02 3.60E-02 2.47E-02 2.17E-05 8.07E-05 0.00E+00 
5 2.68E-04 1.33E-03 1.88E-02 1.02E-02 1.17E-02 4.63E-05 7.93E-05 3.46E-05 
5 1.32E-04 6.25E-03 2.80E-02 3.22E-02 5.37E-02 4.88E-04 8.09E-05 3.68E-06 
5 5.20E-04 1.46E-03 1.71E-02 2.62E-02 4.17E-02 1.71E-04 2.54E-05 0.00E+00 
5 2.64E-04 5.09E-03 3.41E-02 3.15E-02 4.73E-02 2.75E-03 4.04E-05 2.70E-06 
5 9.73E-05 2.27E-03 1.28E-02 3.24E-02 3.57E-02 3.72E-05 3.05E-05 3.78E-05 
5 1.38E-04 1.24E-03 1.90E-02 3.24E-02 3.99E-02 3.66E-05 6.90E-05 6.22E-06 
5 3.12E-04 2.46E-03 2.13E-02 3.30E-02 4.28E-02 6.06E-05 1.25E-05 2.70E-06 
Group 3 represents podocytes transfected with control siRNA (negative control); Group 4 
represents IL-13 stimulated podocytes with control siRNA transfection; Group 5 represents IL-




Appendix 5.4: Protein expression index of B7-1, IL-13 receptors, vav1, 
dystroglycan, nephrin and podocin in podocyte siRNA experiments. 
 
Human podocytes protein expression index normalized against GAPDH. 
Group B7-1 IL-13Rα2 vav1 p-vav1 p-vav1/vav1 
3 0.34 0.82 1.34 1.69 1.26 
3 0.71 0.64 1.78 0.27 0.15 
3 0.11 0.37 1.04 1.07 1.03 
3 0.59 0.45 1.68 0.97 0.58 
3 0.63 0.91 1.7 1.96 1.15 
3 0.56 0.67 1.82 1.20 0.66 
3 0.56 0.72 1.82 1.31 0.72 
4 0.79 1.94 0.95 1.56 1.64 
4 0.91 1.51 1.61 1.13 0.7 
4 0.59 0.8 2.62 3.69 1.41 
4 0.66 1.01 0.99 0.78 0.79 
4 0.62 2.05 0.41 0.73 1.77 
4 1.61 1.63 0.42 0.63 1.5 
4 1.28 0.81 0.23 0.34 1.46 
5 1.25 1.9 0.74 0.57 0.77 
5 0.69 0.95 1.15 0.63 0.55 
5 0.95 1.81 1.08 0.60 0.56 
5 3.89 1.14 1.04 0.36 0.35 
5 1.13 0.68 1.07 0.58 0.54 
5 0.63 1.38 0.82 0.16 0.2 
5 0.55 0.77 0.49 0.45 0.92 
Group 3 represents podocytes transfected with control siRNA (negative control); Group 4 
represents IL-13 stimulated podocytes with control siRNA transfection; Group 5 represents IL-




Appendix 5.5: Cortical F-actin scores in podocyte siRNA experiments. 
 
Cortical F-actin scores in podocytes. 
Batch Group Total no. of cells 
Number of cells Scores sum of 
score 0 1 2 3 0 1 2 3 
H30 3 6 0 4 2 0 0 4 4 0 8 
H30 3 3 0 2 1 0 0 2 2 0 4 
H30 3 1 0 1 0 0 0 1 0 0 1 
H30 3 19 0 9 10 0 0 9 20 0 29 
H30 3 21 0 7 13 1 0 7 26 3 36 
H30 3 16 0 9 4 3 0 9 8 9 26 
H30 3 2 0 2 0 0 0 2 0 0 2 
H30 3 5 0 4 0 1 0 4 0 3 7 
H30 3 4 0 2 2 0 0 2 4 0 6 
H30 3 6 0 3 3 0 0 3 6 0 9 
H30 3 1 0 1 0 0 0 1 0 0 1 
H30 Total 84 0 44 35 5 0 44 70 15 129 
H29 3 4 0 3 1 0 0 3 2 0 5 
H29 3 5 0 3 2 0 0 3 4 0 7 
H29 3 14 0 4 7 3 0 4 14 9 27 
H29 3 9 0 5 3 1 0 5 6 3 14 
H29 3 1 0 1 0 0 0 1 0 0 1 
H29 3 19 0 11 7 1 0 11 14 3 28 
H29 3 1 1 0 0 0 0 0 0 0 0 
H29 3 14 0 9 3 2 0 9 6 6 21 
H29 3 1 1 0 0 0 0 0 0 0 0 
H29 Total 68 2 36 23 7 0 36 46 21 103 
H31 3 3 0 3 0 0 0 3 0 0 3 
H31 3 6 0 4 2 0 0 4 4 0 8 
H31 3 13 0 10 3 0 0 10 6 0 16 
H31 3 11 0 7 4 0 0 7 8 0 15 
H31 3 6 0 4 2 0 0 4 4 0 8 
H31 3 12 0 5 7 0 0 5 14 0 19 
H31 3 9 0 5 4 0 0 5 8 0 13 
H31 3 4 0 3 1 0 0 3 2 0 5 
H31 3 6 0 4 2 0 0 4 4 0 8 
H31 3 6 0 2 4 0 0 2 8 0 10 
H31 Total 76 0 47 29 0 0 47 58 0 105 
H30 4 2 0 0 0 2 0 0 0 6 6 
H30 4 2 0 0 0 2 0 0 0 6 6 
H30 4 5 0 0 3 2 0 0 6 6 12 
H30 4 11 0 4 6 1 0 4 12 3 19 
H30 4 13 0 0 12 1 0 0 24 3 27 
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H30 4 11 0 4 4 3 0 4 8 9 21 
H30 4 1 0 0 1 0 0 0 2 0 2 
H30 4 1 0 0 0 1 0 0 0 3 3 
H30 4 8 0 0 3 5 0 0 6 15 21 
H30 4 12 0 0 3 9 0 0 6 27 33 
H30 4 7 0 1 2 4 0 1 4 12 17 
H30 Total 73 0 9 34 30 0 9 68 90 167 
H29 4 6 0 1 0 5 0 1 0 15 16 
H29 4 1 0 0 0 1 0 0 0 3 3 
H29 4 11 0 1 1 9 0 1 2 27 30 
H29 4 11 0 1 8 2 0 1 16 6 23 
H29 4 4 0 0 1 3 0 0 2 9 11 
H29 4 22 0 3 5 14 0 3 10 42 55 
H29 4 3 0 0 0 3 0 0 0 9 9 
H29 4 32 0 10 10 12 0 10 20 36 66 
H29 4 1 1 0 0 0 0 0 0 0 0 
H29 Total 91 1 16 25 49 0 16 50 147 213 
H31 4 5 0 0 0 5 0 0 0 15 15 
H31 4 3 0 0 0 3 0 0 0 9 9 
H31 4 9 0 0 2 7 0 0 4 21 25 
H31 4 4 0 1 2 1 0 1 4 3 8 
H31 4 4 0 0 3 1 0 0 6 3 9 
H31 4 6 0 0 3 3 0 0 6 9 15 
H31 Total 31 0 1 10 20 0 1 20 60 81 
H30 5 11 0 6 4 1 0 6 8 3 17 
H30 5 15 0 10 5 0 0 10 10 0 20 
H30 5 18 0 10 8 0 0 10 16 0 26 
H30 5 11 0 8 2 1 0 8 4 3 15 
H30 5 1 0 1 0 0 0 1 0 0 1 
H30 Total 56 0 35 19 2 0 35 38 6 79 
H29 5 5 0 3 1 1 0 3 2 3 8 
H29 5 1 0 0 0 1 0 0 0 3 3 
H29 5 6 0 2 2 2 0 2 4 6 12 
H29 5 5 0 3 2 0 0 3 4 0 7 
H29 5 5 0 1 1 3 0 1 2 9 12 
H29 5 4 1 2 1 0 0 2 2 0 4 
H29 5 1 0 0 1 0 0 0 2 0 2 
H29 5 5 1 2 0 2 0 2 0 6 8 
H29 Total 32 2 13 8 9 0 13 16 27 56 
H31 5 7 0 1 2 4 0 1 4 12 17 
H31 5 1 0 1 0 0 0 1 0 0 1 
H31 5 3 0 1 0 2 0 1 0 6 7 
H31 5 11 0 5 6 0 0 5 12 0 17 
H31 5 19 0 14 5 0 0 14 10 0 24 
H31 5 13 0 8 4 1 0 8 8 3 19 
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H31 5 10 0 6 4 0 0 6 8 0 14 
H31 5 6 0 2 4 0 0 2 8 0 10 
H31 Total 70 0 38 25 7 0 38 50 21 109 
Group 3 represents podocytes transfected with control siRNA (negative control); Group 4 
represents IL-13 stimulated podocytes with control siRNA transfection; Group 5 represents IL-
13 stimulated podocytes with vav1 siRNA transfection.  
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Appendix 5.6: RhoA and Rac1 activities in podocyte siRNA experiments. 
 
Normalized RhoA and Rac1 activities in podocytes. 
Group RhoA Rac1 
3 3.23 0.97 
3 2.63 0.86 
3 2.97 0.96 
3 1.23 0.73 
3 0.29 0.31 
3 0.08 0.42 
3 0.82 0.74 
4 3.86 0.87 
4 3.46 1.6 
4 4.12 1.8 
4 1.23 0.92 
4 1.03 0.71 
4 1.64 1.03 
4 1.81 1.25 
5 2.88 0.71 
5 1.68 0.47 
5 2.77 1.02 
5 0.77 1.04 
5 2.1 0.19 
5 1.33 0.35 
5 1.17 0.69 
Group 3 represents podocytes transfected with control siRNA (negative control); Group 4 
represents IL-13 stimulated podocytes with control siRNA transfection; Group 5 represents IL-
13 stimulated podocytes with vav1 siRNA transfection. 
 
